<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/css" href="gpml.css" ?>
<!DOCTYPE set SYSTEM "gpml.dtd">
<set>
<article>
<articleinfo>
<bibliomisc>MEDLINE:17473920</bibliomisc>
</articleinfo>
<title>
<sentence>Pharmacokinetics of <cons lex="methadone" sem="G_DRUG">methadone</cons> in human-immunodeficiency-virus-infected patients receiving <cons lex="nevirapine" sem="G_DRUG">nevirapine</cons> once daily.</sentence>
</title>
<abstract>
<sentence>The effect of <cons lex="nevirapine" sem="G_DRUG">nevirapine</cons> once-daily dosing on the pharmacokinetics of <cons lex="methadone" sem="G_DRUG">methadone</cons> and its main metabolite, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine, was evaluated in ten HIV positive patients on stable <cons lex="methadone" sem="G_DRUG">methadone</cons> therapy.</sentence>
<sentence><cons lex="nevirapine" sem="G_DRUG">Nevirapine</cons> <cons sem="G_NUMBER">200 mg</cons> once daily was administered orally from day 1 to day 14.</sentence>
<sentence>On day 15, <cons lex="nevirapine" sem="G_DRUG">nevirapine</cons> dose was <cons sem="G_CHANGE">increased</cons> to <cons sem="G_NUMBER">400 mg</cons> once daily for the following 7 days of study and thereafter.</sentence>
<sentence>On days 0, 8, and 22, concentration-time profiles of <cons lex="methadone" sem="G_DRUG">methadone</cons> and its metabolite were collected after <cons lex="methadone" sem="G_DRUG">methadone</cons> intake.</sentence>
<sentence>Noncompartmental pharmacokinetic analysis was performed.</sentence>
<sentence>Pharmacokinetic parameters obtained on days 8 and 22 were compared with those obtained before <cons lex="nevirapine" sem="G_DRUG">nevirapine</cons> administration.</sentence>
<sentence>After starting <cons lex="nevirapine" sem="G_DRUG">nevirapine</cons> treatment, nine out of ten patients experienced symptoms of abstinence syndrome, and <cons lex="methadone" sem="G_DRUG">methadone</cons> dose had to be <cons sem="G_CHANGE">increased</cons> by <cons sem="G_NUMBER">20%</cons> on average during the course of the study.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(nevirapine, methadone, DDI)">
<sentence>After 7 days with <cons lex="nevirapine" sem="G_DRUG" type="inducer_1">nevirapine</cons> <cons sem="G_NUMBER">200 mg</cons>, <cons lex="methadone" sem="G_DRUG" type="substrate_1">methadone</cons> <cons sem="G_IVIVPARA">area under the plasma concentration time curve (AUC)</cons> and <cons sem="G_IVIVPARA">maximum concentration (C(max))</cons> values were <cons sem="G_CHANGE">reduced</cons> by <cons sem="G_NUMBER">63.3%</cons> and <cons sem="G_NUMBER">55.2%</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(nevirapine, methadone, DDI)">
<sentence>Switching to high dose <cons lex="nevirapine" sem="G_DRUG" type="inducer_1">nevirapine</cons> (<cons sem="G_NUMBER">400 mg</cons> once daily) did <cons sem="G_NEGATIVEEFFECT">not</cons> result in a <cons sem = "G_CHANGE">greater</cons> <cons sem="G_CHANGE">decrease</cons> in the <cons lex="methadone" sem="G_DRUG" type="substrate_1">methadone</cons> <cons sem="G_IVIVPARA">AUC</cons> and <cons sem="G_IVIVPARA">C(max)</cons> compared with <cons sem="G_NUMBER">200 mg</cons> <cons lex="nevirapine" sem="G_DRUG" type="inducer_1">nevirapine</cons>.</sentence>
</annotation>
<sentence>None of the noncompartmental pharmacokinetic parameters of <cons lex="methadone" sem="G_DRUG">methadone</cons> metabolite evidenced statistically <cons sem="G_CHANGE">significant</cons> differences across the three study periods.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(nevirapine, methadone, DDI)">
<sentence>The <cons sem="G_CHANGE">decrease</cons> in <cons lex="methadone" sem="G_DRUG" type="substrate_1">methadone</cons> <cons sem="G_IVIVPARA">AUC</cons> and <cons sem="G_IVIVPARA">C(max)</cons> administrated once daily was similar to that seen in other studies with <cons lex="nevirapine" sem="G_DRUG" type="inducer_1">nevirapine</cons> administrated twice daily, suggesting that the degree of <cons sem="G_MECHANISM">induction</cons> of <cons lex="methadone" sem="G_DRUG" type="substrate_1">methadone</cons> <cons sem="G_MECHANISM">metabolism</cons> by <cons lex="nevirapine" sem="G_DRUG" type="inducer_1">nevirapine</cons> is similar for both dosing regimens.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:17346248</bibliomisc>
</articleinfo>
<title>
<sentence>A comparative pharmacokinetic study in healthy volunteers of the effect of <cons lex="carbamazepine" sem="G_DRUG">carbamazepine</cons> and <cons lex="oxcarbazepine" sem="G_DRUG">oxcarbazepine</cons> on <cons lex="cyp3a4" sem="G_CYP">cyp3a4</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="carbamazepine" sem="G_DRUG">Carbamazepine (CBZ)</cons> and <cons lex="oxcarbazepine" sem="G_DRUG">oxcarbazepine (OXCZ)</cons> are well-known <cons sem="G_MECHANISM">inducers</cons> of drug <cons sem="G_MECHANISM">metabolism</cons> via <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<sentence>Indirect interaction studies and clinical experience suggest that <cons sem="G_DRUG">CBZ</cons> has a stronger potential in this regard than <cons sem="G_DRUG">OXCZ</cons>.</sentence>
<sentence>However this has never been subject to a direct comparative study.</sentence>
<sentence>We performed a study in healthy volunteers to investigate the relative <cons sem="G_MECHANISM">inductive</cons> effect of <cons sem="G_DRUG">CBZ</cons> and <cons sem="G_DRUG">OXCZ</cons> on <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity using the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="quinidine" sem="G_DRUG">quinidine</cons> as a biomarker reaction.</sentence>
<sentence>Ten healthy, male volunteers participated in an open, randomized crossover study consisting of two periods separated by a 4-week wash-out period.</sentence>
<sentence>The subjects received <cons sem="G_NUMBER">1200 mg</cons> oral <cons sem="G_DRUG">OXCZ</cons> daily for 17 days and <cons sem="G_NUMBER">800 mg</cons> oral <cons sem="G_DRUG">CBZ</cons> for 17 days.</sentence>
<sentence>A single <cons sem="G_NUMBER">200 mg</cons> oral dose of <cons lex="quinidine" sem="G_DRUG">quinidine</cons> was administered at baseline and following administration of <cons sem="G_DRUG">CBZ</cons> and <cons sem="G_DRUG">OXCZ</cons>.</sentence>
<sentence>Outcome parameters were the <cons sem="G_MECHANISM">formation</cons> <cons sem="G_IVIVPARA">clearance</cons> of <cons sem="G_DRUG">3-hydroxyquinidine</cons> dose and the ratio of the <cons sem="G_IVIVPARA">AUC</cons>s of <cons sem="G_DRUG">3-hydroxyquinidine</cons> to <cons lex="quinidine" sem="G_DRUG">quinidine</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(3-hydroxyquinidine, OXCZ, DDI),(3-hydroxyquinidine, CBZ, DDI)">
<sentence><cons sem="G_MECHANISM">Formation</cons> <cons sem="G_IVIVPARA">clearance</cons> of <cons lex="quinidine" sem="G_DRUG" type="M_1" >3-hydroxyquinidine</cons> was <cons sem="G_CHANGE">increased</cons> by means of <cons sem="G_NUMBER">89% (CI: 36-164; p=0.0022)</cons> and <cons sem="G_NUMBER">181% (CI: 120-260, p&lt;0.0001)</cons> after treatment with <cons sem="G_DRUG" type="inducer_1">OXCZ</cons> and <cons sem="G_DRUG" type="inducer_2">CBZ</cons>, respectively, compared to baseline.</sentence>
</annotation>
<sentence>The relative <cons sem="G_MECHANISM">inductive</cons> effect of <cons sem="G_DRUG">CBZ</cons> was <cons sem="G_NUMBER">46%</cons> higher than for <cons sem="G_DRUG">OXCZ</cons>.</sentence>
<annotation sem="INVIVOVDDIS" ddi="(3-hydroxyquinidine, OXCZ, DDI),(3-hydroxyquinidine, CBZ, DDI)">
<sentence><cons sem="G_IVIVPARA">AUC ratio</cons> <cons sem="G_CHANGE">increased</cons> by means of <cons sem="G_NUMBER">161% (CI: 139-187, p&lt;0.0001)</cons> (<cons sem="G_DRUG" type="inducer_1">OXCZ</cons>) and <cons sem="G_NUMBER">222% (CI: 192-257, p&lt;0.0001)</cons> (<cons sem="G_DRUG" type="inducer_2">CBZ</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi=" (Quinidine, OXCZ, ADDI)(Quinidine, CBZ, ADDI) ">
<sentence><cons lex="quinidine" sem="G_DRUG" type="substrate_1">Quinidine</cons> <cons sem="G_IVIVPARA">Cmax</cons> <cons sem="G_CHANGE"><cons sem="G_CHANGE">decrease</cons>d</cons> by means of <cons sem="G_NUMBER">29% (CI: 16-40, p=0.0018)</cons> (<cons sem="G_DRUG" type="inducer_1">OXCZ</cons>) and <cons sem="G_NUMBER">33% (CI: 18-45, p=0.0020)</cons> (<cons sem="G_DRUG" type="inducer_1">CBZ</cons>).</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(Quinidine, OXCZ, ADDI)(Quinidine, CBZ, ADDI)">    
<sentence><cons sem="G_IVIVPARA"><cons sem="G_IVIVPARA">t1/2</cons></cons> <cons sem="G_CHANGE"><cons sem="G_CHANGE">decrease</cons>d</cons> by means of <cons sem="G_NUMBER">12% (CI: 6-17, p&lt;0.0014)</cons> (<cons sem="G_DRUG" type="inducer_1">OXCZ</cons>) and <cons sem="G_NUMBER">32% (CI: 25-38, p&lt;0.0001)</cons> (<cons sem="G_DRUG" type="inducer_2">CBZ</cons>).</sentence>
</annotation>    
<sentence><cons sem="G_IVIVPARA">tmax</cons> was <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">changed</cons> in either period.</sentence>
<annotation sem="INVIVOVDDIS" ddi="(Quinidine, OXCZ, DDI)(Quinidine, CBZ, DDI)">    
<sentence>We confirm a clinically <cons sem="G_CHANGE">significant</cons> <cons sem="G_MECHANISM">inductive</cons> effect of both <cons sem="G_DRUG" type="inducer_1">OXCZ</cons> and <cons sem="G_DRUG" type="inducer_2">CBZ</cons>.</sentence>
</annotation>
<sentence>The <cons sem="G_MECHANISM">inductive</cons> effect of <cons sem="G_DRUG">CBZ</cons> was about <cons sem="G_NUMBER">46%</cons> higher than that of <cons sem="G_DRUG">OXCZ</cons>, a difference that <cons sem = "G_CHANGE">may</cons> be of clinical relevance.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:17345073</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons> on the pharmacokinetics of <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> in HIV-infected patients.</sentence>
</title>
<abstract>
<sentence>To investigate the effect of <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons> on the <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> pharmacokinetics in HIV-infected patients.</sentence>
<sentence>Twelve HIV-infected patients were assigned into a one-sequence, two-period pharmacokinetic interaction study.</sentence>
<sentence>In phase one, the patients received <cons sem="G_NUMBER">400 mg</cons> of <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> as a single oral dose on day 1; in phase two, they received <cons sem="G_NUMBER">600 mg</cons> of <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons> once daily in combination with <cons sem="G_NUMBER">150 mg</cons> of <cons lex="lamivudine" sem="G_DRUG">lamivudine</cons> and <cons sem="G_NUMBER">30 or 40 mg</cons> of <cons lex="stavudine" sem="G_DRUG">stavudine</cons> twice daily on days 2 to 16.</sentence>
<sentence>On day 16, <cons sem="G_NUMBER">400 mg</cons> of <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> was added to the regimen as a single oral dose.</sentence>
<sentence><cons lex="ketoconazole" sem="G_DRUG">Ketoconazole</cons> pharmacokinetics were studied on days 1 and 16.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(efavirenz, ketoconazole, DDI)">
<sentence>Pretreatment with <cons lex="efavirenz" sem="G_DRUG" type="inducer_1">efavirenz</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">clearance</cons> of <cons lex="ketoconazole" sem="G_DRUG" type="substrate_1">ketoconazole</cons> by <cons sem="G_NUMBER">201%</cons>.</sentence>
</annotation>
<sentence><cons sem="G_IVIVPARA">C(max)</cons> and <cons sem="G_IVIVPARA">AUC(0-24)</cons> were <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE"><cons sem="G_CHANGE">decrease</cons>d</cons> by <cons sem="G_NUMBER">44 and 72%</cons>, respectively.</sentence>
<sentence>The <cons sem="G_IVIVPARA">T ((1/2))</cons> was <cons sem="G_CHANGE">significantly</cons> shorter by <cons sem="G_NUMBER">58%</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(efavirenz, ketoconazole, DDI)">      
<sentence><cons lex="efavirenz" sem="G_DRUG" type="inducer_1">Efavirenz</cons> has a <cons sem="G_CHANGE">strong</cons> <cons sem="G_MECHANISM">inducing</cons> effect on the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="ketoconazole" sem="G_DRUG" type="substrate_1">ketoconazole</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:17304149</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> on pharmacokinetics of <cons sem="G_DRUG">paroxetine</cons>: the role of gut transporters.</sentence>
</title>
<abstract>
<sentence>A recent in vitro study has shown that <cons lex="paroxetine" sem="G_DRUG">paroxetine</cons> is a substrate of P-glycoprotein.</sentence>
<sentence>However, there was <cons sem="G_NEGATIVEEFFECT">no</cons> in vivo information indicating the involvement of P-glycoprotein on the pharmacokinetics of <cons lex="paroxetine" sem="G_DRUG">paroxetine</cons>.</sentence>
<sentence>The aim of this study was to examine the effects of <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>, a P-glycoprotein <cons sem="G_MECHANISM">inhibitor</cons>, on the pharmacokinetics of <cons lex="paroxetine" sem="G_DRUG">paroxetine</cons>.</sentence>
<sentence>Two 6 day courses of either <cons sem="G_NUMBER">200 mg</cons> <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> daily or placebo with at least a 4 week washout period were conducted.</sentence>
<sentence>Thirteen volunteers took a single oral <cons sem="G_NUMBER">20 mg</cons> dose of <cons lex="paroxetine" sem="G_DRUG">paroxetine</cons> on day 6 of both courses.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> of <cons lex="paroxetine" sem="G_DRUG">paroxetine</cons> were monitored up to 48 hours after the dosing.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(itraconazole, paroxetine, DDI)">
<sentence>Compared with placebo, <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons> treatment <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">peak plasma concentration (Cmax)</cons> of <cons lex="paroxetine" sem="G_DRUG" type="substrate_1">paroxetine</cons> by <cons sem="G_NUMBER">1.3 fold (6.7 +/- 2.5 versus 9.0 +/- 3.3 ng/mL, P &lt; 0.05)</cons> and the <cons sem="G_IVIVPARA">area under the plasma concentration-time curve from zero to 48 hours  [AUC (0-48)]</cons> of <cons lex="paroxetine" sem="G_DRUG" type="substrate_1">paroxetine</cons> by <cons sem="G_NUMBER">1.5 fold (137 +/- 73 versus 199 +/- 91 ng*h/mL, P &lt; 0.01)</cons>.</sentence>
</annotation>
<sentence>Although <cons sem="G_IVIVPARA">elimination half-life</cons> differed <cons sem="G_CHANGE">significantly</cons> <cons sem="G_NUMBER">(16.1 +/- 3.4 versus 18.8 +/- 5.9 hours, P &lt; 0.05)</cons>, the alteration was small (<cons sem="G_NUMBER">1.1 fold</cons>).</sentence>
<annotation sem="INVIVOCDDIS" ddi="(itraconazole, paroxetine, DDI)">      
<sentence>The present study demonstrated that the <cons sem="G_IVIVPARA">bioavailability</cons> of <cons lex="paroxetine" sem="G_DRUG" type="substrate_1">paroxetine</cons> was <cons sem="G_CHANGE">increased</cons> by <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons>, suggesting a possible involvement of P-glycoprotein in the pharmacokinetics of <cons lex="paroxetine" sem="G_DRUG" type="substrate_1">paroxetine</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:17301736</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="amiodarone" sem="G_DRUG">Amiodarone</cons> interacts with <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> but <cons sem="G_NEGATIVEEFFECT">not</cons> with <cons lex="pravastatin" sem="G_DRUG">pravastatin</cons> disposition kinetics.</sentence>
</title>
<abstract>
<sentence>The aim of this study was to determine the influence of <cons lex="amiodarone" sem="G_DRUG">amiodarone</cons> on the pharmacokinetics of <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> and <cons lex="pravastatin" sem="G_DRUG">pravastatin</cons> in humans.</sentence>
<sentence>This was a prospective, crossover, randomized, open-label study performed in <cons sem="G_NUMBER">12</cons> healthy volunteers comparing the pharmacokinetics of a single oral dose of <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> (<cons sem="G_NUMBER">40 mg</cons>) or <cons lex="pravastatin" sem="G_DRUG">pravastatin</cons> (<cons sem="G_NUMBER">40 mg</cons>) taken alone and after 3 days of <cons lex="amiodarone" sem="G_DRUG">amiodarone</cons> (<cons sem="G_NUMBER">400 mg/day</cons>).</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Amiodarone, simvastatin acid, DDI)(Amiodarone, pravastatin, NDDI)">
<sentence><cons lex="amiodarone" sem="G_DRUG" type="inhibitor_1">Amiodarone</cons> <cons sem="G_CHANGE">increased</cons> <cons lex="simvastatin" sem="G_DRUG" type="M_1">simvastatin acid</cons> <cons sem="G_IVIVPARA">AUC (area under the plasma concentration-time curve)0-24 h</cons>, <cons sem="G_IVIVPARA">peak plasma concentration (Cmax)</cons>, and <cons sem="G_IVIVPARA">t1/2</cons> by <cons sem="G_NUMBER">73% (P=0.02)</cons>, <cons sem="G_NUMBER">100% (P=0.02)</cons>, and <cons sem="G_NUMBER">48% (P=0.06)</cons>, respectively, whereas it did <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">significantly</cons> alter <cons lex="pravastatin" sem="G_DRUG" type="substrate_2">pravastatin</cons> pharmacokinetics.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(Amiodarone, simvastatin acid, DDI)(Amiodarone, simvastatin lactone, DDI)(Amiodarone, pravastatin, DDI)">    
<sentence>Point estimates and <cons sem="G_NUMBER">90%</cons> confidence intervals for <cons lex="simvastatin" sem="G_DRUG" type="M_1">simvastatin acid</cons>, <cons lex="simvastatin" sem="G_DRUG" type="M_2">simvastatin lactone</cons>, and <cons lex="pravastatin" sem="G_DRUG" type="substrate_2">pravastatin</cons> <cons sem="G_IVIVPARA">AUC(0-24 h)</cons> were <cons sem="G_NUMBER">154% (109-216%)</cons>, <cons sem="G_NUMBER">155% (109-227%)</cons>, and <cons sem="G_NUMBER">86% (63-118%)</cons>, respectively.</sentence>
</annotation>
<sentence>If <cons lex="amiodarone" sem="G_DRUG">amiodarone</cons> and a statin have to be simultaneously prescribed, <cons lex="pravastatin" sem="G_DRUG">pravastatin</cons> should be preferred to <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> in order to avoid a drug interaction.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:17223855</bibliomisc>
</articleinfo>
<title>
<sentence>Effects of <cons lex="clarithromycin" sem="G_DRUG">clarithromycin</cons> and <cons sem="G_DRUG">grapefruit juice</cons> on the pharmacokinetics of <cons lex="glibenclamide" sem="G_DRUG">glibenclamide</cons>.</sentence>
</title>
<abstract>
<sentence>Case reports suggest that <cons lex="clarithromycin" sem="G_DRUG">clarithromycin</cons> can <cons sem="G_CHANGE">increase</cons> the glucose-lowering effect of <cons lex="glibenclamide" sem="G_DRUG">glibenclamide</cons> which is <cons sem="G_MECHANISM">metabolized</cons> mainly by <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> and is a substrate for P-glycoprotein and <cons sem="G_CYP">OATP2B1</cons>.</sentence>
<sentence>Our objective was to evaluate whether the <cons sem="G_CYP">P-glycoprotein</cons> <cons sem="G_MECHANISM">inhibitor</cons>, <cons lex="clarithromycin" sem="G_DRUG">clarithromycin</cons>, <cons sem="G_CHANGE">increases</cons> and the putative <cons sem="G_CYP">OATP2B1</cons> <cons sem="G_MECHANISM">inhibitor</cons>, <cons sem="G_DRUG">grapefruit juice</cons>, <cons sem="G_CHANGE">decreases</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons> of <cons lex="glibenclamide" sem="G_DRUG">glibenclamide</cons>.</sentence>
<sentence>In a randomized three-phase crossover study, 12 subjects ingested <cons sem="G_NUMBER">250 mg</cons> <cons lex="clarithromycin" sem="G_DRUG">clarithromycin</cons> or placebo twice daily or <cons sem="G_NUMBER">200 ml</cons> <cons sem="G_DRUG">grapefruit juice</cons> three times daily for 2 days.</sentence>
<sentence>On day 3, they ingested <cons sem="G_NUMBER">0.875 mg</cons> <cons lex="glibenclamide" sem="G_DRUG">glibenclamide</cons> with sugar water or <cons sem="G_DRUG">grapefruit juice</cons>.</sentence>
<sentence>Concentrations of <cons lex="glibenclamide" sem="G_DRUG">glibenclamide</cons> and <cons lex="clarithromycin" sem="G_DRUG">clarithromycin</cons> in plasma, glucose in blood, and excretion of hydroxy-<cons lex="glibenclamide" sem="G_DRUG">glibenclamide</cons> into urine were measured up to 12 h. </sentence> 
<annotation sem="INVIVOCDDIS" ddi="(Clarithromycin, glibenclamide, ADDI)">
<sentence><cons lex="clarithromycin" sem="G_DRUG" type="inhibitor_1">Clarithromycin</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">peak concentration (C(max))</cons> of <cons lex="glibenclamide" sem="G_DRUG" type="substrate_1">glibenclamide</cons> to <cons sem="G_NUMBER">1.25-fold (95% confidence interval (CI) 1.12, 1.40; P &lt; 0.01)</cons> and the <cons sem="G_IVIVPARA">area under the plasma concentration-time curve</cons> to <cons sem="G_NUMBER">1.35-fold (95% CI 1.21, 1.50; P &lt; 0.01)</cons> compared with the placebo phase.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(Clarithromycin, glibenclamide, NDDI)">    
<sentence>The <cons sem="G_IVIVPARA">time to C(max)</cons>, the <cons sem="G_IVIVPARA">half-life</cons> of <cons lex="glibenclamide" sem="G_DRUG" type="substrate_1">glibenclamide</cons>, and the amount of <cons lex="glibenclamide" sem="G_DRUG" type="M_1">hydroxy-glibenclamide</cons> excreted into urine remained <cons sem="G_NEGATIVEEFFECT">unaltered</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Grapefruit juice, glibenclamide, NDDI)">  
<sentence><cons sem="G_DRUG" type="inhibitor_2">Grapefruit juice</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">change</cons> the pharmacokinetics of <cons lex="glibenclamide" sem="G_DRUG" type="substrate_1">glibenclamide</cons>.</sentence>
</annotation>
<sentence><cons lex="clarithromycin" sem="G_DRUG">Clarithromycin</cons> concentrations implied a good compliance.</sentence>
<sentence>Blood glucose did <cons sem="G_NEGATIVEEFFECT">not</cons> deviate between the phases.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Clarithromycin, glibenclamide, ADDI)">  
<sentence><cons lex="clarithromycin" sem="G_DRUG" type="inhibitor_1">Clarithromycin</cons> <cons sem="G_CHANGE">increased</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons> of <cons lex="glibenclamide" sem="G_DRUG" type="substrate_1">glibenclamide</cons>, possibly by <cons sem="G_MECHANISM">inhibiting</cons> P-glycoprotein in the intestinal wall.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(clarithromycin, glibenclamide, DDI)">      
<sentence>Although <cons sem="G_NEGATIVEEFFECT">not</cons> seen with the present study design, <cons lex="clarithromycin" sem="G_DRUG" type="inhibitor_1">clarithromycin</cons> may <cons sem="G_CHANGE">enhance</cons> the effect of <cons lex="glibenclamide" sem="G_DRUG" type="substrate_1">glibenclamide</cons> by <cons sem="G_CHANGE">increasing</cons> <cons sem="G_IVIVPARA">plasma <cons lex="glibenclamide" sem="G_DRUG" type="substrate_1">glibenclamide</cons> concentrations</cons>, which warrants close monitoring of blood glucose during their co-administration.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Grapefruit juice, glibenclamide, NDDI)">     
<sentence><cons sem="G_DRUG" type="inhibitor_2">Grapefruit juice</cons> had <cons sem="G_NEGATIVEEFFECT">no</cons> effect on <cons lex="glibenclamide" sem="G_DRUG" type="substrate_1">glibenclamide</cons> pharmacokinetics.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:17192504</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_CHANGE">Significant</cons> pharmacokinetic and pharmacodynamic interaction of <cons lex="warfarin" sem="G_DRUG">warfarin</cons> with the NO-independent sGC <cons sem="G_MECHANISM">activator</cons> <cons lex="hmr1766" sem="G_DRUG">HMR1766</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="hmr1766" sem="G_DRUG">HMR1766</cons> is a new nitric oxide (NO)-independent <cons sem="G_MECHANISM">activator</cons> of soluble guanylyl cyclase (sGC) in development for the treatment of cardiovascular diseases and chronic heart failure.</sentence>
<sentence>A <cons sem="G_CHANGE">significant</cons> fraction of patients to be treated with <cons lex="hmr1766" sem="G_DRUG">HMR1766</cons> is expected to be maintained on <cons lex="warfarin" sem="G_DRUG">warfarin</cons>.</sentence>
<sentence>Because <cons lex="hmr1766" sem="G_DRUG">HMR1766</cons> is an <cons sem="G_MECHANISM">inhibitor</cons> and <cons lex="warfarin" sem="G_DRUG">warfarin</cons> a substrate of <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, the authors studied whether <cons lex="warfarin" sem="G_DRUG">warfarin</cons> pharmacokinetics and pharmacodynamics are <cons sem="G_CHANGE">influenced</cons> by <cons lex="hmr1766" sem="G_DRUG">HMR1766</cons>.</sentence>
<sentence>Eighteen healthy males were to receive a single oral dose of <cons sem="G_NUMBER">20 mg</cons> <cons lex="warfarin" sem="G_DRUG">warfarin</cons> each under steady-state conditions of <cons lex="hmr1766" sem="G_DRUG">HMR1766</cons> or placebo.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> of <cons lex="hmr1766" sem="G_DRUG">HMR1766</cons>, (R)- and (S)-<cons lex="warfarin" sem="G_DRUG">warfarin</cons>, and its 7-hydroxy-metabolites were determined using high-performance liquid chromatography and prothrombin time, and the international standardized ratio was determined by the nephelometric method.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(HMR1766, (S)-Warfarin, DDI)">
<sentence><cons lex="warfarin" sem="G_DRUG" type="substrate_1">(S)-Warfarin</cons> <cons sem="G_IVIVPARA">AUC(inf)</cons> and <cons sem="G_IVIVPARA">t(1/2)</cons> were <cons sem="G_NUMBER">106,471 h x microg/L</cons> and <cons sem="G_NUMBER">82.92 hours</cons> versus <cons sem="G_NUMBER">33,148 h x microg/L</cons> under <cons lex="hmr1766" sem="G_DRUG" type="inhibitor_1">HMR1766</cons> and <cons sem="G_NUMBER">31.72 hours</cons> under placebo, and the maximum <cons sem="G_CHANGE">decrease</cons> in prothrombin time values after <cons lex="warfarin" sem="G_DRUG" type="substrate_1">warfarin</cons> dosing was <cons sem="G_NUMBER">58.75% versus 39.94%</cons>.</sentence>
</annotation>
<sentence>These data demonstrate a <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>-mediated pharmacokinetic interaction with pharmacodynamic, clinically relevant consequences, which <cons sem = "G_CHANGE">might</cons> require <cons lex="warfarin" sem="G_DRUG">warfarin</cons> dose adjustment.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:17164694</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_MECHANISM">Inhibitory</cons> effects of <cons lex="propafenone" sem="G_DRUG">propafenone</cons> on the pharmacokinetics of <cons lex="caffeine" sem="G_DRUG">caffeine</cons> in humans.</sentence>
</title>
<abstract>
<sentence><cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> is involved in the <cons sem="G_MECHANISM">metabolism</cons> of both <cons lex="caffeine" sem="G_DRUG">caffeine</cons> and <cons lex="propafenone" sem="G_DRUG">propafenone</cons>, a class Ic antiarrhythmic agent.</sentence>
<sentence>Despite the widespread consumption of <cons lex="caffeine" sem="G_DRUG">caffeine</cons>, drug-drug interactions with this agent are often overlooked.</sentence>
<sentence>This study investigated effects of <cons lex="propafenone" sem="G_DRUG">propafenone</cons> on the pharmacokinetics of <cons lex="caffeine" sem="G_DRUG">caffeine</cons>.</sentence>
<sentence>Eight healthy volunteers were included in our study.</sentence>
<sentence>A total of <cons sem="G_NUMBER">300 mg</cons> of <cons lex="caffeine" sem="G_DRUG">caffeine</cons> was given on 2 occasions, once alone and once during the coadministration of <cons sem="G_NUMBER">300 mg</cons> <cons lex="propafenone" sem="G_DRUG">propafenone</cons>.</sentence>
<sentence>Serial blood samples were collected and pharmacokinetic parameters were estimated using a population pharmacokinetic approach.</sentence>
<sentence>A one-compartment PK model with first-order absorption and elimination described <cons sem="G_IVIVPARA">plasma concentration</cons> profiles.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(propafenone, caffeine, ADDI)">
<sentence>Concomitant administration of <cons lex="propafenone" sem="G_DRUG" type="inhibitor_1">propafenone</cons> <cons sem="G_CHANGE"><cons sem="G_CHANGE">decrease</cons>d</cons> <cons lex="caffeine" sem="G_DRUG" type="substrate_1">caffeine</cons> <cons sem="G_IVIVPARA">oral clearance</cons> from <cons sem="G_NUMBER">8.3 +/- 0.9 L/h to 5.4 +/- 0.7 L/h (P &lt; 0.05)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(propafenone, caffeine, DDI)">    
<sentence><cons sem="G_IVIVPARA">Elimination half-life</cons> of <cons lex="caffeine" sem="G_DRUG" type="substrate_1">caffeine</cons> was also <cons sem="G_CHANGE">increased</cons> <cons sem="G_NUMBER">54%</cons> by <cons lex="propafenone" sem="G_DRUG" type="inhibitor_1">propafenone</cons>.</sentence>
</annotation>
<sentence>One of our volunteers was a poor <cons sem="G_MECHANISM">metabolizer</cons> of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(propafenone, caffeine, DDI)">    
<sentence>Concomitant administration of <cons lex="propafenone" sem="G_DRUG" type="inhibitor_1">propafenone</cons> to this volunteer caused the <cons sem = "G_CHANGE">greatest</cons> <cons sem="G_CHANGE">increase</cons> in <cons lex="caffeine" sem="G_DRUG" type="substrate_1">caffeine</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(propafenone, caffeine, DDI)">    
<sentence>These results support the concept of competitive <cons sem="G_MECHANISM">inhibition</cons> between <cons lex="propafenone" sem="G_DRUG" type="inhibitor_1">propafenone</cons> and <cons lex="caffeine" sem="G_DRUG" type="substrate_1">caffeine</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(propafenone, caffeine, DDI)">      
<sentence>Our results suggest that <cons lex="propafenone" sem="G_DRUG" type="inhibitor_1">propafenone</cons> causes <cons sem="G_CHANGE">significant</cons> <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> activity leading to a <cons sem="G_CHANGE">decrease</cons> in the <cons sem="G_IVIVPARA">clearance</cons> of <cons lex="caffeine" sem="G_DRUG" type="substrate_1">caffeine</cons>.</sentence>
</annotation>
<sentence><cons lex="caffeine" sem="G_DRUG">Caffeine</cons> has intrinsic proarrhythmic effects; thus, its coadministration with an antiarrhythmic agent such as <cons lex="propafenone" sem="G_DRUG">propafenone</cons> should be used with caution, especially in patients with poor <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> activity.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:16934051</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_DRUG">Rofecoxib</cons> is a potent <cons sem="G_MECHANISM">inhibitor</cons> of cytochrome <cons lex="cyp1a2" sem="G_CYP">P450 1A2</cons>: studies with <cons lex="tizanidine" sem="G_DRUG">tizanidine</cons> and <cons lex="caffeine" sem="G_DRUG">caffeine</cons> in healthy subjects.</sentence>
</title>
<abstract>
<sentence>Case reports suggest an interaction between <cons sem="G_DRUG">rofecoxib</cons> and the <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> substrate <cons lex="tizanidine" sem="G_DRUG">tizanidine</cons>.</sentence>
<sentence>Our objectives were to explore the extent and mechanism of this possible interaction and to determine the <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> <cons sem="G_MECHANISM">inhibitory</cons> potency of <cons sem="G_DRUG">rofecoxib</cons>.</sentence>
<sentence>In a randomized, double-blind, two-phase cross-over study, nine healthy subjects took <cons sem="G_NUMBER">25 mg</cons> <cons sem="G_DRUG">rofecoxib</cons> or placebo daily for 4 days and, on day 4, each ingested <cons sem="G_NUMBER">4 mg</cons> <cons lex="tizanidine" sem="G_DRUG">tizanidine</cons>.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> and the urinary excretion of <cons lex="tizanidine" sem="G_DRUG">tizanidine</cons>, its metabolites (M) and <cons sem="G_DRUG">rofecoxib</cons>, and pharmacodynamic variables were measured up to 24 h. On day 3, a <cons lex="caffeine" sem="G_DRUG">caffeine</cons> test was performed to estimate <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> activity.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Rofecoxib, tizanidine, DDI)">
<sentence><cons sem="G_DRUG" type="inhibitor_1">rofecoxib</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">area under the plasma concentration-time curve (AUC(0-infinity))</cons> of <cons lex="tizanidine" sem="G_DRUG" type="substrate_1">tizanidine</cons> by <cons sem="G_NUMBER">13.6-fold  [95% confidence interval (CI) 8.0, 15.6; P &lt; 0.001)</cons>, <cons sem="G_IVIVPARA">peak plasma concentration (C(max))</cons> by <cons sem="G_NUMBER">6.1-fold (4.8, 7.3; P &lt; 0.001)</cons> and <cons sem="G_IVIVPARA">elimination half-life (t(1/2))</cons> from <cons sem="G_NUMBER">1.6 to 3.0 h (P &lt; 0.001)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Rofecoxib, tizanidine, DDI)">    
<sentence>Consequently, <cons sem="G_DRUG" type="inhibitor_1">rofecoxib</cons> <cons sem = "G_CHANGE">markedly</cons> <cons sem="G_CHANGE">increased</cons> the blood pressure-lowering and sedative effects of <cons lex="tizanidine" sem="G_DRUG" type="substrate_1">tizanidine</cons> (<cons sem="G_NUMBER">P &lt; 0.05</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Rofecoxib, tizanidine, DDI)">  
<sentence><cons sem="G_DRUG" type="inhibitor_1">rofecoxib</cons> <cons sem="G_CHANGE">increased</cons> <cons sem="G_NUMBER">several fold</cons> the <cons sem="G_DRUG" type="substrate_1">tizanidine</cons>/M-3 and <cons sem="G_DRUG" type="substrate_1">tizanidine</cons>/M-4 ratios in plasma and urine and the <cons sem="G_DRUG" type="substrate_1">tizanidine</cons>/M-5, <cons sem="G_DRUG" type="substrate_1">tizanidine</cons>/M-9 and <cons sem="G_DRUG" type="substrate_1">tizanidine</cons>/M-10 ratios in urine (<cons sem="G_NUMBER">P &lt; 0.05</cons>).</sentence>
</annotation> 
<sentence>In addition, it <cons sem="G_CHANGE">increased</cons> the plasma <cons lex="caffeine" sem="G_DRUG">caffeine</cons>/<cons sem="G_DRUG">paraxanthine</cons> ratio by <cons sem="G_NUMBER">2.4-fold (95% CI 1.4, 3.4; P = 0.008)</cons> and this ratio <cons sem="G_MECHANISM">correlated</cons> with the <cons sem="G_DRUG">tizanidine</cons>/metabolite ratios.</sentence>
<sentence>Finally, the <cons sem="G_IVIVPARA">AUC(0-25)</cons> of <cons sem="G_DRUG">rofecoxib</cons> <cons sem="G_MECHANISM">correlated</cons> with the placebo phase <cons lex="caffeine" sem="G_DRUG">caffeine</cons>/<cons sem="G_DRUG">paraxanthine</cons> ratio (<cons sem="G_NUMBER">r = 0.80, P = 0.01</cons>).</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Rofecoxib, tizanidine, DDI)">  
<sentence><cons sem="G_DRUG" type="inhibitor_1">Rofecoxib</cons> is a potent <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> and it <cons sem = "G_CHANGE">greatly</cons> <cons sem="G_CHANGE">increases</cons> the <cons sem="G_IVIVPARA">plasma concentrations</cons> and adverse effects of <cons lex="tizanidine" sem="G_DRUG" type="substrate_1">tizanidine</cons>.</sentence>
</annotation>
<sentence>The findings suggest that <cons sem="G_DRUG">rofecoxib</cons> itself is also <cons sem="G_MECHANISM">metabolized</cons> by <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, raising concerns about interactions between <cons sem="G_DRUG">rofecoxib</cons> and other <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> substrate and <cons sem="G_MECHANISM">inhibitor</cons> drugs.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:16918719</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> and <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> on the pharmacokinetics of oral <cons lex="lidocaine" sem="G_DRUG">lidocaine</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="lidocaine" sem="G_DRUG">Lidocaine</cons> is <cons sem="G_MECHANISM">metabolized</cons> by cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4 (CYP3A4)</cons> and <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> enzymes, but <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> have had only a <cons sem = "G_CHANGE">minor</cons> effect on its pharmacokinetics.</sentence>
<sentence>We studied the effect of co-administration of <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> (<cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> <cons sem="G_MECHANISM">inhibitor</cons>) and <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> (<cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitor</cons>) on the pharmacokinetics of <cons lex="lidocaine" sem="G_DRUG">lidocaine</cons> in a double-blind, randomized, three-way cross-over study.</sentence>
<sentence>Eight healthy volunteers ingested daily either <cons sem="G_NUMBER">100 mg</cons> <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> and placebo, <cons sem="G_NUMBER">100 mg</cons> <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> and <cons sem="G_NUMBER">1500 mg</cons> <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons>, or their corresponding placebos (control) for five days.</sentence>
<sentence>On day 6, <cons sem="G_NUMBER">1 mg/kg</cons> <cons lex="lidocaine" sem="G_DRUG">lidocaine</cons> was administered orally.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> of <cons lex="lidocaine" sem="G_DRUG">lidocaine</cons>, <cons sem="G_DRUG">monoethylglycinexylidide (MEGX)</cons> and <cons lex="lidocaine" sem="G_DRUG">3-hydroxylidocaine (3-OH-lidocaine)</cons> were measured for 10 hr.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(fluvoxamine, lidocaine, DDI)">
<sentence>During the <cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">fluvoxamine</cons> phase the <cons sem="G_IVIVPARA">area under the plasma concentration-time curve (AUC)</cons> and <cons sem="G_IVIVPARA">peak concentration (Cmax)</cons> of oral <cons lex="lidocaine" sem="G_DRUG" type="substrate_1">lidocaine</cons> were <cons sem="G_NUMBER">305% (P&lt;0.001)</cons> and <cons sem="G_NUMBER">220% (P&lt;0.05)</cons> of the control values.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(fluvoxamine + erythromycin, lidocaine, DDI)">  
<sentence>During the combination of <cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">fluvoxamine</cons> and <cons lex="erythromycin" sem="G_DRUG" type="inhibitor_2">erythromycin</cons>, <cons lex="lidocaine" sem="G_DRUG" type="substrate_1">lidocaine</cons> <cons sem="G_IVIVPARA">AUC</cons> was <cons sem="G_NUMBER">360% (P&lt;0.001)</cons> and <cons sem="G_IVIVPARA">Cmax</cons> <cons sem="G_NUMBER">250% (P&lt;0.05)</cons> of those during placebo.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(fluvoxamine, lidocaine, DDI)(fluvoxamine + erythromycin, lidocaine, ADDI)">   
<sentence><cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">Fluvoxamine</cons> alone had <cons sem="G_NEGATIVEEFFECT">no</cons> statistically <cons sem="G_CHANGE">significant</cons> effect on the <cons sem="G_IVIVPARA">half-life</cons> of <cons lex="lidocaine" sem="G_DRUG" type="substrate_1">lidocaine</cons> (<cons sem="G_IVIVPARA">t1/2</cons>), but during the combination phase <cons sem="G_IVIVPARA">t1/2</cons> (<cons sem="G_NUMBER">3.8 hr</cons>) was <cons sem="G_CHANGE">significantly</cons> longer than during the placebo phase (<cons sem="G_NUMBER">2.4 hr; P&lt;0.01</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(fluvoxamine, lidocaine, DDI)(fluvoxamine + erythromycin, lidocaine, ADDI)">     
<sentence><cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">Fluvoxamine</cons> alone and in the combination with <cons lex="erythromycin" sem="G_DRUG" type="inhibitor_2">erythromycin</cons> <cons sem="G_CHANGE">decreased</cons> <cons lex="lidocaine" sem="G_DRUG" type="M_1">MEGX</cons> <cons sem="G_IVIVPARA">peak concentrations</cons> by approximately <cons sem="G_NUMBER">50% (P&lt;0.001)</cons> and <cons sem="G_NUMBER">30% (P&lt;0.01)</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(fluvoxamine, lidocaine, DDI)">        
<sentence>We conclude that <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> by <cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">fluvoxamine</cons> considerably <cons sem="G_CHANGE">reduces</cons> the presystemic <cons sem="G_MECHANISM">metabolism</cons> of oral <cons lex="lidocaine" sem="G_DRUG" type="substrate_1">lidocaine</cons> and <cons sem = "G_CHANGE">may</cons> <cons sem="G_CHANGE">increase</cons> the risk of <cons lex="lidocaine" sem="G_DRUG" type="substrate_1">lidocaine</cons> toxicity if <cons lex="lidocaine" sem="G_DRUG" type="substrate_1">lidocaine</cons> is ingested.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(fluvoxamine, lidocaine, DDI)(erythromycin, lidocaine, DDI)">   
<sentence>The concomitant use of both <cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">fluvoxamine</cons> and a <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitor</cons> like <cons lex="erythromycin" sem="G_DRUG" type="inhibitor_2">erythromycin</cons> <cons sem = "G_CHANGE">may</cons> further <cons sem="G_CHANGE">increase</cons> plasma <cons lex="lidocaine" sem="G_DRUG" type="substrate_1">lidocaine</cons> concentrations.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:16890574</bibliomisc>
</articleinfo>
<title>
<sentence>Potent cytochrome P450 <cons lex="2c19" sem="G_CYP">2C19</cons> genotype-related interaction between <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> and the cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4</cons> <cons sem="G_MECHANISM">inhibitor</cons> <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons>.</sentence>
</title>
<abstract>
<sentence>Cytochrome P450 (CYP) <cons lex="2c19" sem="G_CYP">2C19</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> are the major enzymes responsible for <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> elimination.</sentence>
<sentence>Because the activity of <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> is under genetic control, the extent of <cons sem="G_MECHANISM">inhibition</cons> with a <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitor</cons> was expected to be modulated by the <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> <cons sem="G_MECHANISM">metabolizer</cons> status.</sentence>
<sentence>This study thus assessed the effect of the potent <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitor</cons> <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> after short-term administration on <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> pharmacokinetics in extensive <cons sem="G_MECHANISM">metabolizers</cons> (EMs) and poor <cons sem="G_MECHANISM">metabolizers</cons> (PMs) of <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>.</sentence>
<sentence>In a randomized, placebo-controlled crossover study, 20 healthy participants who were stratified according to <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> genotype received oral <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> (<cons sem="G_NUMBER">300 mg</cons> twice daily) or placebo for 2 days.</sentence>
<sentence>Together with the first <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> or placebo dose, a single oral dose of <cons sem="G_NUMBER">400 mg</cons> <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> was administered.</sentence>
<sentence><cons lex="voriconazole" sem="G_DRUG">Voriconazole</cons> was determined in plasma and urine by liquid chromatography-mass spectrometry, and pharmacokinetic parameters were estimated by noncompartmental analysis.</sentence>
<sentence>When given alone, the apparent <cons sem="G_IVIVPARA">oral clearance</cons> of <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> after single oral dosing was <cons sem="G_NUMBER">26%+/-16% (P &gt; .05)</cons> lower in <cons sem="G_CYP">CYP2C19*1/*2</cons> individuals and <cons sem="G_NUMBER">66%+/-14% (P &lt; .01)</cons> lower in <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> PMs.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(ritonavir, voriconazole, DDI)">
<sentence>The addition of <cons lex="ritonavir" sem="G_DRUG" type="inhibitor_1">ritonavir</cons> caused a major <cons sem="G_CHANGE">reduction</cons> in <cons lex="voriconazole" sem="G_DRUG" type="substrate_1">voriconazole</cons> apparent <cons sem="G_IVIVPARA">oral clearance</cons> <cons sem="G_NUMBER">(354+/-173 mL/min versus 202+/-139 mL/min, P = .0001)</cons>.</sentence>
</annotation>
<sentence>This <cons sem="G_CHANGE">reduction</cons> occurred in all <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> genotypes (<cons sem="G_NUMBER">463+/-168 mL/min versus 305+/-112 mL/min  [P = .023] for *1/*1, 343+/-127 mL/min versus 190+/-93 mL/min  [P = .008] for *1/*2, and 158+/-54 mL/min versus 22+/-11 mL/min for *2/*2)</cons> and is <cons sem = "G_CHANGE">probably</cons> caused by <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>-mediated <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
<sentence>Coadministration of a potent <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitor</cons> leads to a higher and prolonged exposure with <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> that <cons sem = "G_CHANGE">might</cons> <cons sem="G_CHANGE">increase</cons> the risk of the development of adverse drug reactions on a short-term basis, particularly in <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> PM patients.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:12534644</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of the <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitor</cons> <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> on the pharmacokinetics of <cons sem="G_DRUG">lignocaine</cons> and its pharmacologically active metabolites in subjects with normal and impaired liver function.</sentence>
</title>
<abstract>
<sentence>The objectives of this study were: (i) to evaluate the effect of a cytochrome P450 (CYP) <cons lex="3a4" sem="G_CYP">3A4</cons> <cons sem="G_MECHANISM">inhibitor</cons>, <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons>, on the pharmacokinetics of intravenous <cons sem="G_DRUG">lignocaine</cons> and its two pharmacologically active metabolites, <cons sem="G_DRUG">monoethylglycinexylidide (MEGX)</cons> and <cons sem="G_DRUG">glycinexylidide (GX)</cons>; (ii) to assess whether the effects of the <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> <cons sem="G_MECHANISM">inhibitory</cons> action on <cons sem="G_DRUG">lignocaine</cons> <cons sem="G_IVIVPARA">clearance</cons> and the results of the <cons sem="G_DRUG">MEGX</cons> liver function test depend on liver functional status; and (iii) to determine the effects of both <cons sem="G_CHANGE"><cons sem = "G_CHANGE">moderate</cons></cons> and severe liver dysfunction on the disposition kinetics of <cons sem="G_DRUG">lignocaine</cons>.</sentence>
<sentence>The study was carried out on 10 healthy volunteers, and 10 Child's class A and 10 class C cirrhotic patients, according to a double-blind, randomized, two-way crossover design.</sentence>
<sentence>On day 1 of the investigation, all subjects received three oral doses of <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> (<cons sem="G_NUMBER">600 mg</cons> of the ethylsuccinate ester) or placebo, and two further doses on day 2.</sentence>
<sentence>One hour after the fourth dose, subjects were given <cons sem="G_NUMBER">1 mg kg-1</cons> <cons sem="G_DRUG">lignocaine</cons> intravenously.</sentence>
<sentence>Timed plasma samples were then obtained until 12 h for determination of the concentrations of <cons sem="G_DRUG">lignocaine</cons>, <cons sem="G_DRUG">MEGX</cons> and <cons sem="G_DRUG">GX</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Erythromycin, lignocaine, DDI)(Erythromycin, MEGX, DDI)">
<sentence><cons lex="erythromycin" sem="G_DRUG" type="inhibitor_1">Erythromycin</cons> caused statistically <cons sem="G_CHANGE">significant</cons>, although limited, modifications of <cons lex="lignocaine" sem="G_DRUG" type="substrate_1">lignocaine</cons> and <cons lex="lignocaine" sem="G_DRUG" type="M_1">MEGX</cons> pharmacokinetic parameters.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(Erythromycin, lignocaine, ADDI)">
<sentence>In healthy volunteers, <cons lex="lignocaine" sem="G_DRUG" type="substrate_1">lignocaine</cons> <cons sem="G_IVIVPARA">clearance</cons> was <cons sem="G_CHANGE"><cons sem="G_CHANGE">decrease</cons>d</cons> from <cons sem="G_NUMBER">9.93 to 8.15 ml kg-1 min-1 [mean percentage ratio (95% CI), 82 (65-98)]</cons> and the <cons sem="G_IVIVPARA">half-life</cons> was prolonged from <cons sem="G_NUMBER">2.23 to 02.80 h  [mean percentage ratio (95% CI), 130 (109-151)]</cons>; <cons lex="lignocaine" sem="G_DRUG" type="M_1">MEGX</cons> <cons sem="G_IVIVPARA">area under the concentration-time curve from 0 h to 12 h</cons> was <cons sem="G_CHANGE">increased</cons> from <cons sem="G_NUMBER">665 to 886 ng ml-1 h  [mean percentage ratio (95% CI), 129 (102-156)]</cons>.</sentence>
</annotation>
<sentence>Quantitatively similar modifications were observed in the two cirrhotic groups.</sentence>
<annotation sem="INVIVOVDDIS" ddi="(Erythromycin, GX, NDDI)">
<sentence><cons lex="lignocaine" sem="G_DRUG" type="M_2">GX</cons> concentrations were lowered in all study groups, although <cons sem="G_NEGATIVEEFFECT">not</cons> to statistically <cons sem="G_CHANGE">significant</cons> extents.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Erythromycin, GX, NDDI)">   
<sentence><cons lex="erythromycin" sem="G_DRUG" type="inhibitor_1">Erythromycin</cons> coadministration caused <cons sem="G_NEGATIVEEFFECT">no</cons> appreciable interference with the results of the <cons lex="lignocaine" sem="G_DRUG" type="M_1">MEGX</cons> test.</sentence>
</annotation>
<sentence>Only in patients with Child's grade C liver cirrhosis were lignocaine kinetic parameters <cons sem="G_CHANGE">significantly</cons> altered with respect to healthy volunteers.</sentence>
<sentence>Thus, <cons sem="G_IVIVPARA">clearance</cons> was approximately halved, steady-state volume of distribution was <cons sem="G_CHANGE">increased</cons>, and <cons sem="G_IVIVPARA">terminal half-life</cons> was more than doubled.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Erythromycin, lignocaine, ADDI)">  
<sentence>Although <cons lex="erythromycin" sem="G_DRUG" type="inhibitor_1">erythromycin</cons> only <cons sem = "G_CHANGE">modestly</cons> <cons sem="G_CHANGE">decreases</cons> <cons sem="G_DRUG" type="substrate_1">lignocaine</cons> <cons sem="G_IVIVPARA">clearance</cons>, it causes a concomitant <cons sem="G_NUMBER">elevation</cons> of the concentrations of its pharmacologically active metabolite <cons sem="G_DRUG" type="substrate_2">MEGX</cons>.</sentence>
</annotation>
<sentence>A pharmacodynamic study following lignocaine infusion to steady state appears necessary to assess the actual clinical relevance of these combined effects.</sentence>
<sentence>The degree of liver dysfunction has <cons sem="G_NEGATIVEEFFECT">no</cons> influence on the extent of the <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons>-<cons sem="G_DRUG">lignocaine</cons> interaction, whereas it <cons sem = "G_CHANGE">markedly</cons> influences the extent of the changes in <cons sem="G_DRUG">lignocaine</cons> pharmacokinetics.</sentence>
<sentence>These findings indicate that <cons sem="G_NEGATIVEEFFECT">no</cons> dose adjustment is needed in patients with <cons sem="G_CHANGE"><cons sem = "G_CHANGE">moderate</cons></cons> liver cirrhosis, whereas the <cons sem="G_DRUG">lignocaine</cons> dose should be halved in patients with severe cirrhosis.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:12426514</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="rifampin" sem="G_DRUG">Rifampin</cons> <cons sem = "G_CHANGE">markedly</cons> <cons sem="G_CHANGE">decrease</cons>s <cons sem="G_IVIVPARA">plasma concentrations</cons> of <cons lex="praziquantel" sem="G_DRUG">praziquantel</cons> in healthy volunteers.</sentence>
</title>
<abstract>
<sentence><cons lex="praziquantel" sem="G_DRUG">Praziquantel</cons> is extensively <cons sem="G_MECHANISM">metabolized</cons> by the hepatic cytochrome P450 (CYP) enzymes.</sentence>
<sentence>The <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> isoforms are likely to be major enzymes responsible for <cons lex="praziquantel" sem="G_DRUG">praziquantel</cons> <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
<sentence><cons lex="rifampin" sem="G_DRUG">Rifampin</cons> (INN, rifampicin), a potent enzyme <cons sem="G_MECHANISM">inducer</cons> of CYP-mediated <cons sem="G_MECHANISM">metabolism</cons> (especially <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>, and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>), is known to <cons sem = "G_CHANGE">markedly</cons> <cons sem="G_CHANGE">decrease</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons> and effects of a number coadministered drugs.</sentence>
<sentence>The aim of this investigation was to study the possible pharmacokinetic interaction between <cons lex="rifampin" sem="G_DRUG">rifampin</cons> and <cons lex="praziquantel" sem="G_DRUG">praziquantel</cons>.</sentence>
<sentence>An open, randomized, 2-phase crossover design was used in each study of single or multiple doses.</sentence>
<sentence>In the single-dose study, 10 healthy Thai male volunteers ingested single doses of <cons sem="G_NUMBER">40 mg/kg</cons> <cons lex="praziquantel" sem="G_DRUG">praziquantel</cons> alone (phase 1) or after pretreatment with <cons sem="G_NUMBER">600 mg</cons> of oral <cons lex="rifampin" sem="G_DRUG">rifampin</cons> once daily for 5 days (phase 2).</sentence>
<sentence>In the multiple-dose study, all participants received multiple doses of <cons sem="G_NUMBER">25 mg/kg</cons> <cons lex="praziquantel" sem="G_DRUG">praziquantel</cons> alone (phase 1) or after 5-day pretreatment with <cons sem="G_NUMBER">600 mg</cons> of oral <cons lex="rifampin" sem="G_DRUG">rifampin</cons> once daily (phase 2).</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> of <cons lex="praziquantel" sem="G_DRUG">praziquantel</cons> in each phase were determined by the HPLC method.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(rifampin, praziquantel, DDI)">
<sentence>In the single-dose study, <cons lex="rifampin" sem="G_DRUG" type="inhibitor_1">rifampin</cons> <cons sem="G_CHANGE">decreased</cons> plasma <cons lex="praziquantel" sem="G_DRUG" type="substrate_1">praziquantel</cons> concentrations to undetectable levels in 7 of 10 subjects, whereas <cons lex="praziquantel" sem="G_DRUG" type="substrate_1">praziquantel</cons> concentrations were <cons sem="G_CHANGE">reduced</cons> by <cons lex="rifampin" sem="G_DRUG" type="inhibitor_1">rifampin</cons> to undetectable levels in 5 of 10 subjects in the multiple-dose study.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rifampin, praziquantel, DDI)">
<sentence>In 3 subjects with measurable concentrations in the single-dose study, <cons lex="rifampin" sem="G_DRUG" type="inhibitor_1">rifampin</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE"><cons sem="G_CHANGE">decrease</cons>d</cons> the mean <cons sem="G_IVIVPARA">maximum plasma concentration (C(max))</cons> and <cons sem="G_IVIVPARA">area under the plasma concentration-time curve from 0 to 24 hours  [AUC(0-24)]</cons> of <cons lex="praziquantel" sem="G_DRUG" type="substrate_1">praziquantel</cons> by <cons sem="G_NUMBER">81% (P &lt;.05)</cons> and <cons sem="G_NUMBER">85% (P &lt;.01)</cons>, respectively, whereas <cons lex="rifampin" sem="G_DRUG" type="inhibitor_1">rifampin</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE"><cons sem="G_CHANGE">decrease</cons>d</cons> the mean <cons sem="G_IVIVPARA">C(max)</cons> and <cons sem="G_IVIVPARA">AUC(0-24)</cons> of <cons lex="praziquantel" sem="G_DRUG" type="substrate_1">praziquantel</cons> by <cons sem="G_NUMBER">74% (P &lt;.05)</cons> and <cons sem="G_NUMBER">80% (P &lt;.01)</cons>, respectively, in 5 subjects with measurable concentrations in the multiple-dose study.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rifampin, praziquantel, DDI)">  
<sentence>The mean <cons sem="G_IVIVPARA">C(max)</cons> and <cons sem="G_IVIVPARA">AUC(0-24)</cons> of <cons lex="praziquantel" sem="G_DRUG" type="substrate_1">praziquantel</cons> in subjects whose <cons lex="praziquantel" sem="G_DRUG" type="substrate_1">praziquantel</cons> concentrations could <cons sem="G_NEGATIVEEFFECT">not</cons> be detected in the single-dose study (7 subjects) after <cons lex="rifampin" sem="G_DRUG" type="inhibitor_1">rifampin</cons> pretreatment were <cons sem="G_CHANGE">reduced</cons> by approximately <cons sem="G_NUMBER">99% (P &lt;.001)</cons> and <cons sem="G_NUMBER">94% (P &lt;.001)</cons>, respectively, and in the multiple-dose study (5 subjects), they were <cons sem="G_CHANGE">reduced</cons> by <cons sem="G_NUMBER">98% (P &lt;.05)</cons> and <cons sem="G_NUMBER">89% (P &lt;.01)</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rifampin, praziquantel, DDI)">   
<sentence><cons lex="rifampin" sem="G_DRUG" type="inhibitor_1">Rifampin</cons> <cons sem = "G_CHANGE">greatly</cons> <cons sem="G_CHANGE">decreased</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons> of single and multiple oral doses of <cons lex="praziquantel" sem="G_DRUG" type="substrate_1">praziquantel</cons> to levels lower than that of the minimum therapeutic concentration.</sentence>
</annotation>
<sentence>Because <cons lex="praziquantel" sem="G_DRUG">praziquantel</cons> and <cons lex="rifampin" sem="G_DRUG">rifampin</cons> are widely used in the treatment of liver flukes (Opisthorchis viverrini) and Mycobacterium tuberculosis, respectively, in Thailand and in some other countries in southeast Asia, the possibility of one drug influencing the pharmacokinetics of the other must be considered.</sentence>
<sentence>Therefore simultaneous use of <cons lex="rifampin" sem="G_DRUG">rifampin</cons> and <cons lex="praziquantel" sem="G_DRUG">praziquantel</cons> must be avoided in medical practice to optimize the therapeutic efficacy of <cons lex="praziquantel" sem="G_DRUG">praziquantel</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:12386638</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> of inhaled <cons lex="budesonide" sem="G_DRUG" type="substrate_1">budesonide</cons> and its effects on plasma <cons lex="cortisol" sem="G_DRUG">cortisol</cons> are <cons sem="G_CHANGE">increased</cons> by the cytochrome <cons sem="G_CYP">P4503A4</cons> <cons sem="G_MECHANISM">inhibitor</cons> <cons lex="itraconazole" sem="G_DRUG" type="inhibitor">itraconazole</cons>.</sentence>
</title>
<abstract>
<sentence>Our objective was to examine the effects of <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> on the pharmacokinetics and <cons lex="cortisol" sem="G_DRUG">cortisol</cons>-suppressant activity of <cons lex="budesonide" sem="G_DRUG">budesonide</cons> administered by inhalation.</sentence>
<sentence>In a randomized, double-blind, 2-phase crossover study, 10 healthy subjects took <cons sem="G_NUMBER">200 mg</cons> <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> or placebo orally once a day for 5 days.</sentence>
<sentence>On day 5, 1 hour after the last dose of <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> or placebo, <cons sem="G_NUMBER">1000 microg</cons> <cons lex="budesonide" sem="G_DRUG">budesonide</cons> was administered by inhalation.</sentence>
<sentence>Plasma <cons lex="budesonide" sem="G_DRUG">budesonide</cons> and <cons lex="cortisol" sem="G_DRUG">cortisol</cons> concentrations were measured up to 23 hours.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, budesonide, DDI)">
<sentence><cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">Itraconazole</cons> <cons sem="G_CHANGE">increased</cons> the mean total <cons sem="G_IVIVPARA">area under the plasma concentration-time curve</cons> of inhaled <cons lex="budesonide" sem="G_DRUG" type="substrate_1">budesonide</cons> <cons sem="G_NUMBER">4.2-fold (range, 1.7-fold to 9.8-fold; P &lt;.01)</cons> and the <cons sem="G_IVIVPARA">peak plasma concentration</cons> <cons sem="G_NUMBER">1.6-fold (P &lt;.01)</cons> compared with placebo.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, budesonide, DDI)">
<sentence>The mean <cons sem="G_IVIVPARA">terminal half-life</cons> of <cons lex="budesonide" sem="G_DRUG" type="substrate_1">budesonide</cons> was prolonged from <cons sem="G_NUMBER">1.6 to 6.2 hours (ie, 3.7-fold; range, 1.5-fold to 9.3-fold; P &lt;.001)</cons> by <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, budesonide, DDI)">  
<sentence>The <cons sem = "G_MECHANISM">suppression</cons> of <cons lex="cortisol" sem="G_DRUG" type="substrate_2">cortisol</cons> production after inhalation of <cons lex="budesonide" sem="G_DRUG" type="substrate_1">budesonide</cons> was <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">increased</cons> by <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons> as compared with placebo, as shown by a <cons sem="G_NUMBER">43%</cons> <cons sem="G_CHANGE">reduction</cons> in the <cons sem="G_IVIVPARA">area under the plasma <cons lex="cortisol" sem="G_DRUG" type="substrate_2">cortisol</cons> concentration-time curve from 0.5 to 10 hours</cons> (<cons sem="G_NUMBER">P &lt;.001</cons>) and a <cons sem="G_NUMBER">12%</cons> <cons sem="G_CHANGE">decrease</cons> in the <cons lex="cortisol" sem="G_DRUG">cortisol</cons> concentration measured 23 hours after administration of <cons lex="budesonide" sem="G_DRUG">budesonide</cons>, at 8 am (<cons sem="G_NUMBER">P &lt;.05</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, budesonide, DDI)"> 
<sentence><cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">Itraconazole</cons> <cons sem = "G_CHANGE">markedly</cons> <cons sem="G_CHANGE">increased</cons> systemic exposure to inhaled <cons lex="budesonide" sem="G_DRUG" type="substrate_1">budesonide</cons>, <cons sem = "G_CHANGE">probably</cons> by <cons sem="G_MECHANISM">inhibiting</cons> the cytochrome <cons sem="G_CYP">P4503A4</cons>-mediated <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="budesonide" sem="G_DRUG" type="substrate_1">budesonide</cons> during both the first-pass and the elimination phases.</sentence>
</annotation>
<sentence>This interaction resulted in enhanced systemic effects of <cons lex="budesonide" sem="G_DRUG">budesonide</cons>, as shown by <cons sem = "G_MECHANISM">suppression</cons> of <cons lex="cortisol" sem="G_DRUG">cortisol</cons> production.</sentence>
<sentence>Long-term coadministration of <cons lex="budesonide" sem="G_DRUG">budesonide</cons> and a potent <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitor</cons> <cons sem = "G_CHANGE">may</cons> be associated with an <cons sem="G_CHANGE">increased</cons> risk of adverse effects of <cons lex="budesonide" sem="G_DRUG">budesonide</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:12235444</bibliomisc>
</articleinfo>
<title>
<sentence>Evaluation of potential <cons lex="losartan" sem="G_DRUG">losartan</cons>-<cons lex="phenytoin" sem="G_DRUG">phenytoin</cons> drug interactions in healthy volunteers.</sentence>
</title>
<abstract>
<sentence><cons lex="phenytoin" sem="G_DRUG">Phenytoin</cons>, a cytochrome P450 (CYP) <cons lex="2c9" sem="G_CYP">2C9</cons> substrate, has a narrow therapeutic index and nonlinear pharmacokinetics.</sentence>
<sentence>Therefore there is the potential for <cons sem="G_CHANGE">significant</cons> concentration-related adverse effects when <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons> is coadministered with other <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> substrates.</sentence>
<sentence><cons lex="losartan" sem="G_DRUG">Losartan</cons>, an antihypertensive agent, is also a substrate for <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>.</sentence>
<sentence>Our objective was to assess the effects of <cons lex="losartan" sem="G_DRUG">losartan</cons> on the pharmacokinetics of <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons> and the effects of <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons> on the pharmacokinetics of <cons lex="losartan" sem="G_DRUG">losartan</cons> in a healthy population of volunteers.</sentence>
<sentence>A prospective, randomized, 3-period crossover study was conducted in 16 healthy volunteers with <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons> alone, <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons> in combination with <cons lex="losartan" sem="G_DRUG">losartan</cons>, and <cons lex="losartan" sem="G_DRUG">losartan</cons> alone.</sentence>
<sentence>Each treatment was given for 10 days with a 3-week washout period between treatments.</sentence>
<sentence>On day 10, <cons sem="G_IVIVPARA">plasma concentrations</cons> of <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons> and plasma and urine concentrations of <cons lex="losartan" sem="G_DRUG">losartan</cons> and its active carboxylic-acid metabolite <cons lex="losartan" sem="G_DRUG" type="M_1">E3174</cons> were measured to determine steady-state pharmacokinetic parameters.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(losartan, phenytoin, NDDI)">
<sentence>Coadministration of <cons lex="losartan" sem="G_DRUG" type="inhibitor_1">losartan</cons> had <cons sem="G_NEGATIVEEFFECT">no</cons> effect on the pharmacokinetics of <cons lex="phenytoin" sem="G_DRUG" type="substrate_1">phenytoin</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(phenytoin, losartan, ADDI)">    
<sentence>Coadministration of <cons lex="phenytoin" sem="G_DRUG" type="inhibitor_1">phenytoin</cons> <cons sem="G_CHANGE">increased</cons> the mean <cons sem="G_IVIVPARA">area under the concentration-time curve from time zero to 24 hours [AUC(0-24)]</cons> of <cons lex="losartan" sem="G_DRUG" type="substrate_1">losartan</cons> by <cons sem="G_NUMBER">17% (355 +/- 220 ng x h/mL versus 427 +/- 177 ng x h/mL; P =.1)</cons>, but this difference was <cons sem="G_NEGATIVEEFFECT">not</cons> statistically <cons sem="G_CHANGE">significant</cons>.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(phenytoin, losartan, ADDI)">        
<sentence>In the 14 <cons sem="G_CYP">CYP2C9*1/*1</cons> subjects, the mean <cons sem="G_IVIVPARA">AUC(0-24)</cons> of <cons lex="losartan" sem="G_DRUG" type="substrate_1">losartan</cons> was <cons sem="G_CHANGE">increased</cons> by <cons sem="G_NUMBER">29% (284 +/- 84 ng x h/mL versus 402 +/- 128 ng x h/mL; P =.008)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(phenytoin, losartan, DDI)">   
<sentence>Coadministration of <cons lex="phenytoin" sem="G_DRUG" type="inhibitor_1">phenytoin</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">reduced</cons> the <cons sem="G_IVIVPARA">AUC(0-24)</cons> of <cons lex="losartan" sem="G_DRUG" type="M_1">E3174</cons> by <cons sem="G_NUMBER">63% (1254 +/- 256 ng x h/mL versus 466 +/- 174 ng x h/mL; P =.0001)</cons> and the <cons sem="G_MECHANISM">formation</cons> <cons sem="G_IVIVPARA">clearance</cons> of <cons lex="losartan" sem="G_DRUG" type="substrate_1">losartan</cons> to <cons lex="losartan" sem="G_DRUG" type="M_1">E3174</cons> (<cons sem="G_NUMBER">1.91 +/- 0.8 mL/h per kilogram versus 0.62 +/- 0.4 mL/h per kilogram; P =.0001</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Losartan, phenytoin, NDDI)">     
<sentence><cons lex="losartan" sem="G_DRUG" type="inhibitor_1">Losartan</cons>, a <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> substrate, had <cons sem="G_NEGATIVEEFFECT">no</cons> effect on the pharmacokinetics of <cons lex="phenytoin" sem="G_DRUG" type="substrate_1">phenytoin</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(phenytoin, losartan, DDI)">    
<sentence>However, <cons lex="phenytoin" sem="G_DRUG" type="inhibitor_1">phenytoin</cons> <cons sem="G_MECHANISM">inhibited</cons> the <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>-mediated conversion of <cons lex="losartan" sem="G_DRUG" type="substrate_1">losartan</cons> to <cons lex="losartan" sem="G_DRUG" type="M_1">E3174</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:12189360</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of coadministration of <cons lex="nelfinavir" sem="G_DRUG">nelfinavir</cons>, <cons lex="indinavir" sem="G_DRUG">indinavir</cons>, and <cons lex="saquinavir" sem="G_DRUG">saquinavir</cons> on the pharmacokinetics of <cons lex="amprenavir" sem="G_DRUG">amprenavir</cons>.</sentence>
</title>
<abstract>
<sentence>OBJECTIVE: Pharmacokinetic interactions are expected when human immunodeficiency virus (HIV) protease <cons sem="G_MECHANISM">inhibitors</cons> are coadministered because many are both substrates for and <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<sentence>The goal of this model-based pharmacokinetic analysis was to describe the differences observed in <cons lex="amprenavir" sem="G_DRUG">amprenavir</cons> pharmacokinetics among treatment arms in the Adult AIDS Clinical Trial Group (AACTG) study protocol 398 and to propose mechanisms to account for them.</sentence>
<sentence>METHODS: One hundred seventy-six HIV-positive subjects receiving <cons sem="G_NUMBER">1200 mg</cons> <cons lex="amprenavir" sem="G_DRUG">amprenavir</cons> twice daily as part of AACTG protocol 398 were included in the pharmacokinetic study.</sentence>
<sentence>All patients also received background medications <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons>, <cons sem="G_DRUG">adefovir dipivoxil</cons>, and <cons lex="abacavir" sem="G_DRUG">abacavir</cons> and, depending on the study arm, placebo or one of the following protease <cons sem="G_MECHANISM">inhibitors</cons>: <cons lex="nelfinavir" sem="G_DRUG">nelfinavir</cons>, <cons lex="indinavir" sem="G_DRUG">indinavir</cons>, or <cons lex="saquinavir" sem="G_DRUG">saquinavir</cons>.</sentence>
<sentence>A population pharmacokinetic model was fitted to a total of 565 <cons lex="amprenavir" sem="G_DRUG">amprenavir</cons> concentration measurements.</sentence>
<sentence>The blood samples for concentration measurements were drawn at week 2 (12-hour pharmacokinetic study, approximately 7 samples per study; 46 patients) and at week 24 (6-hour pharmacokinetic study, approximately 5 samples per study; 10 patients).</sentence>
<sentence>In addition, samples were collected at 1 or more follow-up visits (population pharmacokinetic study, 1 to 3 occasions per patient; 150 patients).</sentence>
<annotation sem="INVIVOCDDIS" ddi="(nelfinavir, Amprenavir, ADDI)(indinavir, Amprenavir, DDI)(saquinavir, Amprenavir, NDDI)">
<sentence>Results and Conclusion: <cons lex="amprenavir" sem="G_DRUG" type="substrate_1">Amprenavir</cons> intrinsic <cons sem="G_IVIVPARA">clearance</cons> was <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">reduced</cons> relative to placebo by <cons lex="nelfinavir" sem="G_DRUG" type="inhibitor_1">nelfinavir</cons> <cons sem="G_NUMBER">(-41%)</cons> and <cons lex="indinavir" sem="G_DRUG" type="inhibitor_2">indinavir</cons> <cons sem="G_NUMBER">(-54%)</cons> but <cons sem="G_NEGATIVEEFFECT">not</cons> by <cons lex="saquinavir" sem="G_DRUG" type="inhibitor_3">saquinavir</cons>.</sentence>
</annotation>
<sentence>The absolute magnitude of <cons lex="amprenavir" sem="G_DRUG">amprenavir</cons> intrinsic <cons sem="G_IVIVPARA">clearance</cons> suggests that <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibition</cons> by <cons lex="nelfinavir" sem="G_DRUG">nelfinavir</cons> and <cons lex="indinavir" sem="G_DRUG">indinavir</cons> is balanced by enzymatic <cons sem="G_MECHANISM">induction</cons> in the presence of the background drug(s), most likely <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons>.</sentence>
<annotation sem="INVIVOVDDIS" ddi="(nelfinavir, Amprenavir, DDI)">
<sentence><cons lex="amprenavir" sem="G_DRUG" type="substrate_1">Amprenavir</cons> intrinsic <cons sem="G_IVIVPARA">clearance</cons> apparently <cons sem="G_CHANGE">increases</cons> by more than  <cons sem="G_NUMBER">30%</cons> between weeks 2 and 24, possibly because of the time course of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">induction</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:12172343</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_MECHANISM">Inhibition</cons> of <cons lex="risperidone" sem="G_DRUG">risperidone</cons> <cons sem="G_MECHANISM">metabolism</cons> by <cons lex="fluoxetine" sem="G_DRUG">fluoxetine</cons> in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction.</sentence>
</title>
<abstract>
<sentence>The effect of <cons lex="fluoxetine" sem="G_DRUG">fluoxetine</cons> on the <cons sem="G_IVIVPARA">steady-state plasma concentrations</cons> of <cons lex="risperidone" sem="G_DRUG">risperidone</cons> and its active metabolite 9-hydroxyrisperidone (9-OH-<cons lex="risperidone" sem="G_DRUG">risperidone</cons>) was evaluated in 10 patients with schizophrenia or schizoaffective disorder.</sentence>
<sentence>Patients stabilized on <cons lex="risperidone" sem="G_DRUG">risperidone</cons> (<cons sem="G_NUMBER">4-6 mg/day</cons>) received additional <cons lex="fluoxetine" sem="G_DRUG">fluoxetine</cons> (<cons sem="G_NUMBER">20 mg/day</cons>) to treat concomitant depression.</sentence>
<sentence>One patient dropped out after 1 week due to the occurrence of akathisia associated with <cons sem = "G_CHANGE">markedly</cons> <cons sem="G_CHANGE">increased</cons> plasma <cons lex="risperidone" sem="G_DRUG">risperidone</cons> concentrations.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(fluoxetine, risperidone, ADDI)">
<sentence>In the other subjects, mean <cons sem="G_IVIVPARA">plasma concentrations</cons> of <cons lex="risperidone" sem="G_DRUG" type="substrate_1">risperidone</cons> <cons sem="G_CHANGE">increased</cons> during <cons lex="fluoxetine" sem="G_DRUG" type="inhibitor_1">fluoxetine</cons> administration from <cons sem="G_NUMBER">12 +/- 9 ng/mL</cons> at baseline to<cons sem="G_NUMBER"> 56 +/- 31 at week 4 (p &lt; 0.001)</cons>, while the levels of <cons lex="risperidone" sem="G_DRUG" type="M_1">9-OH-risperidone</cons> were <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_MECHANISM">affected</cons>.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(fluoxetine, risperidone, DDI)">
<sentence>After 4 weeks of combined treatment, the levels of the active moiety (sum of the concentrations of <cons lex="risperidone" sem="G_DRUG" type="substrate_1">risperidone</cons> and <cons lex="risperidone" sem="G_DRUG" type="M_1">9-OH-risperidone</cons>) <cons sem="G_CHANGE">increased</cons> by <cons sem="G_NUMBER">75% (range, 9-204%, p &lt; 0.01)</cons> compared with baseline.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(fluoxetine, risperidone, DDI)">  
<sentence>The mean plasma <cons sem="G_DRUG" type="substrate_1">risperidone</cons>/<cons lex="risperidone" sem="G_DRUG" type="M_1">9-OH-risperidone</cons> ratio also <cons sem="G_CHANGE">increased</cons> <cons sem="G_CHANGE">significantly</cons>.</sentence>
</annotation>
<sentence>During the second week of adjunctive therapy, two patients developed Parkinsonian symptoms, which were controlled with anticholinergic medication.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(fluoxetine, risperidone, DDI)"> 
<sentence>These findings indicate that <cons lex="fluoxetine" sem="G_DRUG" type="inhibitor_1">fluoxetine</cons>, a potent <cons sem="G_MECHANISM">inhibitor</cons> of the cytochrome P450 enzyme <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> and a less potent <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, <cons sem = "G_CHANGE">reduces</cons> the <cons sem="G_IVIVPARA">clearance</cons> of <cons lex="risperidone" sem="G_DRUG" type="substrate_1">risperidone</cons> by <cons sem="G_MECHANISM">inhibiting</cons> its 9-hydroxylation or alternative metabolic pathways.</sentence>
</annotation>
<sentence>This interaction <cons sem = "G_CHANGE">may</cons> lead to toxic plasma <cons lex="risperidone" sem="G_DRUG">risperidone</cons> concentrations.</sentence>
<sentence>In addition to careful clinical observation, monitoring plasma <cons lex="risperidone" sem="G_DRUG">risperidone</cons> levels <cons sem = "G_CHANGE">may</cons> be of value in patients given adjunctive therapy with <cons lex="fluoxetine" sem="G_DRUG">fluoxetine</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:12047483</bibliomisc>
</articleinfo>
<title>
<sentence>Single- and multiple-dose pharmacokinetics of <cons lex="bosentan" sem="G_DRUG">bosentan</cons> and its interaction with <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>.</sentence>
</title>
<abstract>
<sentence>The present study was conducted to characterize the single- and multiple-dose pharmacokinetics of <cons lex="bosentan" sem="G_DRUG">bosentan</cons>, a dual endothelin receptor antagonist, and to investigate a possible pharmacokinetic interaction with <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>.</sentence>
<sentence>In a randomized, two-way crossover study, 10 healthy male subjects received treatments A and B. Treatment A consisted of a single dose of <cons sem="G_NUMBER">62.5 mg</cons> <cons lex="bosentan" sem="G_DRUG">bosentan</cons> on day 1 followed by <cons sem="G_NUMBER">62.5 mg</cons> twice daily for 5.5 days.</sentence>
<sentence>Treatment B consisted of <cons lex="bosentan" sem="G_DRUG">bosentan</cons> (<cons sem="G_NUMBER">62.5 mg twice daily</cons>) for 5.5 days plus concomitant <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> (<cons sem="G_NUMBER">200 mg</cons> once daily) for 6 days.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> of <cons lex="bosentan" sem="G_DRUG">bosentan</cons> and its three metabolites were measured on days 1 and 7 of treatment A and on day 6 of treatment B. </sentence>
<sentence><cons lex="bosentan" sem="G_DRUG" type="substrate_1">Bosentan</cons> was absorbed and eliminated with a <cons sem="G_IVIVPARA">tmax</cons> of <cons sem="G_NUMBER">4.5 h (range 3.5-6.0 h)</cons> and a <cons sem="G_IVIVPARA">t(1/2)</cons> of <cons sem="G_NUMBER">5.4 h (95% CI; 4.5, 6.6)</cons>.</sentence>
<sentence>Upon multiple dosing, the exposure to <cons lex="bosentan" sem="G_DRUG">bosentan</cons> was <cons sem="G_CHANGE">reduced</cons> by <cons sem="G_NUMBER">33%</cons> without <cons sem="G_CHANGE">change</cons> in <cons sem="G_IVIVPARA">tmax</cons> and <cons sem="G_IVIVPARA">t(1/2)</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(ketoconazole, Bosentan, DDI)">
<sentence>Concomitant administration of <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">Cmax</cons> and <cons sem="G_IVIVPARA">AUC</cons> of <cons lex="bosentan" sem="G_DRUG" type="substrate_1">bosentan</cons> <cons sem="G_NUMBER">2.1- (95% CI; 1.5, 2.7)</cons> and <cons sem="G_NUMBER">2.3-fold (95% CI; 1.8, 2.9)</cons>, respectively.</sentence>
</annotation>
<sentence>Exposure to the metabolites was low and represented less than <cons sem="G_NUMBER">25%</cons> of that to <cons lex="bosentan" sem="G_DRUG">bosentan</cons> both after single and multiple doses.</sentence>
<annotation sem="INVIVOVDDIS" ddi="(ketoconazole, Bosentan, DDI)">
<sentence>In the presence of <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons>, <cons sem="G_MECHANISM">formation</cons> of the metabolites was <cons sem="G_MECHANISM">inhibited</cons>.</sentence>
</annotation>
<sentence>The multiple-dose pharmacokinetics of <cons lex="bosentan" sem="G_DRUG">bosentan</cons> are consistent with the phenomenon of auto-<cons sem="G_MECHANISM">induction</cons>.</sentence>
<annotation sem="INVIVOVDDIS" ddi="(ketoconazole, Bosentan, DDI)">  
<sentence>In the presence of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitors</cons>, <cons lex="bosentan" sem="G_DRUG" type="substrate_1">bosentan</cons> concentrations <cons sem = "G_CHANGE">may</cons> be <cons sem="G_CHANGE">increased</cons> <cons sem="G_NUMBER">2-fold</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11994058</bibliomisc>
</articleinfo>
<title>
<sentence>The roles of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> and stereoselectivity in the clinical pharmacokinetics of <cons lex="chlorpheniramine" sem="G_DRUG">chlorpheniramine</cons>.</sentence>
</title>
<abstract>
<sentence>To examine the stereoselective disposition of <cons lex="chlorpheniramine" sem="G_DRUG">chlorpheniramine</cons> and to evaluate the role of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> in <cons lex="chlorpheniramine" sem="G_DRUG">chlorpheniramine</cons> pharmacokinetics in humans.</sentence>
<sentence>Eight healthy volunteers (six extensive <cons sem="G_MECHANISM">metabolizers</cons> with respect to <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> and two poor <cons sem="G_MECHANISM">metabolizers</cons>) received a single <cons sem="G_NUMBER">8 mg</cons> oral dose of rac-<cons lex="chlorpheniramine" sem="G_DRUG">chlorpheniramine</cons> either given alone or following administration of <cons lex="quinidine" sem="G_DRUG">quinidine</cons> <cons sem="G_NUMBER">50 mg</cons> every 6 h for 2 days prior to the study day and every 6 h thereafter until the end of the study.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> of (S)-(+)- and (R)-(-)-enantiomers of <cons lex="chlorpheniramine" sem="G_DRUG">chlorpheniramine</cons> were determined using liquid chromatography/mass spectrometry.</sentence>
<sentence>In extensive <cons sem="G_MECHANISM">metabolizers</cons>, mean <cons sem="G_IVIVPARA">Cmax</cons> was <cons sem = "G_CHANGE">greater</cons> (<cons sem="G_NUMBER">12.55+/-1.51 ng ml-1vs 5.38+/-0.44 ng ml-1</cons>) and <cons sem="G_IVIVPARA">CLoral</cons> was lower <cons sem="G_NUMBER">(0.49+/-0.08 l h-1 kg-1vs 1.07+/-0.15 l h-1 kg-1)</cons> for (S)-(+)- than for (R)-(-)-<cons lex="chlorpheniramine" sem="G_DRUG">chlorpheniramine</cons> (<cons sem="G_NUMBER">P&lt;0.005</cons>).</sentence>
<annotation sem="INVIVOCDDIS" ddi="(quinidine, (S)-(-)-chlorpheniramine, DDI)">
<sentence>For <cons lex="chlorpheniramine" sem="G_DRUG" type="substrate_1">(S)-(+)-chlorpheniramine</cons>, administration of <cons lex="quinidine" sem="G_DRUG" type="inhibitor">quinidine</cons>, an <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>, resulted in an <cons sem="G_CHANGE">increase</cons> in <cons sem="G_IVIVPARA">Cmax</cons> to <cons sem="G_NUMBER">13.94+/-1.51 (P&lt;0.01)</cons>, a <cons sem="G_CHANGE">reduction</cons> in <cons sem="G_IVIVPARA">CLoral</cons> to <cons sem="G_NUMBER">0.22+/-0.03 l h-1 kg-1 (P&lt;0.01)</cons>, and a prolongation of <cons sem="G_IVIVPARA">elimination half-life</cons> from <cons sem="G_NUMBER">18.0+/-2.0 h to 29.3+/-2.0 h (P&lt;0.001)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(quinidine, (R)-(-)-chlorpheniramine, DDI)">  
<sentence>Administration of <cons lex="quinidine" sem="G_DRUG" type="inhibitor">quinidine</cons> <cons sem="G_CHANGE"><cons sem="G_CHANGE">decrease</cons>d</cons> <cons sem="G_IVIVPARA">CLoral</cons> for <cons lex="chlorpheniramine" sem="G_DRUG" type="substrate_2">(R)-(-)-chlorpheniramine</cons> to <cons sem="G_NUMBER">0.60+/-0.10 l h-1 kg-1 (P&lt;0.005)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(chlorpheniramine , quinidine , ADDI)">
<sentence>In <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> poor <cons sem="G_MECHANISM">metabolizers</cons>, systemic exposure was <cons sem = "G_CHANGE">greater</cons> after <cons lex="chlorpheniramine" sem="G_DRUG" type="substrate_3">chlorpheniramine</cons> alone than in extensive <cons sem="G_MECHANISM">metabolizers</cons>, and administration of <cons lex="quinidine" sem="G_DRUG" type="inhibitor">quinidine</cons> resulted in a <cons sem="G_CHANGE">slight</cons> <cons sem="G_CHANGE">increase</cons> in <cons sem="G_IVIVPARA">CLoral</cons>.</sentence>
</annotation>
<sentence>Stereoselective elimination of <cons lex="chlorpheniramine" sem="G_DRUG">chlorpheniramine</cons> occurs in humans, with the most pharmacologically active (S)-(+)-enantiomer cleared more slowly than the (R)-(-)-enantiomer.</sentence>
<sentence><cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> plays a role in the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="chlorpheniramine" sem="G_DRUG">chlorpheniramine</cons> in humans.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11966672</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="omeprazole" sem="G_DRUG">Omeprazole</cons> hydroxylation is <cons sem="G_MECHANISM">inhibited</cons> by a single dose of <cons lex="moclobemide" sem="G_DRUG">moclobemide</cons> in homozygotic EM genotype for <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>.</sentence>
</title>
<abstract>
<sentence>The pharmacokinetics of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> and its metabolites in healthy subjects were evaluated to determine if a single dose of <cons lex="moclobemide" sem="G_DRUG">moclobemide</cons> <cons sem="G_MECHANISM">inhibited</cons> <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> activity.</sentence>
<sentence>Sixteen volunteers, of whom eight were extensive <cons sem="G_MECHANISM">metabolizers</cons> (EM) and eight were poor <cons sem="G_MECHANISM">metabolizers</cons> for <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>, participated in two studies.</sentence>
<sentence>Venous blood samples were collected for 24 h after oral ingestion of <cons sem="G_NUMBER">40 mg</cons> <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> with or without <cons sem="G_NUMBER">300 mg</cons> <cons lex="moclobemide" sem="G_DRUG">moclobemide</cons> coadministration.</sentence>
<sentence>The pharmacokinetic <cons sem="G_CHANGE">change</cons> of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons>, <cons lex="omeprazole" sem="G_DRUG" type="M_1">omeprazole sulphone</cons> and <cons lex="omeprazole" sem="G_DRUG" type="M_2">5-hydroxyomeprazole</cons> concentrations were assessed to test for an interaction between <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> and <cons lex="moclobemide" sem="G_DRUG">moclobemide</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(moclobemide, omeprazole, DDI)">
<sentence>The coadministration of <cons lex="moclobemide" sem="G_DRUG" type="inhibitor_1">moclobemide</cons> in EMs approximately <cons sem="G_NUMBER">doubled</cons> the mean <cons sem="G_IVIVPARA">AUC</cons> <cons sem="G_NUMBER">(from 1834 to 3760 ng ml(-1) h)</cons> and <cons sem="G_IVIVPARA">C(max)</cons> <cons sem="G_NUMBER">(from 987 to 1649 ng ml(-1))</cons> of <cons lex="omeprazole" sem="G_DRUG" type="substrate_1">omeprazole</cons>, and <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">AUC</cons> of <cons lex="omeprazole" sem="G_DRUG" type="M_1">omeprazole sulphone</cons> without changing <cons sem="G_IVIVPARA">AUC ratio</cons> of <cons lex="omeprazole" sem="G_DRUG" type="substrate_1">omeprazole</cons> to <cons lex="omeprazole" sem="G_DRUG" type="M_1">omeprazole sulphone</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(moclobemide, omeprazole, DDI)">
<sentence><cons lex="moclobemide" sem="G_DRUG" type="inhibitor_1">Moclobemide</cons> coadministration more than <cons sem="G_NUMBER">doubled</cons> the <cons sem="G_IVIVPARA">AUC ratio</cons> of <cons lex="omeprazole" sem="G_DRUG" type="substrate_1">omeprazole</cons> to <cons lex="omeprazole" sem="G_DRUG" type="M_2">5-hydroxyomeprazole</cons> <cons sem="G_NUMBER">(from 2.5 to 5.3)</cons> in EMs, too.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(moclobemide, omeprazole, DDI)">
<sentence>There was a <cons sem="G_CHANGE">significant</cons> <cons sem="G_CHANGE">decrease</cons> in <cons sem="G_IVIVPARA">Cmax</cons> and <cons sem="G_IVIVPARA">AUC</cons> of <cons lex="omeprazole" sem="G_DRUG" type="M_2">5-hydroxyomeprazole</cons> in PMs but <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_CHANGE">significant</cons> changes were seen in the results for <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> and <cons lex="omeprazole" sem="G_DRUG" type="M_1">omeprazole sulphone</cons> <cons sem="G_IVIVPARA">AUC</cons>s.</sentence>
</annotation>
<sentence>A single dose of <cons lex="moclobemide" sem="G_DRUG">moclobemide</cons> resulted in <cons sem="G_CHANGE">significant</cons> <cons sem = "G_MECHANISM">suppression</cons> of <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> activity in EMs.</sentence>
<sentence>We conclude that physicians prescribing <cons lex="moclobemide" sem="G_DRUG">moclobemide</cons> should pay attention to its pharmacokinetic interactions even on the first day of coadministration with <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> substrates.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11932962</bibliomisc>
</articleinfo>
<title>
<sentence>Influence of <cons lex="fluconazole" sem="G_DRUG">fluconazole</cons> on the pharmacokinetics of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> in healthy volunteers.</sentence>
</title>
<abstract>
<sentence>Influence of <cons lex="fluconazole" sem="G_DRUG">fluconazole</cons> on the pharmacokinetics of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> was evaluated by single oral administration of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> capsule <cons sem="G_NUMBER">20 mg</cons> (control group), or single oral administration of <cons lex="fluconazole" sem="G_DRUG">fluconazole</cons> capsule, <cons sem="G_NUMBER">100 mg</cons>, and <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons>, <cons sem="G_NUMBER">20 mg</cons>, after 4 days of daily oral administration of <cons lex="fluconazole" sem="G_DRUG">fluconazole</cons>, <cons sem="G_NUMBER">100 mg</cons> (treated group), to <cons sem="G_NUMBER">18</cons> healthy male volunteers.</sentence>
<sentence><cons lex="omeprazole" sem="G_DRUG">Omeprazole</cons> is <cons sem="G_CHANGE">extensively</cons> <cons sem = "G_MECHANISM">metabolized</cons> in the liver through 5-hydroxylation and sulfoxidation reactions <cons sem = "G_MECHANISM">catalyzed</cons> predominantly by <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, respectively.</sentence>
<sentence><cons lex="fluconazole" sem="G_DRUG">Fluconazole</cons> is a potent competitive <cons sem = "G_MECHANISM">inhibitor</cons> of <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> and a weak <cons sem = "G_MECHANISM">inhibitor</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<annotation sem="INVIVOVDDIS" ddi="(omeprazole , fluconazole , DDI)">  
<sentence>In treated group, the <cons sem="G_IVIVPARA">area under the plasma concentration-time curve</cons> of <cons lex="omeprazole" sem="G_DRUG" type="substrate_1">omeprazole</cons> from time zero to time infinity (<cons sem="G_IVIVPARA">AUC</cons>) was <cons sem="G_CHANGE">significantly</cons> greater <cons sem="G_NUMBER">(3090 vs 491 ng h/ml)</cons>, <cons sem="G_IVIVPARA">terminal half-life</cons> of <cons lex="omeprazole" sem="G_DRUG" type="substrate_1">omeprazole</cons> was <cons sem="G_CHANGE">significantly</cons> longer (<cons sem="G_NUMBER">2.59 vs 0.85 h</cons>), and <cons sem="G_IVIVPARA">peak plasma concentration</cons> of <cons lex="omeprazole" sem="G_DRUG" type="substrate_1">omeprazole</cons> (<cons sem="G_IVIVPARA">C(max)</cons>) was <cons sem="G_CHANGE">significantly</cons> higher (<cons sem="G_NUMBER">746 vs 311 ng/ml</cons>) than that in control group.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(omeprazole , fluconazole , DDI)">  
<sentence>The <cons sem="G_CHANGE">greater</cons> <cons sem="G_IVIVPARA">AUC</cons> and higher <cons sem="G_IVIVPARA">C(max)</cons> in treated group could be due to <cons sem = "G_MECHANISM">inhibition</cons> of <cons lex="omeprazole" sem="G_DRUG" type="substrate_1">omeprazole</cons> <cons sem="G_MECHANISM">metabolism</cons> by <cons lex="fluconazole" sem="G_DRUG" type="inhibitor_1">fluconazole</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11851636</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem = "G_MECHANISM">Correlation</cons> between <cons lex="midazolam" sem="G_DRUG">midazolam</cons> and <cons lex="lignocaine" sem="G_DRUG">lignocaine</cons> pharmacokinetics and MEGX formation in healthy volunteers.</sentence>
</title>
<abstract>
<sentence>The objectives of the present investigation were: (a) to determine the <cons sem = "G_MECHANISM">correlation</cons> between <cons lex="lignocaine" sem="G_DRUG">lignocaine</cons> and <cons lex="midazolam" sem="G_DRUG">midazolam</cons> pharmacokinetics following intravenous administration in healthy volunteers, (b) to determine the effects of treatment with an <cons sem = "G_MECHANISM">inhibitor</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> (<cons lex="erythromycin" sem="G_DRUG">erythromycin</cons>) on this <cons sem = "G_MECHANISM">correlation</cons> and (c) to assess the precision of the <cons sem="G_DRUG">MEGX</cons>-test as a sole predictor of <cons lex="lignocaine" sem="G_DRUG">lignocaine</cons> and <cons lex="midazolam" sem="G_DRUG">midazolam</cons> pharmacokinetics.</sentence>
<sentence>The study was conducted in <cons sem="G_NUMBER">four</cons> male and <cons sem="G_NUMBER">four</cons> female healthy volunteers, aged between 21 and 26 years, who received <cons sem="G_NUMBER">1 mg kg-1</cons> <cons lex="lignocaine" sem="G_DRUG">lignocaine</cons> HCl i.v. on days 1, 3, 5, 9 and 10 of the investigation.</sentence>
<sentence>On days 5 and 10 they also received <cons lex="midazolam" sem="G_DRUG">midazolam</cons>, <cons sem="G_NUMBER">0.075 mg kg-1 i.v.</cons> and from days 6-10 they took <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> <cons sem="G_NUMBER">500 mg</cons> orally, four times daily.</sentence>
<sentence>Following administration of <cons lex="lignocaine" sem="G_DRUG">lignocaine</cons> and <cons lex="midazolam" sem="G_DRUG">midazolam</cons>, frequent venous blood samples were obtained for determination of the concentrations of <cons lex="lignocaine" sem="G_DRUG">lignocaine</cons>, <cons sem="G_DRUG">MEGX</cons> and <cons lex="midazolam" sem="G_DRUG">midazolam</cons>.</sentence>
<sentence>In the absence of <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> a statistically <cons sem="G_CHANGE">significant</cons> linear <cons sem = "G_MECHANISM">correlation</cons> was observed between the <cons sem="G_IVIVPARA">clearance</cons> of <cons lex="lignocaine" sem="G_DRUG">lignocaine</cons> and <cons lex="midazolam" sem="G_DRUG">midazolam</cons> (<cons sem="G_NUMBER">CL(<cons lex="midazolam" sem="G_DRUG">midazolam</cons>)= 0.41 x CL(<cons lex="lignocaine" sem="G_DRUG">lignocaine</cons>)+ 1.2; r(2) = 0.857; P &lt; 0.001</cons>).</sentence>
<sentence><cons lex="erythromycin" sem="G_DRUG">Erythromycin</cons> cotreatment resulted in a loss of the <cons sem = "G_MECHANISM">correlation</cons> between the two <cons sem="G_IVIVPARA">clearances</cons> (<cons sem="G_NUMBER">r(2) = 0.39; P = 0.1</cons>).</sentence>
<annotation sem="INVIVOCDDIS" ddi="(erythromycin , midazolam   , DDI)">  
<sentence><cons lex="erythromycin" sem="G_DRUG" type="inhibitor_1">Erythromycin</cons> caused a statistically <cons sem="G_CHANGE">significant</cons> <cons sem="G_CHANGE">reduction</cons> in <cons lex="midazolam" sem="G_DRUG" type="substrate_1">midazolam</cons> <cons sem="G_IVIVPARA">clearance</cons> <cons sem="G_NUMBER">from the original value of 3.8 to 2.5 (95% CI for the difference -2.27, -0.35) ml kg-1 min-1</cons>.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(erythromycin , lignocaine , DDI)">  
<sentence>Interestingly there was <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem = "G_CHANGE">significant</cons> <cons sem="G_CHANGE">change</cons> in the <cons sem="G_IVIVPARA">clearance</cons> of <cons lex="lignocaine" sem="G_DRUG">lignocaine</cons> (<cons sem="G_NUMBER">6.4 vs 5.8 (95% CI for the difference -2.74, -1.51) ml kg-1 min-1</cons>).</sentence>
</annotation>
<sentence>Furthermore <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem = "G_MECHANISM">correlation</cons> at all was observed between the <cons sem="G_DRUG">MEGX</cons>-test and <cons lex="lignocaine" sem="G_DRUG">lignocaine</cons> or <cons lex="midazolam" sem="G_DRUG">midazolam</cons> <cons sem="G_IVIVPARA">clearances</cons>.</sentence>
<sentence>Considering the data on day 1, 3 and 5 the intra-individual coefficient of variation in the <cons sem="G_DRUG">MEGX</cons>-test was <cons sem="G_NUMBER">45.3% at 15 min and 23.5% at 30 min</cons>, respectively.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(lignocaine  , midazolam   , DDI)">  
<sentence>It is concluded that there is a <cons sem = "G_CHANGE">significant</cons> <cons sem = "G_MECHANISM">correlation</cons> between <cons lex="lignocaine" sem="G_DRUG" type="substrate_2">lignocaine</cons> and <cons lex="midazolam" sem="G_DRUG" type="substrate_1">midazolam</cons> <cons sem="G_IVIVPARA">clearances</cons> but this <cons sem = "G_MECHANISM">correlation</cons> is lost after <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem = "G_MECHANISM">inhibition</cons> by <cons lex="erythromycin" sem="G_DRUG" type="inhibitor_1">erythromycin</cons>.</sentence>
</annotation>
<sentence>The <cons sem="G_DRUG">MEGX</cons>-test is of <cons sem="G_NEGATIVEEFFECT">no</cons> value in assessing intra- and inter-individual variability in <cons lex="midazolam" sem="G_DRUG">midazolam</cons> <cons sem="G_IVIVPARA">clearance</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11753267</bibliomisc>
</articleinfo>
<title>
<sentence>Different effects of <cons sem="G_DRUG">St John's wort</cons> on the pharmacokinetics of <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> and <cons lex="pravastatin" sem="G_DRUG">pravastatin</cons>.</sentence>
</title>
<abstract>
<sentence><cons sem="G_DRUG">St John's wort</cons>, a widely used herbal product, is an <cons sem = "G_MECHANISM">inducer</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and it <cons sem="G_CHANGE">decreases</cons> blood concentrations of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> substrates.</sentence>
<sentence>The effects of <cons sem="G_DRUG">St John's wort</cons> on the pharmacokinetics of 3-hydroxy-3-methylglutaryl coenzyme A reductase <cons sem = "G_MECHANISM">inhibitors</cons> <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> (an inactive lactone pro-drug) and <cons lex="pravastatin" sem="G_DRUG">pravastatin</cons> were determined in this study.</sentence>
<sentence><cons sem="G_NUMBER">Sixteen</cons> healthy male subjects (<cons sem="G_NUMBER">n = 8</cons> in group 1 and <cons sem="G_NUMBER">n = 8</cons> in group 2) took a <cons sem="G_DRUG">St John's wort</cons> caplet (<cons sem="G_NUMBER">300 mg</cons>) or matching placebo three times a day for 14 days in a double-blind, crossover study.</sentence>
<sentence>On day 14, a single oral dose of <cons sem = "G_NUMBER">10 mg</cons> <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> and <cons sem="G_NUMBER">20 mg</cons> <cons lex="pravastatin" sem="G_DRUG">pravastatin</cons> was given to subjects in group 1 and group 2, respectively.</sentence>
<sentence>Blood samples were obtained during a 24-hour period after the administration of each drug.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(St John's wort  , simvastatin    , DDI)">  
<sentence>Repeated <cons sem="G_DRUG" type="inducer_1">St John's wort</cons> treatment tended to lower plasma <cons lex="simvastatin" sem="G_DRUG" type="substrate_1">simvastatin</cons> concentration and <cons sem = "G_CHANGE">significantly</cons> (<cons sem="G_NUMBER">P &lt;.05</cons>) lowered concentrations of <cons lex="simvastatin" sem="G_DRUG" type="M_1">simvastatin hydroxy acid</cons>, its active metabolite.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(St John's wort  , simvastatin    , DDI)">  
<sentence><cons sem="G_IVIVPARA">The peak concentration in plasma</cons> (ratio, <cons sem="G_NUMBER">0.72 of placebo</cons>) of <cons lex="simvastatin" sem="G_DRUG" type="M_1">simvastatin hydroxy acid</cons> tended to be <cons sem="G_CHANGE">decreased</cons> and its <cons sem="G_IVIVPARA">area under the plasma concentration-time curve between time zero and 24 hours</cons> after administration (ratio, <cons sem="G_NUMBER">0.48 of placebo</cons>) was <cons sem = "G_CHANGE">significantly</cons> <cons sem="G_CHANGE">decreased</cons> (<cons sem="G_NUMBER">P &lt;.05</cons>) by <cons sem="G_DRUG" type="inducer_1">St John's wort</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(St John's wort  , pravastatin     , NDDI)">  
<sentence>On the other hand, <cons sem="G_DRUG" type="inducer_1">St John's wort</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> influence plasma <cons lex="pravastatin" sem="G_DRUG" type="substrate_2">pravastatin</cons> concentration.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(St John's wort  , pravastatin     , NDDI)">  
<sentence><cons sem="G_NEGATIVEEFFECT">No</cons> <cons sem = "G_CHANGE">significant</cons> differences were observed in the <cons sem="G_IVIVPARA">elimination half-life</cons> of <cons lex="simvastatin" sem="G_DRUG" type="substrate_1">simvastatin</cons> or <cons lex="pravastatin" sem="G_DRUG" type="substrate_2">pravastatin</cons> between the placebo and <cons sem="G_DRUG" type="inducer_1">St John's Wort</cons> trials.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(St John's wort  , simvastatin    , DDI)">      
<sentence>This study showed that <cons sem="G_DRUG" type="inhibitor_1">St John's wort</cons> <cons sem="G_CHANGE">decreases</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons> of <cons lex="simvastatin" sem="G_DRUG" type="substrate_1">simvastatin</cons> but <cons sem="G_NEGATIVEEFFECT">not</cons> of <cons lex="pravastatin" sem="G_DRUG" type="substrate_2">pravastatin</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(St John's wort  , simvastatin    , DDI)">     
<sentence>Because <cons lex="simvastatin" sem="G_DRUG" type="substrate_1">simvastatin</cons> is extensively <cons sem = "G_MECHANISM">metabolized</cons> by <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> in the intestinal wall and liver, which are <cons sem = "G_MECHANISM">induced</cons> by <cons sem="G_DRUG" type="inducer_1">St John's wort</cons>, it is likely that this interaction is partly caused by the enhancement of the <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>-mediated first-pass <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="simvastatin" sem="G_DRUG" type="substrate_1">simvastatin</cons> in the small intestine and liver.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11709322</bibliomisc>
</articleinfo>
<title>
<sentence>Pharmacokinetic interactions between <cons lex="nelfinavir" sem="G_DRUG">nelfinavir</cons> and 3-hydroxy-3-methylglutaryl coenzyme A reductase <cons sem="G_MECHANISM">inhibitors</cons> <cons lex="atorvastatin" sem="G_DRUG">atorvastatin</cons> and <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons>.</sentence>
</title>
<abstract>
<sentence>3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase <cons sem="G_MECHANISM">inhibitors</cons> are effective agents in lowering <cons lex="cholesterol" sem="G_DRUG">cholesterol</cons> and <cons sem="G_DRUG">triglycerides</cons> and are being used by human immunodeficiency virus-positive patients to treat the lipid elevation that may be associated with antiretroviral therapy.</sentence>
<sentence>Many HMG-CoA reductase <cons sem="G_MECHANISM">inhibitors</cons> and protease <cons sem="G_MECHANISM">inhibitors</cons> are <cons sem="G_MECHANISM">metabolized</cons> by the same cytochrome P450 enzyme <cons lex="3a4" sem="G_CYP">3A4</cons> (<cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>).</sentence>
<sentence>In addition, many protease <cons sem="G_MECHANISM">inhibitors</cons> are potent <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<sentence>Therefore, coadministration of these two classes of drugs may cause <cons sem="G_CHANGE">significant</cons> drug interactions.</sentence>
<sentence>This open-label, multiple-dose study was performed to determine the interactions between <cons lex="nelfinavir" sem="G_DRUG">nelfinavir</cons>, a protease <cons sem="G_MECHANISM">inhibitor</cons>, and two HMG-CoA reductase <cons sem="G_MECHANISM">inhibitors</cons>, <cons lex="atorvastatin" sem="G_DRUG">atorvastatin</cons> and <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons>, in healthy volunteers.</sentence>
<sentence><cons sem="G_NUMBER">Thirty-two</cons> healthy subjects received either <cons lex="atorvastatin" sem="G_DRUG">atorvastatin</cons> calcium (<cons sem="G_NUMBER">10 mg</cons> once a day) or <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> (<cons sem="G_NUMBER">20 mg</cons> once a day) for the first 14 days of the study.</sentence>
<sentence><cons lex="nelfinavir" sem="G_DRUG">Nelfinavir</cons> (<cons sem="G_NUMBER">1,250 mg</cons> twice a day) was added on days 15 to 28.</sentence>
<sentence>Pharmacokinetic assessment was performed on days 14 and 28.</sentence>
<sentence>The study drugs were well tolerated.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Nelfinavir  , atorvastatin     , DDI)">  
<sentence><cons lex="nelfinavir" sem="G_DRUG" type="inhibitor_1">Nelfinavir</cons> <cons sem = "G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">steady-state area under the plasma concentration-time curve during one dosing period (AUC(tau))</cons> of <cons lex="atorvastatin" sem="G_DRUG" type="substrate_1">atorvastatin</cons> <cons sem="G_NUMBER">74%</cons> and <cons sem="G_IVIVPARA">the maximum concentration (C(max))</cons> of <cons lex="atorvastatin" sem="G_DRUG" type="substrate_1">atorvastatin</cons> <cons sem="G_NUMBER">122%</cons> and <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">AUC(tau)</cons> of <cons lex="simvastatin" sem="G_DRUG" type="substrate_2">simvastatin</cons> <cons sem="G_NUMBER">505%</cons> and the <cons sem="G_IVIVPARA">C(max)</cons> of <cons lex="simvastatin" sem="G_DRUG" type="substrate_2">simvastatin</cons> <cons sem="G_NUMBER">517%</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Nelfinavir  , atorvastatin     , NDDI)">  
<sentence><cons sem="G_NEGATIVEEFFECT">Neither</cons> <cons lex="atorvastatin" sem="G_DRUG" type="inhibitor_2">atorvastatin</cons> nor <cons lex="simvastatin" sem="G_DRUG" type="inhibitor_3">simvastatin</cons> appeared to alter the pharmacokinetics of <cons lex="nelfinavir" sem="G_DRUG" type="substrate_3">nelfinavir</cons>.</sentence>
</annotation>
<sentence>It is recommended that coadministration of <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> with <cons lex="nelfinavir" sem="G_DRUG">nelfinavir</cons> should be avoided, whereas <cons lex="atorvastatin" sem="G_DRUG">atorvastatin</cons> should be used with <cons lex="nelfinavir" sem="G_DRUG">nelfinavir</cons> with caution.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11673750</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons lex="rifampin" sem="G_DRUG">rifampin</cons> and tobacco smoking on the pharmacokinetics of <cons lex="ropivacaine" sem="G_DRUG">ropivacaine</cons>.</sentence>
</title>
<abstract>
<sentence>Our objective was to assess the effect of <cons lex="rifampin" sem="G_DRUG">rifampin</cons> (INN, <cons sem="G_DRUG">rifampicin</cons>) and tobacco smoking on the pharmacokinetics of <cons lex="ropivacaine" sem="G_DRUG">ropivacaine</cons>.</sentence>
<sentence>A randomized, 2-phase, crossover study was performed in both a group of 10 healthy nonsmokers and a group of 8 healthy smokers.</sentence>
<sentence>In both groups each subject ingested daily for 5 days either placebo or <cons sem="G_NUMBER">600 mg</cons> <cons lex="rifampin" sem="G_DRUG">rifampin</cons>.</sentence>
<sentence>On day 6 each subject received intravenously over 30 minutes a single dose of <cons sem="G_NUMBER">0.6 mg/kg</cons> <cons lex="ropivacaine" sem="G_DRUG">ropivacaine</cons>.</sentence>
<sentence><cons lex="ropivacaine" sem="G_DRUG">Ropivacaine</cons>, <cons lex="ropivacaine" sem="G_DRUG" type="M_1">3-hydroxyropivacaine (3-OH-ropivacaine)</cons>, and <cons sem="G_DRUG">(S) -2',6'-pipecoloxylidide (PPX)</cons> in venous plasma and urine were measured for up to 12 hours and 24 hours, respectively.</sentence>
<sentence>Pharmacokinetic parameters were calculated with noncompartmental methods, and t tests were used for comparisons between the phases and between the smokers and nonsmokers.</sentence>
<sentence>The electrocardiogram was monitored for 3 hours.</sentence>
<sentence>There were <cons sem="G_NEGATIVEEFFECT">no</cons> statistically <cons sem="G_CHANGE">significant</cons> differences in <cons sem="G_IVIVPARA">the area under the plasma concentration-time curve (AUC)</cons>, <cons sem="G_IVIVPARA">plasma clearance (CL)</cons>, or <cons sem="G_IVIVPARA">half-life (t(1/2))</cons> of <cons lex="ropivacaine" sem="G_DRUG">ropivacaine</cons> between the smokers and nonsmokers.</sentence>
<sentence>However, smokers excreted in urine <cons sem="G_NUMBER">31%</cons> more <cons lex="ropivacaine" sem="G_DRUG" type="M_1">3-OH-ropivacaine</cons> and <cons sem="G_NUMBER">62%</cons> less <cons lex="ropivacaine" sem="G_DRUG" type="M_2">PPX</cons> than nonsmokers did.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(rifampin  , ropivacaine      , DDI)">  
<sentence><cons lex="rifampin" sem="G_DRUG" type="inducer_1">Rifampin</cons> <cons sem="G_CHANGE">decreased</cons> the <cons sem="G_IVIVPARA">AUC</cons> of <cons lex="ropivacaine" sem="G_DRUG" type="substrate_1">ropivacaine</cons> in nonsmokers by <cons sem="G_NUMBER">52%</cons> and in smokers by <cons sem="G_NUMBER">38%</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rifampin  , ropivacaine      , DDI)">  
<sentence>In nonsmokers <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">CL</cons> of <cons lex="ropivacaine" sem="G_DRUG" type="substrate_1">ropivacaine</cons> by <cons sem="G_NUMBER">93%</cons> and shortened its <cons sem="G_IVIVPARA">t(1/2)</cons> by <cons sem="G_NUMBER">25%</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rifampin  , ropivacaine      , ADDI)">  
<sentence>In smokers <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">CL</cons> of <cons lex="ropivacaine" sem="G_DRUG" type="substrate_1">ropivacaine</cons> by <cons sem="G_NUMBER">47%</cons> and shortened its <cons sem="G_IVIVPARA">t(1/2)</cons> by <cons sem="G_NUMBER">20%</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rifampin  , ropivacaine      , DDI)">  
<sentence><cons lex="rifampin" sem="G_DRUG" type="inducer_1">Rifampin</cons> <cons sem="G_CHANGE">decreased</cons> the urinary excretion of <cons lex="ropivacaine" sem="G_DRUG" type="M_1">3-OH-ropivacaine</cons> in nonsmokers by <cons sem="G_NUMBER">74%</cons> and in smokers by <cons sem="G_NUMBER">68%</cons>, and it <cons sem="G_CHANGE">increased</cons> the excretion of <cons lex="ropivacaine" sem="G_DRUG" type="M_2">PPX</cons> by <cons sem="G_NUMBER">97%</cons> and <cons sem="G_NUMBER">158%,</cons>, respectively.</sentence>
</annotation>
<sentence><cons sem="G_NEGATIVEEFFECT">No</cons> clinically <cons sem="G_CHANGE">significant</cons> differences in the QTc times were found between the groups or treatments.</sentence>
<sentence>Tobacco smoking <cons sem="G_CHANGE">increases</cons> the excretion of <cons lex="ropivacaine" sem="G_DRUG" type="M_1">3-OH-ropivacaine</cons> in urine, probably because of the <cons sem="G_CHANGE">increased</cons> cytochrome P450 (CYP) <cons lex="1a2" sem="G_CYP">1A2</cons>-mediated <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="ropivacaine" sem="G_DRUG">ropivacaine</cons>, and <cons sem="G_CHANGE">decreases</cons> the excretion of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>-formed <cons lex="ropivacaine" sem="G_DRUG" type="M_2">PPX</cons> in urine.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(rifampin  , ropivacaine      , DDI)">  
<sentence><cons lex="rifampin" sem="G_DRUG" type="inducer_1">Rifampin</cons> considerably <cons sem="G_CHANGE">increases</cons> the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="ropivacaine" sem="G_DRUG" type="substrate_1">ropivacaine</cons> to <cons lex="ropivacaine" sem="G_DRUG" type="M_2">PPX</cons> and <cons sem="G_CHANGE">decreases</cons> the <cons sem="G_MECHANISM">metabolism</cons> to <cons lex="ropivacaine" sem="G_DRUG" type="M_1">3-OH-ropivacaine</cons> in both nonsmokers and smokers.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11503008</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="erythromycin" sem="G_DRUG">Erythromycin</cons> <cons sem="G_CHANGE">increases</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons> of <cons sem="G_DRUG">alpha-dihydroergocryptine</cons> in humans.</sentence>
</title>
<abstract>
<sentence>Our objective was to investigate the potential for relevant pharmacotherapeutic interaction between cytochrome P4503A4 (<cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>)-<cons sem="G_MECHANISM">inhibiting</cons> agents such as <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> and the <cons lex="dopamine" sem="G_DRUG">dopamine</cons> agonist <cons sem="G_DRUG">alpha-dihydroergocryptine (DHEC)</cons>.</sentence>
<sentence>The study was carried out as a single-center, controlled, nonblinded, 2-way crossover clinical trial with randomly allocated period-balanced sequences, investigating two treatments of a single oral dose of <cons sem="G_NUMBER">10 mg</cons> <cons sem="G_DRUG">DHEC</cons> (on the morning of day 1), once administered alone (reference), once along with a 4-day treatment (days -2 to 1) of <cons sem="G_NUMBER">500 mg</cons> <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> 3 times daily.</sentence>
<sentence>Periods were separated by a washout of at least 14 days.</sentence>
<sentence><cons sem="G_NUMBER">Nine</cons> healthy white male volunteers, 22 to 42 years old, with a body weight range of <cons sem="G_NUMBER">58 to 90 kg</cons> (body mass index, <cons sem="G_NUMBER">20.2-25.1 kg x m(-2)</cons>) began the study.</sentence>
<sentence>One subject discontinued prematurely, and 8 concluded the study in accordance with the study protocol.</sentence>
<sentence>The plasma and urinary pharmacokinetics of <cons sem="G_DRUG">DHEC</cons> and its metabolites were characterized by a large variability.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(erythromycin  , DHEC , DDI)">  
<sentence>Concomitant treatment with <cons lex="erythromycin" sem="G_DRUG" type="inhibitor_1">erythromycin</cons> led to respective <cons sem="G_CHANGE">increases</cons> of <cons sem="G_NUMBER">9.5 (95% confidence interval  [CI], 6.5 to 13.9)</cons> and <cons sem="G_NUMBER">16.5 (95% CI, 8.7 to 31.5) times</cons> the <cons sem="G_IVIVPARA">maximum observed plasma drug concentration</cons> and <cons sem="G_IVIVPARA">the area under the time course of the plasma concentrations</cons> up to the last quantifiable concentration after dosing of unchanged <cons sem="G_DRUG" type="substrate_1">DHEC</cons> (determined by radioimmunoassay).</sentence>
</annotation>
<sentence>The 24-hour urinary excretion was on average 11 times larger (<cons sem="G_NUMBER">95% CI, 5.9 to 20.7</cons>).</sentence>
<sentence>Qualitatively similar findings were recorded for the total of <cons sem="G_DRUG">DHEC</cons> plus metabolites (as determined by enzyme immunoassay).</sentence>
<sentence>The concomitant use of <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> or similarly <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>-<cons sem="G_MECHANISM">inhibiting</cons> agents along with direct dopaminergic agonists such as the ergoline <cons sem="G_DRUG">DHEC</cons> may cause a clinically relevant <cons sem="G_CHANGE">increase</cons> in pharmacokinetic exposure, which may induce exaggerated dopaminergic effects.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11452245</bibliomisc>
</articleinfo>
<title>
<sentence>The cytochrome <cons sem="G_CYP">P4503A4</cons> <cons sem="G_MECHANISM">inhibitor</cons> <cons lex="clarithromycin" sem="G_DRUG">clarithromycin</cons> <cons sem="G_CHANGE">increases</cons> the <cons sem="G_IVIVPARA">plasma concentrations</cons> and effects of <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons>.</sentence>
</title>
<abstract>
<sentence>Our objective was to study the effects of the macrolide antibiotic <cons lex="clarithromycin" sem="G_DRUG">clarithromycin</cons> on the pharmacokinetics and pharmacodynamics of <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons>, a novel short-acting antidiabetic drug.</sentence>
<sentence>In a randomized, double-blind, 2-phase crossover study, 9 healthy volunteers were treated for 4 days with <cons sem="G_NUMBER">250 mg</cons> oral <cons lex="clarithromycin" sem="G_DRUG">clarithromycin</cons> or placebo twice daily.</sentence>
<sentence>On day 5 they received a single dose of <cons sem="G_NUMBER">250 mg</cons> <cons lex="clarithromycin" sem="G_DRUG">clarithromycin</cons> or placebo, and 1 hour later a single dose of <cons sem="G_NUMBER">0.25 mg</cons> <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons> was given orally.</sentence>
<sentence>Plasma <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons>, serum insulin, and blood glucose concentrations were measured up to 7 hours.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Clarithromycin  ,repaglinide  , ADDI)">  
<sentence><cons lex="clarithromycin" sem="G_DRUG" type="inhibitor_1">Clarithromycin</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">mean total area under the concentration-time curve</cons> of <cons lex="repaglinide" sem="G_DRUG" type="substrate_1">repaglinide</cons> by <cons sem="G_NUMBER">40% (P &lt;.0001)</cons> and <cons sem="G_IVIVPARA">the peak plasma concentration</cons> by <cons sem="G_NUMBER">67% (P &lt;.005)</cons> compared with placebo.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Clarithromycin  ,repaglinide  , DDI)">  
<sentence>The <cons sem="G_IVIVPARA">mean elimination half-life</cons> of <cons lex="repaglinide" sem="G_DRUG" type="substrate_1">repaglinide</cons> was prolonged from <cons sem="G_NUMBER">1.4 to 1.7 hours (P &lt;.05)</cons> by <cons lex="clarithromycin" sem="G_DRUG" type="inhibitor_1">clarithromycin</cons>.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(Clarithromycin  ,repaglinide  , DDI)">  
<sentence><cons lex="clarithromycin" sem="G_DRUG">Clarithromycin</cons> <cons sem="G_CHANGE">increased</cons> <cons sem="G_IVIVPARA">the mean incremental area under the concentration-time curve from 0 to 3 hours</cons> of serum insulin by <cons sem="G_NUMBER">51% (P &lt;.05)</cons> and the maximum <cons sem="G_CHANGE">increase</cons> in the serum insulin concentration by <cons sem="G_NUMBER">61% (P &lt;.01)</cons> compared with placebo.</sentence>
</annotation>
<sentence><cons sem="G_NEGATIVEEFFECT">no</cons> statistically <cons sem="G_CHANGE">significant</cons> differences were found in the blood glucose concentrations between the placebo and <cons lex="clarithromycin" sem="G_DRUG">clarithromycin</cons> phases.</sentence>
<annotation sem="INVIVOVDDIS" ddi="(Clarithromycin  ,repaglinide  , DDI)">  
<sentence>Even low doses of the cytochrome <cons sem="G_CYP">P4503A4 (CYP3A4)</cons> <cons sem="G_MECHANISM">inhibitor</cons> <cons lex="clarithromycin" sem="G_DRUG" type="inhibitor_1">clarithromycin</cons> <cons sem="G_CHANGE">increase</cons> the <cons sem="G_IVIVPARA">plasma concentrations</cons> and effects of <cons lex="repaglinide" sem="G_DRUG" type="substrate_1">repaglinide</cons>.</sentence>
</annotation>
<sentence>Concomitant use of <cons lex="clarithromycin" sem="G_DRUG">clarithromycin</cons> or other potent <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> with <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons> may <cons sem="G_CHANGE">enhance</cons> its blood glucose-lowering effect and <cons sem="G_CHANGE">increase</cons> the risk of hypoglycemia.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11422002</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> on the pharmacokinetics of <cons lex="prednisolone" sem="G_DRUG">prednisolone</cons> and <cons lex="methylprednisolone" sem="G_DRUG">methylprednisolone</cons> and <cons lex="cortisol" sem="G_DRUG">cortisol</cons> secretion in healthy subjects.</sentence>
</title>
<abstract>
<sentence><cons lex="itraconazole" sem="G_DRUG">Itraconazole</cons> is a potent <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity and is often used in combination with <cons sem="G_DRUG">corticosteroids</cons>.</sentence>
<sentence>Since the latter are partly <cons sem="G_MECHANISM">metabolized</cons> by <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, we studied the interaction between <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>, <cons lex="prednisone" sem="G_DRUG">prednisone</cons> and <cons lex="methylprednisolone" sem="G_DRUG">methylprednisolone</cons> in healthy male subjects.</sentence>
<sentence>The effects of 4 days administration of oral <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> (<cons sem="G_NUMBER">400 mg</cons> on the first day then <cons sem="G_NUMBER">200 mg</cons> day-1 for 3 days) on the pharmacokinetics of <cons lex="prednisolone" sem="G_DRUG">prednisolone</cons> after a single oral dose of <cons lex="prednisone" sem="G_DRUG">prednisone</cons> (<cons sem="G_NUMBER">60 mg</cons>) and the pharmacokinetics of <cons lex="methylprednisolone" sem="G_DRUG">methylprednisolone</cons> after single oral dose of <cons lex="methylprednisolone" sem="G_DRUG">methylprednisolone</cons> (<cons sem="G_NUMBER">48 mg</cons>) were studied in 14 healthy male subjects in a two-period cross-over trial.</sentence>
<sentence>Plasma <cons lex="cortisol" sem="G_DRUG">cortisol</cons> concentrations were determined as a pharmacodynamic index.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole  ,methylprednisolone   , DDI)">  
<sentence><cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">Itraconazole</cons> <cons sem="G_CHANGE">increased</cons> <cons sem="G_IVIVPARA">the mean area under the <cons lex="methylprednisolone" sem="G_DRUG" type="substrate_1">methylprednisolone</cons> concentration-time curve</cons> from <cons sem="G_NUMBER">2773 ng ml-1 h to 7011 ng ml-1 h (P &lt; 0.001)</cons> and <cons sem="G_IVIVPARA">the elimination half-life</cons> from <cons sem="G_NUMBER">3.2 h to 5.5 h (P &lt; 0.001)</cons>.</sentence>
</annotation>
<sentence>The pharmacokinetics of <cons lex="prednisolone" sem="G_DRUG">prednisolone</cons> were unchanged.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Cortisol  ,methylprednisolone   , DDI)">  
<sentence><cons lex="cortisol" sem="G_DRUG" type="substrate_2">Cortisol</cons> concentrations at 24 h were lower after administration of <cons lex="methylprednisolone" sem="G_DRUG" type="substrate_1">methylprednisolone</cons> with <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons> than after <cons lex="methylprednisolone" sem="G_DRUG" type="substrate_1">methylprednisolone</cons> alone (<cons sem="G_NUMBER">24 ng ml-1 vs 109 ng ml-1, P &lt; 0.001</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(itraconazole  ,methylprednisolone   , DDI)">  
<sentence><cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">Itraconazole</cons> <cons sem="G_CHANGE">increased</cons> <cons lex="methylprednisolone" sem="G_DRUG" type="substrate_1">methylprednisolone</cons> concentrations <cons sem="G_CHANGE">markedly</cons> with enhanced <cons sem="G_MECHANISM">suppression</cons> of endogenous <cons lex="cortisol" sem="G_DRUG" type="substrate_2">cortisol</cons> secretion, but had <cons sem="G_NEGATIVEEFFECT">no</cons> effect on <cons lex="prednisolone" sem="G_DRUG" type="substrate_3">prednisolone</cons> pharmacokinetics.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(itraconazole  ,methylprednisolone   , DDI)">  
<sentence>The pharmacokinetic interaction between <cons lex="methylprednisolone" sem="G_DRUG" type="substrate_1">methylprednisolone</cons> and <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons> is probably related to <cons sem="G_MECHANISM">inhibition</cons> of hepatic <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity by <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11406737</bibliomisc>
</articleinfo>
<title>
<sentence>Effects of <cons lex="rifampin" sem="G_DRUG">rifampin</cons> on the pharmacokinetics and pharmacodynamics of <cons lex="glyburide" sem="G_DRUG">glyburide</cons> and <cons lex="glipizide" sem="G_DRUG">glipizide</cons>.</sentence>
</title>
<abstract>
<sentence>To study the effects of <cons lex="rifampin" sem="G_DRUG">rifampin</cons> (INN, <cons lex="rifampin" sem="G_DRUG">rifampicin</cons>) on the pharmacokinetics and pharmacodynamics of <cons lex="glyburide" sem="G_DRUG">glyburide</cons> (INN, <cons lex="glibenclamide" sem="G_DRUG">glibenclamide</cons>) and <cons lex="glipizide" sem="G_DRUG">glipizide</cons>, 2 sulfonylurea antidiabetic drugs.</sentence>
<sentence>Two separate, randomized, 2-phase, crossover studies with an identical design were conducted.</sentence>
<sentence>In each study, 10 healthy volunteers received <cons sem="G_NUMBER">600 mg</cons> <cons lex="rifampin" sem="G_DRUG">rifampin</cons> or placebo once daily for 5 days.</sentence>
<sentence>On day 6, a single dose of <cons sem="G_NUMBER">1.75 mg</cons> <cons lex="glyburide" sem="G_DRUG">glyburide</cons> (study I) or <cons sem="G_NUMBER">2.5 mg</cons> <cons lex="glipizide" sem="G_DRUG">glipizide</cons> (study II) was administered orally.</sentence>
<sentence>Plasma <cons lex="glyburide" sem="G_DRUG">glyburide</cons> and <cons lex="glipizide" sem="G_DRUG">glipizide</cons> and blood glucose concentrations were measured for 12 hours.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(rifampin   ,glyburide    , ADDI)">  
<sentence>In study I, <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons> <cons sem="G_CHANGE">decreased</cons> the <cons sem="G_IVIVPARA">area under the plasma concentration--time curve  [AUC(0-infinity)]</cons> of <cons lex="glyburide" sem="G_DRUG" type="substrate_1">glyburide</cons> by <cons sem="G_NUMBER">39% (P &lt;.001)</cons> and the <cons sem="G_IVIVPARA">peak plasma concentration</cons> by <cons sem="G_NUMBER">22% (P =.01)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rifampin   ,glyburide     , ADDI)">  
<sentence>The <cons sem="G_IVIVPARA">elimination half-life</cons> of <cons lex="glyburide" sem="G_DRUG" type="substrate_1">glyburide</cons> was shortened from <cons sem="G_NUMBER">2.0 to 1.7 hours (P &lt;.05)</cons> by <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons>.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(rifampin   ,glyburide     , ADDI)">  
<sentence>The blood glucose decremental <cons sem="G_IVIVPARA">AUC(0-7)</cons> (net area below baseline) and the maximum <cons sem="G_CHANGE">decrease</cons> in the blood glucose concentration were <cons sem="G_CHANGE">decreased</cons> by <cons sem="G_NUMBER">44% (P =.05)</cons> and <cons sem="G_NUMBER">36% (P &lt;.001)</cons>, respectively, by <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rifampin   ,glyburide     , ADDI)">  
<sentence>In study II, <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons> <cons sem="G_CHANGE">decreased</cons> the <cons sem="G_IVIVPARA">AUC(0-infinity)</cons> of <cons lex="glipizide" sem="G_DRUG" type="substrate_1">glipizide</cons> by <cons sem="G_NUMBER">22% (P &lt;.05)</cons> and shortened its <cons sem="G_IVIVPARA">half-life</cons> from <cons sem="G_NUMBER">3.0 to 1.9 hours (P =.01)</cons>.</sentence>
</annotation>
<sentence><cons sem="G_NEGATIVEEFFECT">No</cons> statistically <cons sem="G_CHANGE">significant</cons> differences in the blood glucose concentrations were found between the phases; however, 4 subjects had <cons sem="G_CHANGE">moderate</cons> hypoglycemia during the placebo phase but only 1 subject had moderate hypoglycemia during the <cons lex="rifampin" sem="G_DRUG">rifampin</cons> phase.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(rifampin   ,glyburide     , DDI)">  
<sentence><cons lex="rifampin" sem="G_DRUG" type="inducer_1">Rifampin</cons> <cons sem="G_CHANGE">moderately</cons> <cons sem="G_CHANGE">decreased</cons> the <cons sem="G_IVIVPARA">plasma concentrations</cons> and effects of <cons lex="glyburide" sem="G_DRUG" type="substrate_1">glyburide</cons> but had only a <cons sem="G_CHANGE">slight</cons> effect on <cons lex="glipizide" sem="G_DRUG" type="substrate_1">glipizide</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rifampin   ,glyburide     , DDI)">  
<sentence>The mechanism underlying the interaction between <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons> and <cons lex="glyburide" sem="G_DRUG" type="substrate_1">glyburide</cons> is probably <cons sem="G_MECHANISM">induction</cons> of either <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> or P-glycoprotein or both.</sentence>
</annotation>
<sentence>Induction of <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> would explain the <cons sem="G_CHANGE">increased</cons> systemic elimination of <cons lex="glipizide" sem="G_DRUG">glipizide</cons>.</sentence>
<sentence>It is probable that the blood glucose--lowering effect of <cons lex="glyburide" sem="G_DRUG">glyburide</cons> is <cons sem="G_CHANGE">reduced</cons> during concomitant treatment with <cons lex="rifampin" sem="G_DRUG">rifampin</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(rifampin   ,glyburide     , DDI)">  
<sentence>In some patients, the effects of <cons lex="glipizide" sem="G_DRUG" type="substrate_1">glipizide</cons> may also be <cons sem="G_CHANGE">reduced</cons> by <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11180018</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="rifampin" sem="G_DRUG">Rifampin</cons> greatly <cons sem="G_CHANGE">reduces</cons> plasma <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> and <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> acid concentrations.</sentence>
</title>
<abstract>
<sentence><cons lex="rifampin" sem="G_DRUG">Rifampin (rifampicin)</cons> is a potent <cons sem="G_MECHANISM">inducer</cons> of several cytochrome P450 (CYP) enzymes, including <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<sentence>The <cons lex="cholesterol" sem="G_DRUG">cholesterol</cons>-lowering drug <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> has an extensive first-pass <cons sem="G_MECHANISM">metabolism</cons>, and it is partially <cons sem="G_MECHANISM">metabolized</cons> by <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<sentence>This study was conducted to investigate the effect of <cons lex="rifampin" sem="G_DRUG">rifampin</cons> on the pharmacokinetics of <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons>.</sentence>
<sentence>In a randomized cross-over study with two phases and a washout of 4 weeks, 10 healthy volunteers received a 5-day pretreatment with <cons lex="rifampin" sem="G_DRUG">rifampin</cons> (<cons sem="G_NUMBER">600 mg</cons> daily) or placebo.</sentence>
<sentence>On day 6, a single <cons sem="G_NUMBER">40-mg</cons> dose of <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> was administered orally.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> of <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> and its active metabolite <cons lex="simvastatin" sem="G_DRUG" type="M_1">simvastatin acid</cons> were measured up to 12 hours with a sensitive liquid chromatography-ion spray tandem mass spectrometry method.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(rifampin   ,simvastatin, DDI)">  
<sentence><cons lex="rifampin" sem="G_DRUG" type="inducer_1">Rifampin</cons> <cons sem="G_CHANGE">decreased</cons> <cons sem="G_IVIVPARA">the total area under the plasma concentration-time curve</cons> of <cons lex="simvastatin" sem="G_DRUG" type="substrate_1">simvastatin</cons> and <cons lex="simvastatin" sem="G_DRUG" type="M_1">simvastatin acid</cons> by <cons sem="G_NUMBER">87% (P &lt; .001) and 93% (P &lt; .001)</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rifampin   ,simvastatin, DDI)">  
<sentence>Also the <cons sem="G_IVIVPARA">peak concentrations</cons> of both <cons lex="simvastatin" sem="G_DRUG" type="substrate_1">simvastatin</cons> and <cons lex="simvastatin" sem="G_DRUG" type="M_1">simvastatin acid</cons> were <cons sem="G_CHANGE">reduced greatly</cons> (by <cons sem="G_NUMBER">90%</cons>) by <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons> (<cons sem="G_NUMBER">P &lt; .001</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rifampin   ,simvastatin, NDDI)">  
<sentence>On the other hand, <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons> had <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_CHANGE">significant</cons> effect on the <cons sem="G_IVIVPARA">elimination half-life</cons> of <cons lex="simvastatin" sem="G_DRUG" type="substrate_1">simvastatin</cons> or <cons lex="simvastatin" sem="G_DRUG" type="M_1">simvastatin acid</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rifampin   ,simvastatin, DDI)">  
<sentence><cons lex="rifampin" sem="G_DRUG" type="inducer_1">Rifampin</cons> greatly <cons sem="G_CHANGE">decreases</cons> the <cons sem="G_IVIVPARA">plasma concentrations</cons> of <cons lex="simvastatin" sem="G_DRUG" type="substrate_1">simvastatin</cons> and <cons lex="simvastatin" sem="G_DRUG" type="M_1">simvastatin acid</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rifampin   ,simvastatin, NDDI)">  
<sentence>Because the <cons sem="G_IVIVPARA">elimination half-life</cons> of <cons lex="simvastatin" sem="G_DRUG" type="substrate_1">simvastatin</cons> was <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_MECHANISM">affected</cons> by <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons>, <cons sem="G_MECHANISM">induction</cons> of the <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>-mediated first-pass <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="simvastatin" sem="G_DRUG" type="substrate_1">simvastatin</cons> in the intestine and the liver probably explains this interaction.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(rifampin   ,simvastatin, DDI)">  
<sentence>Concomitant use of potent <cons sem="G_MECHANISM">inducers</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> can lead to a considerably <cons sem="G_CHANGE">reduced</cons> <cons lex="cholesterol" sem="G_DRUG" type="substrate_3">cholesterol</cons>-lowering efficacy of <cons lex="simvastatin" sem="G_DRUG" type="substrate_1">simvastatin</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11103752</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="rifampin" sem="G_DRUG">Rifampin</cons> <cons sem="G_CHANGE">decreases</cons> the <cons sem="G_IVIVPARA">plasma concentrations</cons> and effects of <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons>.</sentence>
</title>
<abstract>
<sentence>To study the effects of <cons lex="rifampin" sem="G_DRUG">rifampin (INN, rifampicin)</cons> on the pharmacokinetics and pharmacodynamics of <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons>, a new short-acting antidiabetic drug.</sentence>
<sentence>In a randomized, two-phase crossover study, nine healthy volunteers were given a 5-day pretreatment with <cons sem="G_NUMBER">600 mg</cons> <cons lex="rifampin" sem="G_DRUG">rifampin</cons> or matched placebo once daily.</sentence>
<sentence>On day 6 a single <cons sem="G_NUMBER">0.5-mg</cons> dose of <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons> was administered.</sentence>
<sentence>Plasma <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons> and blood glucose concentrations were measured up to 7 hours.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(rifampin   ,repaglinide , DDI)">  
<sentence><cons lex="rifampin" sem="G_DRUG" type="inducer_1">Rifampin</cons> <cons sem="G_CHANGE">decreased</cons> the <cons sem="G_IVIVPARA">total area under the concentration-time curve</cons> of <cons lex="repaglinide" sem="G_DRUG" type="substrate_1">repaglinide</cons> by <cons sem="G_NUMBER">57% (P &lt; .001)</cons> and the <cons sem="G_IVIVPARA">peak plasma <cons lex="repaglinide" sem="G_DRUG" type="substrate_1">repaglinide</cons> concentration</cons> by <cons sem="G_NUMBER">41% (P = .001)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(rifampin   ,repaglinide , DDI)">  
<sentence>The <cons sem="G_IVIVPARA">elimination half-life</cons> of <cons lex="repaglinide" sem="G_DRUG" type="substrate_1">repaglinide</cons> was <cons sem="G_CHANGE">shortened</cons> from <cons sem="G_NUMBER">1.5 to 1.1 hours (P &lt; .01)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(rifampin   ,repaglinide , DDI)">  
<sentence>The blood glucose decremental <cons sem="G_IVIVPARA">area under the concentration-time curve from 0 to 3 hours</cons> was <cons sem="G_CHANGE">reduced</cons> from <cons sem="G_NUMBER">0.94 to -0.23 mmol/L x h (P &lt; .05)</cons>, and the maximum <cons sem="G_CHANGE">decrease</cons> in blood glucose concentration from <cons sem="G_NUMBER">1.6 to 1.0 mmol/L (P &lt; .05)</cons> by <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rifampin   ,repaglinide , DDI)">  
<sentence><cons lex="rifampin" sem="G_DRUG" type="inducer_1">Rifampin</cons> considerably <cons sem="G_CHANGE">decreases</cons> the <cons sem="G_IVIVPARA">plasma concentrations</cons> of <cons lex="repaglinide" sem="G_DRUG" type="substrate_1">repaglinide</cons> and also <cons sem="G_CHANGE">reduces</cons> its effects.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(rifampin   ,repaglinide , DDI)">  
<sentence>This interaction is probably caused by <cons sem="G_MECHANISM">induction</cons> of the <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>-mediated <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="repaglinide" sem="G_DRUG" type="substrate_1">repaglinide</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rifampin   ,repaglinide , ADDI)">  
<sentence>It is probable that the effects of <cons lex="repaglinide" sem="G_DRUG" type="substrate_1">repaglinide</cons> are <cons sem="G_CHANGE">decreased</cons> during treatment with <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons> or other potent <cons sem="G_MECHANISM">inducers</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, such as <cons lex="carbamazepine" sem="G_DRUG" type="inducer_2">carbamazepine</cons>, <cons lex="phenytoin" sem="G_DRUG" type="inducer_3">phenytoin</cons>, or <cons sem="G_DRUG" type="inducer_4">St John's wort</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:10626755</bibliomisc>
</articleinfo>
<title>
<sentence>Stereospecific analysis of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> supports <cons lex="artemisinin" sem="G_DRUG">artemisinin</cons> as a potent <cons sem="G_MECHANISM">inducer</cons> of <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>.</sentence>
</title>
<abstract>
<sentence>The purpose of the study was to determine the enantiomer pharmacokinetics of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> and 5-hydroxy-<cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> before and after administration of the antimalarial <cons lex="artemisinin" sem="G_DRUG">artemisinin</cons> to confirm artemisinin's ability to <cons sem="G_MECHANISM">induce</cons> <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>.</sentence>
<sentence><cons sem="G_NUMBER">Nine</cons> healthy male Vietnamese subjects were given a single <cons sem="G_NUMBER">20 mg</cons> dose of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> orally 1 week before (day - 7) <cons lex="artemisinin" sem="G_DRUG">artemisinin</cons> administration.</sentence>
<sentence><cons lex="artemisinin" sem="G_DRUG">Artemisinin</cons> was then given orally (<cons sem="G_NUMBER">500 mg</cons>) for 7 days (days 1-7).</sentence>
<sentence>On days 1 and 7, a single <cons sem="G_NUMBER">20 mg</cons> dose of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> was coadministered with <cons lex="artemisinin" sem="G_DRUG">artemisinin</cons>.</sentence>
<sentence>After a washout period of 6 days, a single <cons sem="G_NUMBER">20 mg</cons> dose of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> was again administered together with a single <cons sem="G_NUMBER">500 mg</cons> of <cons lex="artemisinin" sem="G_DRUG">artemisinin</cons> (day 14).</sentence>
<sentence>Stereoselective pharmacokinetics of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> and 5-hydroxyomeprazole was determined on days of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> administration.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(artemisinin    ,omeprazole  , DDI)">  
<sentence>Seven days of <cons lex="artemisinin" sem="G_DRUG" type="inducer_1">artemisinin</cons> administration <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">decreased</cons> the <cons sem="G_IVIVPARA">AUC</cons> of both <cons lex="omeprazole" sem="G_DRUG" type="substrate_1">omeprazole</cons> enantiomers (day 7), compared with day 1 (<cons sem="G_NUMBER">P &lt; 0.001</cons>).</sentence>
</annotation>
<sentence>All values were normalized after the washout period.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(artemisinin    ,omeprazole  , DDI)">  
<sentence><cons lex="artemisinin" sem="G_DRUG" type="inducer_1">Artemisinin</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">AUC ratio</cons> of <cons lex="omeprazole" sem="G_DRUG" type="M_1">R-5-hydroxyomeprazole</cons>/<cons lex="omeprazole" sem="G_DRUG" type="substrate_2">R-omeprazole</cons> <cons sem="G_CHANGE">significantly</cons> (<cons sem="G_NUMBER">P &lt; 0.01</cons>) on day 7.</sentence>
</annotation>
<sentence>The <cons sem="G_IVIVPARA">AUC ratio</cons> of <cons lex="omeprazole" sem="G_DRUG" type="M_2">omeprazole sulphone</cons>/<cons lex="omeprazole" sem="G_DRUG">S-omeprazole</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> differ between study days.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(artemisinin    ,omeprazole  , DDI)">  
<sentence><cons lex="artemisinin" sem="G_DRUG" type="inducer_1">Artemisinin</cons> <cons sem="G_CHANGE">decreased</cons> the <cons sem="G_IVIVPARA">AUC</cons> of <cons lex="omeprazole" sem="G_DRUG" type="substrate_3">S-omeprazole</cons> to the same extent as that of <cons lex="omeprazole" sem="G_DRUG" type="substrate_2">R-omeprazole</cons> in extensive <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> metabolizers.</sentence>
</annotation>
<sentence>Suggesting that <cons lex="artemisinin" sem="G_DRUG">artemisinin</cons> <cons sem="G_CHANGE">induces</cons> a different enzyme in addition to <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>.</sentence>
<sentence>These results support and strengthen earlier findings that <cons lex="artemisinin" sem="G_DRUG">artemisinin</cons> induces <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> as well as at least one enzyme other than <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:10594487</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons>, <cons lex="disulfiram" sem="G_DRUG">disulfiram</cons>, <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>, grapefruit juice and <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> on the pharmacokinetics of <cons lex="quinidine" sem="G_DRUG">quinidine</cons>.</sentence>
</title>
<abstract>
<sentence>In vitro studies suggest that the oxidation of <cons lex="quinidine" sem="G_DRUG">quinidine</cons> to 3-hydroxyquinidine is a specific marker reaction for <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity.</sentence>
<sentence>To assess the possible use of this reaction as an in vivo marker of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity, we studied the involvement of cytochromes <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> in the in vivo oxidative <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="quinidine" sem="G_DRUG">quinidine</cons>.</sentence>
<sentence>An open study of 30 healthy young male volunteers was performed.</sentence>
<sentence>The pharmacokinetics of a <cons sem="G_NUMBER">200 mg</cons> single oral dose of <cons lex="quinidine" sem="G_DRUG">quinidine</cons> was studied before and during daily administration of <cons sem="G_NUMBER">100 mg</cons> <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons>, a <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> substrate (<cons sem="G_NUMBER">n=6</cons>); <cons sem="G_NUMBER">200 mg</cons> <cons lex="disulfiram" sem="G_DRUG">disulfiram</cons>, an <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> (<cons sem="G_NUMBER">n=6</cons>); <cons sem="G_NUMBER">100 mg</cons> <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>, an <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> (<cons sem="G_NUMBER">n=6</cons>); <cons sem="G_NUMBER">250 ml</cons> single strength <cons sem="G_DRUG">grapefruit juice</cons> twice daily, an <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> (<cons sem="G_NUMBER">n=6</cons>); <cons sem="G_NUMBER">250 mg</cons> of <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> 4 times daily, an <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> (<cons sem="G_NUMBER">n=6</cons>).</sentence>
<sentence>Probes of other enzyme activities, <cons lex="caffeine" sem="G_DRUG">caffeine</cons> (<cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>), <cons sem="G_DRUG">sparteine</cons> (<cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>), <cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons> (<cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>), <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons> (<cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>) and <cons lex="cortisol" sem="G_DRUG">cortisol</cons> (<cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>) were also studied.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(diclofenac    ,quinidine   , ADDI)">   
<sentence>Concomitant administration of <cons lex="diclofenac" sem="G_DRUG" type="inhibitor_1">diclofenac</cons> <cons sem="G_CHANGE">reduced</cons> the <cons sem="G_IVIVPARA">partial clearance</cons> of <cons lex="quinidine" sem="G_DRUG" type="substrate_1">quinidine</cons> by N-oxidation by <cons sem="G_NUMBER">27%</cons>, while <cons sem="G_NEGATIVEEFFECT">no</cons> effect was found for other pharmacokinetic parameters of <cons lex="quinidine" sem="G_DRUG" type="substrate_1">quinidine</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(disulfiram    ,quinidine   , NDDI)">    
<sentence>Concomitant administration of <cons lex="disulfiram" sem="G_DRUG" type="inhibitor_2">disulfiram</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> alter any of the pharmacokinetic parameters of <cons lex="quinidine" sem="G_DRUG" type="substrate_1">quinidine</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(itraconazole   ,quinidine   , DDI)">    
<sentence>Concomitant administration of <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_3">itraconazole</cons> <cons sem="G_CHANGE">reduced</cons> <cons lex="quinidine" sem="G_DRUG" type="substrate_1">quinidine</cons> <cons sem="G_IVIVPARA">total clearance</cons>, <cons sem="G_IVIVPARA">partial clearance</cons> by 3-hydroxylation and <cons sem="G_IVIVPARA">partial clearance</cons> by N-oxidation by <cons sem="G_NUMBER">61</cons>, <cons sem="G_NUMBER">84</cons> and <cons sem="G_NUMBER">73%</cons>, respectively.</sentence>
</annotation>
<sentence>The <cons sem="G_IVIVPARA">renal clearance</cons> was <cons sem="G_CHANGE">reduced</cons> by <cons sem="G_NUMBER">60%</cons> and the <cons sem="G_IVIVPARA">elimination half-life</cons> <cons sem="G_CHANGE">increased</cons> by <cons sem="G_NUMBER">35%</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(grapefruit juice    ,quinidine   , ADDI)">      
<sentence>Concomitant administration of <cons sem="G_DRUG" type="inhibitor_3">grapefruit juice</cons> <cons sem="G_CHANGE">reduced</cons> the <cons sem="G_IVIVPARA">total clearance</cons> of <cons lex="quinidine" sem="G_DRUG" type="substrate_1">quinidine</cons> and its <cons sem="G_IVIVPARA">partial clearance</cons> by 3-hydroxylation and N-oxidation by <cons sem="G_NUMBER">15</cons>, <cons sem="G_NUMBER">19</cons> and <cons sem="G_NUMBER">27%</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(grapefruit juice    ,quinidine   , ADDI)">     
<sentence>The <cons sem="G_IVIVPARA">elimination half-life</cons> of <cons lex="quinidine" sem="G_DRUG" type="substrate_1">quinidine</cons> was <cons sem="G_CHANGE">increased</cons> by <cons sem="G_NUMBER">19%</cons>.</sentence>
</annotation>
<sentence>The <cons lex="caffeine" sem="G_DRUG">caffeine</cons> metabolic index was <cons sem="G_CHANGE">reduced</cons> by <cons sem="G_NUMBER">25%</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(grapefruit juice    ,quinidine   , ADDI)">  
<sentence>Concomitant administration of <cons lex="erythromycin" sem="G_DRUG" type="inhibitor_4">erythromycin</cons> <cons sem="G_CHANGE">reduced</cons> the <cons sem="G_IVIVPARA">total clearance</cons> of <cons lex="quinidine" sem="G_DRUG" type="substrate_1">quinidine</cons> and its <cons sem="G_IVIVPARA">partial clearance</cons> by 3-hydroxylation and N-oxidation by <cons sem="G_NUMBER">34</cons>, <cons sem="G_NUMBER">50</cons> and <cons sem="G_NUMBER">33%</cons>, respectively.</sentence>
</annotation>
<sentence><cons sem="G_IVIVPARA">Cmax</cons> was <cons sem="G_CHANGE">increased</cons> by <cons sem="G_NUMBER">39%</cons>.</sentence>
<sentence>The results confirm an important role for <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> in the oxidation of <cons lex="quinidine" sem="G_DRUG">quinidine</cons> in vivo, and this applies particularly to the formation of 3-hydroxyquinidine.</sentence>
<sentence>While a minor contribution of <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> to the N-oxidation of <cons lex="quinidine" sem="G_DRUG">quinidine</cons> is possible, a major involvement of the <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> or <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> enzymes in the oxidation of <cons lex="quinidine" sem="G_DRUG">quinidine</cons> in vivo is unlikely.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:10583027</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="ketoconazole" sem="G_DRUG">Ketoconazole</cons> inhibits the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="tolterodine" sem="G_DRUG">tolterodine</cons> in subjects with deficient <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> activity.</sentence>
</title>
<abstract>
<sentence>To investigate the pharmacokinetics and safety of <cons lex="tolterodine" sem="G_DRUG">tolterodine</cons> and <cons lex="tolterodine" sem="G_DRUG">tolterodine</cons> metabolites after single-and multiple-dose administration in the absence and presence of <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, an <cons sem="G_MECHANISM">inhibitor</cons> of cytochrome P450 (CYP) <cons lex="3a4" sem="G_CYP">3A4</cons>, in healthy volunteers with deficient <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> activity, i.e. poor metabolisers of <cons lex="debrisoquine" sem="G_DRUG">debrisoquine</cons>.</sentence>
<sentence>Eight healthy volunteers received single oral doses (<cons sem="G_NUMBER">2 mg</cons>) of <cons lex="tolterodine" sem="G_DRUG">tolterodine</cons> l-tartrate.</sentence>
<sentence>Following a wash-out period of about 3 months, six of the subjects participated in a multiple-dose (<cons sem="G_NUMBER">1 mg twice daily</cons>) phase of the study.</sentence>
<sentence><cons lex="ketoconazole" sem="G_DRUG">Ketoconazole</cons> <cons sem="G_NUMBER">200 mg</cons> was given once daily for 4-4.5 days during both the single and multiple dose <cons lex="tolterodine" sem="G_DRUG">tolterodine</cons> administration phases.</sentence>
<sentence>Blood samples were drawn and the pharmacokinetics of <cons lex="tolterodine" sem="G_DRUG">tolterodine</cons> and its metabolites were determined.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(tolterodine ,ketoconazole, DDI)">  
<sentence>A <cons sem="G_CHANGE">decrease</cons> (<cons sem="G_NUMBER">P&lt;0.01</cons>) in <cons sem="G_IVIVPARA">apparent oral clearance</cons> of <cons lex="tolterodine" sem="G_DRUG" type="substrate_1">tolterodine</cons>, from <cons sem="G_NUMBER">10- 12 l h-1 to 4.3-4.7 l h-1</cons>, was obtained during concomitant administration of <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons>, yielding at least a <cons sem="G_NUMBER">two-fold</cons> <cons sem="G_CHANGE">increase</cons> in the <cons sem="G_IVIVPARA">area under the serum concentration-time curve</cons> after single as well as after multiple doses following single dose administration of <cons lex="tolterodine" sem="G_DRUG" type="substrate_1">tolterodine</cons>.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(tolterodine ,ketoconazole, DDI)">  
<sentence>The mean (+/-s.d.) <cons sem="G_IVIVPARA">terminal half-life</cons> <cons sem="G_CHANGE">increased</cons> by <cons sem="G_NUMBER">50%</cons> from <cons sem="G_NUMBER">9.7+/-2.7 h to 15+/-5.4 h</cons> in the presence of <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(tolterodine ,ketoconazole, DDI)">  
<sentence><cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> is the major enzyme involved in the elimination of <cons lex="tolterodine" sem="G_DRUG" type="substrate_1">tolterodine</cons> in individuals with deficient <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> activity (poor metabolisers), since <cons sem="G_IVIVPARA">oral clearance</cons> of <cons lex="tolterodine" sem="G_DRUG" type="substrate_1">tolterodine</cons> <cons sem="G_CHANGE">decreased</cons> by <cons sem="G_NUMBER">60%</cons> during <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> coadministration.</sentence>
</annotation>
<sentence>This <cons sem="G_MECHANISM">inhibition</cons> resulted in <cons sem="G_NUMBER">2.1-fold</cons> <cons sem="G_CHANGE">increase</cons> in <cons sem="G_IVIVPARA">AUC</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:10583026</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="fluoxetine" sem="G_DRUG">Fluoxetine</cons> <cons sem="G_MECHANISM">inhibits</cons> the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="tolterodine" sem="G_DRUG">tolterodine</cons>-pharmacokinetic implications and proposed clinical relevance.</sentence>
</title>
<abstract>
<sentence>To investigate the <cons sem="G_CHANGE">change</cons> in disposition of <cons lex="tolterodine" sem="G_DRUG">tolterodine</cons> during coadministration of the potent cytochrome P450 <cons lex="2d6" sem="G_CYP">2D6 (CYP2D6)</cons> inhibitor <cons lex="fluoxetine" sem="G_DRUG">fluoxetine</cons>.</sentence>
<sentence>Thirteen patients received <cons lex="tolterodine" sem="G_DRUG">tolterodine</cons> l-tartrate <cons sem="G_NUMBER">2 mg</cons> twice daily for 2.5 days, followed by <cons lex="fluoxetine" sem="G_DRUG">fluoxetine</cons> <cons sem="G_NUMBER">20 mg</cons> once daily for 3 weeks and then concomitant administration for an additional 2.5 days.</sentence>
<sentence>They were characterized as extensive metabolizers (EM1 with one functional <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> gene, EM2 with two functional genes) or poor metabolizers (PM).</sentence>
<sentence>Nine patients, three EM2 and four EM1 and two PM, completed the trial.</sentence>
<sentence>Following <cons lex="tolterodine" sem="G_DRUG">tolterodine</cons> administration, the <cons sem="G_IVIVPARA">area under the serum concentration-time curve (AUC)</cons> of <cons lex="tolterodine" sem="G_DRUG">tolterodine</cons> was <cons sem="G_NUMBER">4.4-times</cons> and <cons sem="G_NUMBER">30-times</cons> higher among EM1 and PM, respectively, compared with EM2.</sentence>
<sentence>The <cons sem="G_IVIVPARA">AUC</cons> of the 5-hydroxymethyl metabolite (5-HM) was <cons sem="G_NEGATIVEEFFECT">not</cons> quantifiable in PM.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(fluoxetine  ,tolterodine , DDI)">  
<sentence><cons lex="fluoxetine" sem="G_DRUG" type="inhibitor_1">Fluoxetine</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">decreased</cons> (<cons sem="G_NUMBER">P&lt;0.002</cons>) the <cons sem="G_IVIVPARA">oral clearance</cons> of <cons lex="tolterodine" sem="G_DRUG" type="substrate_1">tolterodine</cons> by <cons sem="G_NUMBER">93%</cons> in EM2 and by <cons sem="G_NUMBER">80%</cons> in EM1.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(fluoxetine  ,tolterodine , DDI)">  
<sentence>The <cons sem="G_IVIVPARA">AUC</cons> of <cons lex="tolterodine" sem="G_DRUG" type="M_1">5-HM</cons> <cons sem="G_CHANGE">increased</cons> in EM2 and <cons sem="G_CHANGE">decreased</cons> in EM1.</sentence>
</annotation>
<sentence>However, the exposure to the active moiety (unbound <cons lex="tolterodine" sem="G_DRUG">tolterodine</cons> +5-HM) was <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">increased</cons> in the two phenotypes.</sentence>
<sentence>The subdivision of the EM group showed a <cons sem="G_NUMBER">2.1-fold</cons> <cons sem="G_CHANGE">increase</cons> in active moiety in EM2 but the exposure was still similar to EM1 compared with before the interaction.</sentence>
<sentence>The study suggests a difference in the pharmacokinetics of <cons lex="tolterodine" sem="G_DRUG">tolterodine</cons> and its 5-hydroxymethyl metabolite depending on the number of functional <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> genes.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(fluoxetine  ,tolterodine , DDI)">  
<sentence><cons lex="fluoxetine" sem="G_DRUG" type="inhibitor_1">Fluoxetine</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_MECHANISM">inhibited</cons> the hydroxylation of <cons lex="tolterodine" sem="G_DRUG" type="substrate_1  ">tolterodine</cons>.</sentence>
</annotation> 
<sentence>Despite the effect on the pharmacokinetics of <cons lex="tolterodine" sem="G_DRUG">tolterodine</cons> in extensive metabolizers, the clinical effect is expected to be within normal variation.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:10579479</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="fluoxetine" sem="G_DRUG">Fluoxetine</cons> impairs the <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>-mediated <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="propafenone" sem="G_DRUG">propafenone</cons> enantiomers in healthy Chinese volunteers.</sentence>
</title>
<abstract>
<sentence>To determine the effect of <cons sem="G_NUMBER">20 mg/day</cons> <cons lex="fluoxetine" sem="G_DRUG">fluoxetine</cons> on the pharmacokinetics of <cons lex="propafenone" sem="G_DRUG">propafenone</cons> enantiomers and <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> activity by phenotyping with <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons>.</sentence>
<sentence><cons sem="G_NUMBER">Nine</cons> healthy Chinese volunteers (seven men and two women) were included in a two-phase study.</sentence>
<sentence><cons lex="dextromethorphan" sem="G_DRUG">Dextromethorphan</cons> (<cons sem="G_NUMBER">20 mg</cons>) was given before and after subjects took <cons sem="G_NUMBER">20 mg/day</cons> <cons lex="fluoxetine" sem="G_DRUG">fluoxetine</cons> for 10 days, and the <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons> metabolic ratio was calculated to determine <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> phenotype.</sentence>
<sentence>Pharmacokinetic studies of <cons lex="propafenone" sem="G_DRUG">propafenone</cons> enantiomers after a single oral <cons sem="G_NUMBER">400 mg</cons> dose before and after pretreatment with <cons sem="G_NUMBER">20 mg/day</cons> <cons lex="fluoxetine" sem="G_DRUG">fluoxetine</cons> for 10 days were also conducted in these subjects.</sentence>
<sentence>Reversed-phase HPLC with precolumn derivatization was used to determine enantiomeric concentrations of <cons lex="propafenone" sem="G_DRUG">propafenone</cons> in plasma.</sentence>
<sentence>Mean <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons> metabolic ratios before and after <cons lex="fluoxetine" sem="G_DRUG">fluoxetine</cons> therapy were <cons sem="G_NUMBER">0.028 +/- 0.031 and 0.080 +/- 0.058</cons>, respectively (<cons sem="G_NUMBER">P = .001</cons>), indicating that a strong <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> by <cons lex="fluoxetine" sem="G_DRUG">fluoxetine</cons> activity was observed in Chinese subjects.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(fluoxetine   ,Propafenone  , DDI)">  
<sentence><cons lex="propafenone" sem="G_DRUG" type="substrate_1">Propafenone</cons> <cons sem="G_MECHANISM">metabolism</cons> was also impaired <cons sem="G_CHANGE">significantly</cons> after <cons lex="fluoxetine" sem="G_DRUG" type="inhibitor_1">fluoxetine</cons> treatment.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(fluoxetine   ,Propafenone  , DDI)">  
<sentence>The <cons sem="G_IVIVPARA">elimination half-life</cons>, <cons sem="G_IVIVPARA">peak concentration</cons>, and <cons sem="G_IVIVPARA">area under the curve from 0 hours to infinity</cons> of two enantiomers after <cons lex="fluoxetine" sem="G_DRUG" type="inhibitor_1">fluoxetine</cons> therapy were <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">increased</cons> compared with those at baseline (<cons sem="G_NUMBER">P &lt; .01</cons>), whereas <cons sem="G_IVIVPARA">oral clearance</cons> <cons sem="G_CHANGE">decreased</cons> from <cons sem="G_NUMBER">75.01 +/- 17.69 L/h to 49.36 +/- 8.62 L/h</cons> for <cons lex="propafenone" sem="G_DRUG" type="substrate_2">S-propafenone</cons> (<cons sem="G_NUMBER">P = .005</cons>) and from <cons sem="G_NUMBER">107.62 +/- 33.82 L/h to 70.60 +/- 12.42 L/h</cons> for <cons lex="propafenone" sem="G_DRUG" type="substrate_3">R-propafenone</cons> (<cons sem="G_NUMBER">P = .027</cons>).</sentence>
</annotation>   
<annotation sem="INVIVOCDDIS" ddi="(fluoxetine   ,Propafenone  , ADDI)">  
<sentence>In addition, <cons lex="fluoxetine" sem="G_DRUG" type="inhibitor">fluoxetine</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">peak concentration</cons> of <cons lex="propafenone" sem="G_DRUG" type="substrate_2">S-propafenone</cons> by <cons sem="G_NUMBER">39%</cons> and that of <cons lex="propafenone" sem="G_DRUG" type="substrate_3">R-propafenone</cons> by <cons sem="G_NUMBER">71% (P &lt; .05)</cons>.</sentence>
</annotation>   
<annotation sem="INVIVOCDDIS" ddi="(fluoxetine   ,Propafenone  , ADDI)">  
<sentence>A <cons sem="G_CHANGE">significant</cons> <cons sem="G_CHANGE">increase</cons> of the time to reach <cons sem="G_IVIVPARA">peak concentration</cons> was observed only in the R-enantiomer and <cons sem="G_NEGATIVEEFFECT">not</cons> in the S-enantiomer of <cons lex="propafenone" sem="G_DRUG" type="substrate_1">propafenone</cons> after <cons lex="fluoxetine" sem="G_DRUG" type="inhibitor_1">fluoxetine</cons> therapy.</sentence>
</annotation>    
<sentence>There were <cons sem="G_NEGATIVEEFFECT">no</cons> differences in the percentage changes of PR and QRS intervals before or after <cons lex="fluoxetine" sem="G_DRUG">fluoxetine</cons> pretreatment at the time observed (<cons sem="G_NUMBER">P &gt; .05</cons>).</sentence>
<annotation sem="INVIVOCDDIS" ddi="(fluoxetine   ,dextromethorphan  , DDI)">  
<sentence>We conclude that <cons lex="fluoxetine" sem="G_DRUG" type="inhibitor_1">fluoxetine</cons> may cause <cons sem="G_CHANGE">significant</cons> <cons sem="G_MECHANISM">inhibition</cons> of the <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> activity as determined by <cons lex="dextromethorphan" sem="G_DRUG" type="substrate_4">dextromethorphan</cons> phenotyping.</sentence>
</annotation>    
<sentence>This <cons sem="G_MECHANISM">inhibition</cons> impairs the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="propafenone" sem="G_DRUG">propafenone</cons> enantiomers in Chinese subjects.</sentence>
<sentence>Caution must be exercised when <cons lex="fluoxetine" sem="G_DRUG">fluoxetine</cons> and <cons lex="propafenone" sem="G_DRUG">propafenone</cons> are coadministered to avoid potential toxicity.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:10579472</bibliomisc>
</articleinfo>
<title>
<sentence>The roles of cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4</cons> and <cons lex="1a2" sem="G_CYP">1A2</cons> in the 3-hydroxylation of <cons lex="quinine" sem="G_DRUG">quinine</cons> in vivo.</sentence>
</title>
<abstract>
<sentence>To investigate the roles of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> in the 3-hydroxylation of <cons lex="quinine" sem="G_DRUG">quinine</cons> in vivo.</sentence>
<sentence>In a randomized, three-way crossover study, <cons sem="G_NUMBER">nine</cons> healthy Swedish volunteers received single oral doses of <cons lex="quinine" sem="G_DRUG">quinine</cons> hydrochloride (<cons sem="G_NUMBER">500 mg</cons>), <cons lex="quinine" sem="G_DRUG">quinine</cons> hydrochloride (<cons sem="G_NUMBER">500 mg</cons>) plus <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> (<cons sem="G_NUMBER">100 mg</cons> twice daily for 3 days), and <cons lex="quinine" sem="G_DRUG">quinine</cons> hydrochloride (<cons sem="G_NUMBER">500 mg</cons>) plus <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> (<cons sem="G_NUMBER">25 mg</cons> twice daily for 2 days) on three different occasions.</sentence>
<sentence>Blood and urine samples were collected before <cons lex="quinine" sem="G_DRUG">quinine</cons> intake and up to 96 hours thereafter.</sentence>
<sentence>Plasma and urine samples were analyzed for both <cons lex="quinine" sem="G_DRUG">quinine</cons> and its main metabolite <cons lex="quinine" sem="G_DRUG" type="M_1">3-hydroxyquinine</cons> with HPLC methods.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(ketoconazole    ,quinine   , ADDI)(fluvoxamine     ,quinine   , NDDI)"> 
<sentence>Coadministration with <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> (which <cons sem="G_MECHANISM">inhibits</cons> <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>) <cons sem="G_CHANGE">decreased</cons> the <cons sem="G_IVIVPARA">mean apparent oral clearance</cons> of <cons lex="quinine" sem="G_DRUG" type="substrate_1">quinine</cons> <cons sem="G_CHANGE">significantly</cons> (<cons sem="G_NUMBER">P &lt; .001</cons>) by <cons sem="G_NUMBER">31% (from 8.7 to 6.0 L/h)</cons>, whereas coadministration with <cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_2">fluvoxamine</cons> (which <cons sem="G_MECHANISM">inhibits</cons> <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> and to some extent <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>) had <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_CHANGE">significant</cons> effect (<cons sem="G_NUMBER">P &gt; .05</cons>) on the <cons sem="G_IVIVPARA">mean apparent oral clearance</cons> of <cons lex="quinine" sem="G_DRUG" type="substrate_1">quinine</cons>.</sentence>
</annotation>   
<annotation sem="INVIVOCDDIS" ddi="(ketoconazole    ,quinine   , ADDI)"> 
<sentence>Coadministration with <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> also <cons sem="G_CHANGE">decreased</cons> the <cons sem="G_IVIVPARA">mean area under the plasma concentration versus time curve (AUC)</cons> of <cons lex="quinine" sem="G_DRUG" type="M_1">3-hydroxyquinine</cons> (from <cons sem="G_NUMBER">28.4 to 19.7 micromol x h x L(-1); P &lt; .001</cons>), whereas coadministration with <cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_2">fluvoxamine</cons> <cons sem="G_CHANGE">increased</cons> <cons lex="quinine" sem="G_DRUG" type="M_1">3-hydroxyquinine</cons> <cons sem="G_IVIVPARA">AUC</cons> <cons sem="G_CHANGE">significantly</cons> (from <cons sem="G_NUMBER">28.4 to 30.2 micromol x h x L(-1); P &lt; .05</cons>).</sentence>
</annotation>   
<sentence>Cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4</cons> is important for the 3-hydroxylation of <cons lex="quinine" sem="G_DRUG">quinine</cons> in vivo.</sentence>
<sentence>On the other hand, <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> had <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_CHANGE">significant</cons> effect on this metabolic pathway.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9390107</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="itraconazole" sem="G_DRUG">Itraconazole</cons> <cons sem="G_CHANGE">increases</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons> of <cons lex="quinidine" sem="G_DRUG">quinidine</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="quinidine" sem="G_DRUG">Quinidine</cons> is eliminated mainly by <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>-mediated <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
<sentence><cons lex="itraconazole" sem="G_DRUG">Itraconazole</cons> interacts with some but <cons sem="G_NEGATIVEEFFECT">not</cons> all of the substrates of <cons sem="G_CYP">CYP3A4</cons>; it is therefore important to study the possible interaction of <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> with <cons lex="quinidine" sem="G_DRUG">quinidine</cons>.</sentence>
<sentence>A double-blind, randomized, two-phase crossover study design was used with <cons sem="G_NUMBER">nine</cons> healthy volunteers.</sentence>
<sentence><cons lex="itraconazole" sem="G_DRUG">Itraconazole</cons> (<cons sem="G_NUMBER">200 mg</cons>) or placebo was ingested once a day for 4 days.</sentence>
<sentence>A single <cons sem="G_NUMBER">100 mg</cons> oral dose of <cons lex="quinidine" sem="G_DRUG">quinidine</cons> sulfate was ingested on day 4.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> of <cons lex="quinidine" sem="G_DRUG">quinidine</cons>, <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>, and hydroxyitraconazole, as well as cumulative excretion of <cons lex="quinidine" sem="G_DRUG">quinidine</cons> into urine, were determined up to 24 hours.</sentence>
<sentence>The ECG, heart rate, and blood pressure were also recorded up to 24 hours.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(itraconazole     ,quinidine    , DDI)"> 
<sentence>On average the <cons sem="G_IVIVPARA">peak plasma concentration</cons> of <cons lex="quinidine" sem="G_DRUG" type="substrate_1">quinidine</cons> <cons sem="G_CHANGE">increased</cons> to <cons sem="G_NUMBER">1.6-fold (p &lt; 0.05)</cons>, and the <cons sem="G_IVIVPARA">area under the concentration-time curve</cons> of <cons lex="quinidine" sem="G_DRUG" type="substrate_1">quinidine</cons> <cons sem="G_CHANGE">increased</cons> to <cons sem="G_NUMBER">2.4-fold (p &lt; 0.01)</cons> by <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons>.</sentence>
</annotation>  
<annotation sem="INVIVOCDDIS" ddi="(itraconazole     ,quinidine    , DDI)"> 
<sentence>The <cons sem="G_IVIVPARA">elimination half-life</cons> of <cons lex="quinidine" sem="G_DRUG" type="substrate_1">quinidine</cons> was prolonged <cons sem="G_NUMBER">1.6-fold (p &lt; 0.001)</cons>, and <cons sem="G_IVIVPARA">the area under the <cons lex="quinidine" sem="G_DRUG" type="M_1">3-hydroxyquinidine</cons>/<cons lex="quinidine" sem="G_DRUG" type="substrate_1">quinidine</cons> ratio-time curve</cons> <cons sem="G_CHANGE">decreased</cons> to <cons sem="G_NUMBER">one-fifth (p &lt; 0.001)</cons> by <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons>.</sentence>
</annotation>  
<annotation sem="INVIVOCDDIS" ddi="(itraconazole     ,quinidine    , DDI)"> 
<sentence>The <cons sem="G_IVIVPARA">renal clearance</cons> of <cons lex="quinidine" sem="G_DRUG" type="substrate_1">quinidine</cons> <cons sem="G_CHANGE">decreased</cons> <cons sem="G_NUMBER">50% (p &lt; 0.001)</cons> by <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons>, whereas the <cons sem="G_DRUG" type="substrate_2">creatinine</cons> <cons sem="G_IVIVPARA">clearance</cons> was <cons sem="G_MECHANISM">unaffected</cons>.</sentence>
</annotation>  
<sentence>The QTc interval correlated with the concentrations of <cons lex="quinidine" sem="G_DRUG">quinidine</cons> during both <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> and placebo phases (<cons sem="G_NUMBER">r2 = 0.71 and r2 = 0.79, respectively; p &lt; 0.01</cons>), although only minor <cons sem="G_CHANGE">changes</cons> between the phases were observed in other pharmacodynamic variables.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(itraconazole     ,quinidine    , DDI)"> 
<sentence><cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">Itraconazole</cons> <cons sem="G_CHANGE">increases</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons> of oral <cons lex="quinidine" sem="G_DRUG" type="substrate_1">quinidine</cons>, probably by <cons sem="G_MECHANISM">inhibiting</cons> the <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> isozyme during the first-pass and elimination phases of <cons lex="quinidine" sem="G_DRUG" type="substrate_1">quinidine</cons>.</sentence>
</annotation>  
<annotation sem="INVIVOCDDIS" ddi="(itraconazole     ,quinidine    , DDI)"> 
<sentence>The <cons sem="G_CHANGE">decreased</cons> renal <cons sem="G_IVIVPARA">clearance</cons> of <cons lex="quinidine" sem="G_DRUG" type="substrate_1">quinidine</cons> might be the result of the <cons sem="G_MECHANISM">inhibition</cons> of <cons sem="G_CYP">P-glycoprotein</cons>-mediated tubular secretion of <cons lex="quinidine" sem="G_DRUG" type="substrate_1">quinidine</cons> by <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons>.</sentence>
</annotation>  
<sentence>The concentrations of <cons lex="quinidine" sem="G_DRUG">quinidine</cons> should be closely monitored if <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> or some other potent <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> <cons sem="G_IVIVPARA">inhibitors</cons> are used with <cons lex="quinidine" sem="G_DRUG">quinidine</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9333111</bibliomisc>
</articleinfo>
<title>
<sentence>Plasma <cons lex="buspirone" sem="G_DRUG">buspirone</cons> concentrations are <cons sem="G_CHANGE">greatly</cons> <cons sem="G_CHANGE">increased</cons> by <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> and <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>.</sentence>
</title>
<abstract>
<sentence>The <cons sem="G_IVIVPARA">oral bioavailability</cons> of <cons lex="buspirone" sem="G_DRUG">buspirone</cons> is very low as a result of extensive first-pass <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
<sentence><cons lex="erythromycin" sem="G_DRUG">Erythromycin</cons> and <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> are potent <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, and they <cons sem="G_CHANGE">increase</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons> and effects of certain drugs, for example, oral <cons lex="midazolam" sem="G_DRUG">midazolam</cons> and <cons lex="triazolam" sem="G_DRUG">triazolam</cons>.</sentence>
<sentence>The possible interactions of <cons lex="buspirone" sem="G_DRUG">buspirone</cons> with <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> and <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> have <cons sem="G_NEGATIVEEFFECT">not</cons> been studied before.</sentence>
<sentence>The pharmacokinetics and pharmacodynamics of <cons lex="buspirone" sem="G_DRUG">buspirone</cons> were investigated in a randomized, double-blind, double-dummy crossover study with three phases.</sentence>
<sentence>Eight young healthy volunteers took either <cons sem="G_NUMBER">1.5 gm/day</cons> <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons>, <cons sem="G_NUMBER">200 mg/day</cons> <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>, or placebo orally for 4 days.</sentence>
<sentence>On day 4, <cons sem="G_NUMBER">10 mg</cons> <cons lex="buspirone" sem="G_DRUG">buspirone</cons> was administered orally.</sentence>
<sentence>Timed blood samples were collected up to 18 hours, and the effects of <cons lex="buspirone" sem="G_DRUG">buspirone</cons> were measured with four psychomotor tests up to 8 hours.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(erythromycin,buspirone, DDI)(itraconazole ,buspirone, DDI)"> 
<sentence><cons lex="erythromycin" sem="G_DRUG" type="inhibitor_1">Erythromycin</cons> and <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_2">itraconazole</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">mean area under the plasma concentration-time curve from time zero to infinity  [AUC(0-infinity]</cons> of <cons lex="buspirone" sem="G_DRUG" type="substrate_1">buspirone</cons> about <cons sem="G_NUMBER">sixfold (p &lt; 0.05)</cons> and <cons sem="G_NUMBER">19-fold (p &lt; 0.01)</cons>, respectively, compared with placebo.</sentence>
</annotation>  
<annotation sem="INVIVOCDDIS" ddi="(erythromycin,buspirone, DDI)(itraconazole ,buspirone, DDI)"> 
<sentence>The <cons sem="G_IVIVPARA">mean peak plasma concentration (Cmax)</cons> of <cons lex="buspirone" sem="G_DRUG" type="substrate_1">buspirone</cons> was <cons sem="G_CHANGE">increased</cons> about <cons sem="G_NUMBER">fivefold (p &lt; 0.01)</cons> and <cons sem="G_NUMBER">13-fold (p &lt; 0.01)</cons> by <cons lex="erythromycin" sem="G_DRUG" type="inhibitor_1">erythromycin</cons> and <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_2">itraconazole</cons>, respectively.</sentence>
</annotation>  
<sentence>These interactions were evident in each subject, although a striking interindividual variability in the extent of both interactions was observed.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(erythromycin,buspirone, NDDI)(itraconazole ,buspirone, NDDI)"> 
<sentence>The <cons sem="G_IVIVPARA">elimination half-life</cons> of <cons lex="buspirone" sem="G_DRUG" type="substrate_1">buspirone</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> seem to be prolonged by either <cons lex="erythromycin" sem="G_DRUG" type="inhibitor_1">erythromycin</cons> or <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_2">itraconazole</cons>.</sentence>
</annotation>  
<sentence>The effect of <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> on the <cons sem="G_IVIVPARA">Cmax</cons> and <cons sem="G_IVIVPARA">AUC(0-infinity)</cons> of <cons lex="buspirone" sem="G_DRUG">buspirone</cons> was <cons sem="G_CHANGE">significantly</cons> (<cons sem="G_NUMBER">p &lt; 0.01</cons>) greater than that of <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons>.</sentence>
<sentence>The greatly elevated plasma <cons lex="buspirone" sem="G_DRUG">buspirone</cons> concentrations resulted in <cons sem="G_CHANGE">increased</cons> (<cons sem="G_NUMBER">p &lt; 0.05</cons>) pharmacodynamic effects (as measured by the Digit Symbol Substitution test and the Critical Flicker Fusion test) and in side effects of <cons lex="buspirone" sem="G_DRUG">buspirone</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(erythromycin,buspirone, DDI)(itraconazole ,buspirone, DDI)"> 
<sentence>Both <cons lex="erythromycin" sem="G_DRUG" type="inhibitor_1">erythromycin</cons> and <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_2">itraconazole</cons> <cons sem="G_CHANGE">greatly</cons> <cons sem="G_CHANGE">increased</cons> <cons sem="G_IVIVPARA">plasma <cons lex="buspirone" sem="G_DRUG" type="substrate_1">buspirone</cons> concentrations</cons>, obviously by <cons sem="G_MECHANISM">inhibiting</cons> its <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>-mediated first-pass <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
</annotation>  
<sentence>These pharmacokinetic interactions were accompanied by impairment of psychomotor performance and side effects of <cons lex="buspirone" sem="G_DRUG">buspirone</cons>.</sentence>
<sentence>The dose of <cons lex="buspirone" sem="G_DRUG">buspirone</cons> should be <cons sem="G_CHANGE">greatly</cons> <cons sem="G_CHANGE">reduced</cons> during concomitant treatment with <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons>, <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>, or other potent <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9333103</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="fluvoxamine" sem="G_DRUG">Fluvoxamine</cons> <cons sem="G_MECHANISM">inhibits</cons> the <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>-catalyzed bioactivation of <cons sem="G_DRUG">chloroguanide</cons>.</sentence>
</title>
<abstract>
<sentence>To investigate the interaction between <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> and <cons sem="G_DRUG">chloroguanide (INN, <cons lex="proguanil" sem="G_DRUG">proguanil</cons>)</cons> to confirm that <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> <cons sem="G_MECHANISM">inhibits</cons> <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>.</sentence>
<sentence>The study was carried out with a randomized, in vivo, crossover design.</sentence>
<sentence><cons sem="G_NUMBER">Six</cons> volunteers were extensive metabolizers of the S-<cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons> oxidation polymorphism, and <cons sem="G_NUMBER">six</cons> volunteers were poor metabolizers.</sentence>
<sentence>In period A of the study, each subject took <cons sem="G_NUMBER">200 mg</cons> <cons sem="G_DRUG">chloroguanide</cons> orally.</sentence>
<sentence>In period B, each subject took <cons sem="G_NUMBER">100 mg/day</cons> <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> for 8 days and on day 6 ingested <cons sem="G_NUMBER">200 mg</cons> <cons sem="G_DRUG">chloroguanide</cons>.</sentence>
<sentence>In both periods, blood and urine were sampled at regular intervals.</sentence>
<sentence><cons sem="G_DRUG">Chloroguanide</cons> and its two metabolites <cons lex="chloroguanide" sem="G_DRUG" type="M_1">cycloguanil</cons> and <cons lex="chloroguanide" sem="G_DRUG" type="M_2">4-chlorphenylbiguanide</cons> in plasma and in urine were assayed by means of HPLC.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(fluvoxamine  ,chloroguanide     , DDI)"> 
<sentence>During <cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">fluvoxamine</cons> use, the median of the <cons sem="G_IVIVPARA">total clearance</cons> of <cons sem="G_DRUG" type="substrate_1">chloroguanide</cons> <cons sem="G_CHANGE">decreased</cons> in a statistically <cons sem="G_CHANGE">significant</cons> way from <cons sem="G_NUMBER">1282 ml/min to 782 ml/min</cons> among the extensive metabolizers, whereas there was <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_CHANGE">change</cons> among the poor metabolizers.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(fluvoxamine  ,chloroguanide     , DDI)"> 
<sentence>The <cons sem="G_IVIVPARA">partial clearance</cons> of <cons lex="chloroguanide" sem="G_DRUG" type="substrate_1">chloroguanide</cons> by means of <cons lex="chloroguanide" sem="G_DRUG" type="M_1">cydoguanil</cons> and <cons lex="chloroguanide" sem="G_DRUG" type="M_2">4-chlorphenylbiguanide</cons> formation among the extensive metabolizers <cons sem="G_CHANGE">decreased</cons> from <cons sem="G_NUMBER">222 ml/min and 97 ml/min before to 33 ml/min and 11 ml/min</cons> during <cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">fluvoxamine</cons> intake, respectively.</sentence>
</annotation>
<sentence>Among poor metabolizers the corresponding values were <cons sem="G_NUMBER">35 ml/min and 7.6 ml/min before and 38 ml/min and 6.9 ml/min</cons> during <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> intake.</sentence>
<sentence>For each metabolite <cons sem="G_IVIVPARA">clearance</cons> the <cons sem="G_CHANGE">change</cons> was statistically <cons sem="G_CHANGE">significant</cons> among the extensive metabolizers but <cons sem="G_NEGATIVEEFFECT">not</cons> among the poor metabolizers.</sentence>
<sentence>Both <cons lex="chloroguanide" sem="G_DRUG" type="M_1">cycloguanil</cons> and <cons lex="chloroguanide" sem="G_DRUG" type="M_2">4-chlorphenylbiguanide</cons> formation <cons sem="G_IVIVPARA">clearances</cons> were statistically <cons sem="G_CHANGE">significantly</cons> higher among the extensive metabolizers than the poor metabolizers in period A but <cons sem="G_NEGATIVEEFFECT">not</cons> in period B (phenocopy).</sentence>
<sentence><cons lex="fluvoxamine" sem="G_DRUG">Fluvoxamine</cons> is an effective <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9272811</bibliomisc>
</articleinfo>
<title>
<sentence>Loss of analgesic effect of <cons lex="morphine" sem="G_DRUG">morphine</cons> due to coadministration of <cons lex="rifampin" sem="G_DRUG">rifampin</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="methadone" sem="G_DRUG">Methadone</cons> withdrawal symptoms have been reported in drug addicts treated with the tuberculostatic <cons lex="rifampin" sem="G_DRUG">rifampin</cons>.</sentence>
<sentence>Whereas this interaction can be explained by <cons sem="G_MECHANISM">induction</cons> of phase I drug <cons sem="G_MECHANISM">metabolism</cons> (<cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>), knowledge about <cons sem="G_MECHANISM">induction</cons> of phase II <cons sem="G_MECHANISM">metabolism</cons> (e.g., UDP-glucuronosyltransferases = UGTs) and its influence on drug effects in man, however, is very limited.</sentence>
<sentence>The potent analgesic <cons lex="morphine" sem="G_DRUG">morphine</cons> is <cons sem="G_MECHANISM">metabolized</cons> by more than one UGT to the active metabolite <cons lex="morphine" sem="G_DRUG">morphine</cons>-6-glucuronide and to <cons lex="morphine" sem="G_DRUG">morphine</cons>-3-glucuronide, which is devoid of analgesic activity.</sentence>
<sentence>Thus, differential <cons sem="G_MECHANISM">induction</cons> of UGTs involved in <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="morphine" sem="G_DRUG">morphine</cons> might lead to <cons sem="G_CHANGE">decreased</cons> or <cons sem="G_CHANGE">increased</cons> analgesic effects, depending on which UGT is preferentially <cons sem="G_MECHANISM">induced</cons>.</sentence>
<sentence>We therefore investigated the influence of the potent enzyme inducer <cons lex="rifampin" sem="G_DRUG">rifampin</cons> on analgesic effects and pharmacokinetics of <cons lex="morphine" sem="G_DRUG">morphine</cons>, which is primarily eliminated by phase II <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
<sentence><cons sem="G_NUMBER">Ten</cons> healthy male volunteers participated in this double-blind, placebo-controlled study with double crossover design.</sentence>
<sentence><cons lex="morphine" sem="G_DRUG">Morphine</cons> (<cons sem="G_NUMBER">10 mg p.o.</cons>) and placebo were administered on two separate occasions before and near the end of 13 days of treatment with <cons lex="rifampin" sem="G_DRUG">rifampin</cons> (<cons sem="G_NUMBER">600 mg/day</cons>).</sentence>
<sentence>Blood samples were collected for <cons sem="G_NUMBER">31 h.</cons> <cons lex="morphine" sem="G_DRUG">Morphine</cons> effects on pain sensation were determined using the cold pressor test.</sentence>
<sentence>When <cons lex="morphine" sem="G_DRUG">morphine</cons> was given alone, the opioid elicited a <cons sem="G_CHANGE">significant</cons> <cons sem="G_CHANGE">increase</cons> in pain threshold and pain tolerance in comparison to placebo (<cons sem="G_NUMBER">P &lt; or = 0.05</cons>).</sentence>
<sentence>However, following administration of <cons lex="rifampin" sem="G_DRUG">rifampin</cons> <cons sem="G_NEGATIVEEFFECT">no</cons> analgesic effect of <cons lex="morphine" sem="G_DRUG">morphine</cons> was observed.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(rifampin ,morphine    , DDI)"> 
<sentence>In agreement, <cons sem="G_IVIVPARA">the area under the serum concentration-time curve (AUC)</cons> of <cons lex="morphine" sem="G_DRUG" type="substrate_1">morphine</cons> and the <cons sem="G_IVIVPARA">maximum serum concentration</cons> of <cons lex="morphine" sem="G_DRUG" type="substrate_1">morphine</cons> were considerably <cons sem="G_CHANGE">reduced</cons> during coadministration of <cons lex="rifampin" sem="G_DRUG" type="inducer">rifampin</cons> (<cons sem="G_NUMBER">-27.7 +/- 19.3%</cons> and <cons sem="G_NUMBER">-40.7 +/- 27.1%; P &lt; or = 0.01</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rifampin ,morphine    , DDI)"> 
<sentence>Moreover, during treatment with <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons> a proportional <cons sem="G_CHANGE">reduction</cons> of <cons sem="G_IVIVPARA">AUCs</cons> of <cons lex="morphine" sem="G_DRUG" type="M_1">morphine-3-glucuronide</cons> (<cons sem="G_NUMBER">P &lt; or = 0.01</cons>), <cons lex="morphine" sem="G_DRUG" type="M_2">morphine-6-glucuronide</cons> (<cons sem="G_NUMBER">P &lt; or = 0.05</cons>) and <cons lex="morphine" sem="G_DRUG" type="substrate_1">morphine</cons> was observed.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rifampin ,morphine    , DDI)"> 
<sentence>Since urinary recoveries of both <cons lex="morphine" sem="G_DRUG" type="M_1">morphine-3-glucuronide</cons> and <cons lex="morphine" sem="G_DRUG" type="M_2">morphine-6-glucuronide</cons> were also <cons sem="G_CHANGE">reduced</cons> during administration of <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons>, there is <cons sem="G_NEGATIVEEFFECT">no</cons> evidence for a contribution of UGT <cons sem="G_MECHANISM">induction</cons> to the observed interaction.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rifampin ,morphine    , DDI)"> 
<sentence>In summary, a major drug interaction was observed between <cons lex="morphine" sem="G_DRUG" type="substrate_1">morphine</cons> and <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons>, which could <cons sem="G_NEGATIVEEFFECT">not</cons> be attributed to induction of UGTs, but resulted in a complete loss of analgesic effects of the opioid.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9246018</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="tacrolimus" sem="G_DRUG">Tacrolimus</cons> <cons sem="G_IVIVPARA">oral bioavailability</cons> doubles with coadministration of <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>.</sentence>
</title>
<abstract>
<sentence>To quantitate the effect of <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, an azole antifungal agent and potent <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and <cons sem="G_CYP">P-glycoprotein</cons>, on the <cons sem="G_IVIVPARA">bioavailability</cons> of <cons lex="tacrolimus" sem="G_DRUG">tacrolimus</cons>, a substrate of the <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> system and of <cons sem="G_CYP">P-glycoprotein</cons>.</sentence>
<sentence>The pharmacokinetics of <cons lex="tacrolimus" sem="G_DRUG">tacrolimus</cons> were studied in <cons sem="G_NUMBER">six</cons> healthy volunteers (two women and four men) in a four-dose study after each received single doses of <cons lex="tacrolimus" sem="G_DRUG">tacrolimus</cons> alone (<cons sem="G_NUMBER">0.1 mg/kg</cons> orally and <cons sem="G_NUMBER">0.025 mg/kg</cons> intravenously) and with coadministered <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> (<cons sem="G_NUMBER">200 mg</cons> orally at bedtime for 12 days).</sentence>
<sentence>The dose of <cons lex="tacrolimus" sem="G_DRUG">tacrolimus</cons> was <cons sem="G_CHANGE">reduced</cons> during the <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> phase (<cons sem="G_NUMBER">0.04 mg/kg</cons> orally; <cons sem="G_NUMBER">0.01 mg/kg</cons> intravenously).</sentence>
<sentence><cons lex="ketoconazole" sem="G_DRUG">Ketoconazole</cons> and <cons lex="tacrolimus" sem="G_DRUG">tacrolimus</cons> doses were separated by approximately 10 hours.</sentence>
<sentence>Whole blood <cons lex="tacrolimus" sem="G_DRUG">tacrolimus</cons> concentrations were determined by enzyme-linked immunosorbent assay.</sentence>
<sentence>Estimated pharmacokinetic parameters in whole blood (mean +/- SD) before and with <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> were calculated with noncompartmental techniques.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(ketoconazole   ,tacrolimus     , NDDI)"> 
<sentence>Coadministration of <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> consistently <cons sem="G_MECHANISM">affect</cons> <cons lex="tacrolimus" sem="G_DRUG" type="substrate_1">tacrolimus</cons> <cons sem="G_IVIVPARA">clearance</cons> (<cons sem="G_NUMBER">55.6 +/- 16.7 ml/hr/kg versus 42.5 +/- 7.6 ml/hr/kg</cons>), and steady-state volume of distribution was unchanged (<cons sem="G_NUMBER">0.99 +/- 0.26 L/kg versus 0.93 +/- 0.25 L/kg</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(ketoconazole   ,tacrolimus  , DDI)"> 
<sentence>However, a <cons sem="G_CHANGE">significant</cons> <cons sem="G_CHANGE">increase</cons> in <cons lex="tacrolimus" sem="G_DRUG" type="substrate_1">tacrolimus</cons> <cons sem="G_IVIVPARA">bioavailability</cons> (<cons sem="G_NUMBER">14% +/- 5% versus 30% +/- 8%; p &lt; 0.01</cons>) was observed with coadministered <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons>.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(ketoconazole   ,tacrolimus  , NDDI)"> 
<sentence>Hepatic <cons sem="G_IVIVPARA">bioavailability</cons> was unchanged by the presence of <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> (<cons sem="G_NUMBER">96% +/- 1% versus 97% +/- 1%</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(ketoconazole   ,tacrolimus  , DDI)"> 
<sentence>Because <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> alter hepatic <cons sem="G_IVIVPARA">bioavailability</cons> and because 10 hours separated administration times of the drugs, it appears that the <cons sem="G_CHANGE">marked</cons> <cons sem="G_CHANGE">increase</cons> in <cons lex="tacrolimus" sem="G_DRUG" type="substrate_1">tacrolimus</cons> <cons sem="G_IVIVPARA">bioavailability</cons> can be explained by <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> having a local <cons sem="G_MECHANISM">inhibitory</cons> effect on <cons lex="tacrolimus" sem="G_DRUG" type="substrate_1">tacrolimus</cons> gut <cons sem="G_MECHANISM">metabolism</cons> or on intestinal <cons sem="G_CYP">P-glycoprotein</cons> activity.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9159561</bibliomisc>
</articleinfo>
<title>
<sentence>Concentrations and effects of <cons lex="zopiclone" sem="G_DRUG">zopiclone</cons> are <cons sem="G_CHANGE">greatly</cons> <cons sem="G_CHANGE">reduced</cons> by <cons sem="G_DRUG">rifampicin</cons>.</sentence>
</title>
<abstract>
<sentence>The effects of <cons sem="G_DRUG">rifampicin</cons> on the pharmacokinetics and pharmacodynamics of <cons lex="zopiclone" sem="G_DRUG">zopiclone</cons>, a non-benzodiazepine hypnotic, were studied.</sentence>
<sentence>In a randomized, placebo-controlled cross-over study with two phases, <cons sem="G_NUMBER">eight</cons> young healthy volunteers took either <cons sem="G_NUMBER">600 mg</cons> <cons sem="G_DRUG">rifampicin</cons> or placebo once daily for 5 days.</sentence>
<sentence>On the 6th day, <cons sem="G_NUMBER">10 mg</cons> <cons lex="zopiclone" sem="G_DRUG">zopiclone</cons> was administered orally.</sentence>
<sentence>Plasma <cons lex="zopiclone" sem="G_DRUG">zopiclone</cons> concentrations and effects of <cons lex="zopiclone" sem="G_DRUG">zopiclone</cons> were measured for 10 h. </sentence>
<annotation sem="INVIVOCDDIS" ddi="(rifampicin     ,zopiclone  , DDI)"> 
<sentence>The <cons sem="G_IVIVPARA">total area under the plasma <cons lex="zopiclone" sem="G_DRUG" type="substrate_1">zopiclone</cons> concentration-time curve</cons> after <cons sem="G_DRUG" type="inducer_1">rifampicin</cons> was <cons sem="G_NUMBER">18.0% (95% CI 13.5-22.5%)</cons> of that after placebo (<cons sem="G_NUMBER">86.1 +/- 34.5 ng ml(-1) h vs 473 +/- 114 ng ml(-1) h (mean +/- s.d.); P&lt;0.001</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rifampicin     ,zopiclone  , DDI)"> 
<sentence><cons sem="G_DRUG" type="inducer_1">Rifampicin</cons> <cons sem="G_CHANGE">decreased</cons> the <cons sem="G_IVIVPARA">peak plasma concentration</cons> of <cons lex="zopiclone" sem="G_DRUG" type="substrate_1">zopiclone</cons> from <cons sem="G_NUMBER">76.9 +/- 27.2 ng ml(-1) to 22.5 +/- 6.0 ng ml(-1) (P&lt;0.001)</cons> and the <cons sem="G_IVIVPARA">half-life</cons> from <cons sem="G_NUMBER">3.8 +/- 0.6 h to 2.3 +/- 0.9 h (P&lt;0.005)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rifampicin     ,zopiclone  , DDI)"> 
<sentence>A <cons sem="G_CHANGE">significant</cons> (<cons sem="G_NUMBER">P&lt;0.02</cons>) <cons sem="G_CHANGE">reduction</cons> in the effects of <cons lex="zopiclone" sem="G_DRUG" type="substrate_1">zopiclone</cons> was seen in three of the five psychomotor tests used (digit symbol substitution test, critical flicker fusion test and Maddox wing test) after <cons sem="G_DRUG" type="inducer_1">rifampicin</cons> pretreatment.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rifampicin     ,zopiclone  , DDI)"> 
<sentence>The strong interaction of <cons sem="G_DRUG" type="inducer_1">rifampicin</cons> with <cons lex="zopiclone" sem="G_DRUG" type="substrate_1">zopiclone</cons> is due to <cons sem="G_CHANGE">enhanced</cons> <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="zopiclone" sem="G_DRUG" type="substrate_1">zopiclone</cons>.</sentence>
</annotation>
<sentence><cons lex="zopiclone" sem="G_DRUG">Zopiclone</cons> may show a <cons sem="G_CHANGE">reduced</cons> hypnotic effect when used concomitantly with <cons sem="G_NUMBER" type="inducer">rifampicin</cons> or other potent <cons sem="G_MECHANISM">inducers</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> such as <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons> and <cons lex="carbamazepine" sem="G_DRUG">carbamazepine</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9272412</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="itraconazole" sem="G_DRUG">Itraconazole</cons> <cons sem="G_CHANGE">moderately</cons> <cons sem="G_CHANGE">increases</cons> serum concentrations of <cons lex="oxybutynin" sem="G_DRUG">oxybutynin</cons> but does <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_MECHANISM">affect</cons> those of the active metabolite.</sentence>
</title>
<abstract>
<sentence><cons lex="oxybutynin" sem="G_DRUG">Oxybutynin</cons> has low <cons sem="G_IVIVPARA">oral bioavailability</cons> due to an extensive presystemic <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
<sentence>It has been suggested that the biotransformation of <cons lex="oxybutynin" sem="G_DRUG">oxybutynin</cons> is dependent on <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>.</sentence>
<sentence>Because <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>, a widely used mycotic, is a potent <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, we wanted to study a possible interaction between <cons lex="oxybutynin" sem="G_DRUG">oxybutynin</cons> and <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>.</sentence>
<sentence>In this double-blind, randomized, two-phase cross-over study, <cons sem="G_NUMBER">ten</cons> healthy volunteers received either <cons sem="G_NUMBER">200 mg</cons> <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> or placebo for 4 days.</sentence>
<sentence>On day 4, each volunteer ingested a single dose of <cons sem="G_NUMBER">5 mg</cons> <cons lex="oxybutynin" sem="G_DRUG">oxybutynin</cons>.</sentence>
<sentence>Serum concentrations of <cons lex="oxybutynin" sem="G_DRUG">oxybutynin</cons>, its active metabolite <cons lex="oxybutynin" sem="G_DRUG" type="M_1">N-desethyloxybutynin</cons>, and <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> were monitored over 24 h. </sentence>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole      ,oxybutynin   , DDI)"> 
<sentence><cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">Itraconazole</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">increased</cons> both the <cons sem="G_IVIVPARA">area under the serum drug concentration-time curve (AUC0-t)</cons> and the <cons sem="G_IVIVPARA">peak concentration</cons> of <cons lex="oxybutynin" sem="G_DRUG" type="substrate_1">oxybutynin</cons> <cons sem="G_NUMBER">twofold</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole      ,oxybutynin   , DDI)"> 
<sentence>The <cons sem="G_IVIVPARA">AUC0-t</cons> and the <cons sem="G_IVIVPARA">peak concentration</cons> of <cons lex="oxybutynin" sem="G_DRUG" type="M_1">N-desethyloxybutynin</cons> were <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_MECHANISM">affected</cons> by <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole      ,oxybutynin   , DDI)"> 
<sentence><cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">Itraconazole</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">change</cons> the peak time or the <cons sem="G_IVIVPARA">elimination half-life</cons> of either <cons lex="oxybutynin" sem="G_DRUG" type="substrate_1">oxybutynin</cons> or <cons lex="oxybutynin" sem="G_DRUG" type="M_1">N-desethyloxybutynin</cons>.</sentence>
</annotation>
<sentence>The occurrence of adverse events after <cons lex="oxybutynin" sem="G_DRUG" type="substrate_1">oxybutynin</cons> administration was <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">increased</cons> by <cons lex="itraconazole" sem="G_DRUG" type="inhibitor">itraconazole</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole      ,oxybutynin   , NDDI)"> 
<sentence><cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">Itraconazole</cons> <cons sem="G_CHANGE">moderately</cons> <cons sem="G_CHANGE">increases</cons> serum concentrations of <cons lex="oxybutynin" sem="G_DRUG" type="substrate_1">oxybutynin</cons>, probably by <cons sem="G_MECHANISM">inhibiting</cons> the <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>-mediated <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole      ,oxybutynin   , NDDI)"> 
<sentence>However, the concentrations of <cons lex="oxybutynin" sem="G_DRUG" type="M_1">N-desethyloxybutynin</cons> were practically unchanged.</sentence>
</annotation>
<sentence>Since about <cons sem="G_NUMBER">90%</cons> of the antimuscarinic activity of <cons lex="oxybutynin" sem="G_DRUG">oxybutynin</cons> is attributable to <cons lex="oxybutynin" sem="G_DRUG" type="M_1">N-desethyloxybutynin</cons>, any interaction of <cons lex="oxybutynin" sem="G_DRUG">oxybutynin</cons> with <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibiting</cons> drugs has only minor clinical significance.</sentence>
</abstract>
</article>
</set>
